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Abstract 
Adverse drug reactions (ADRs) are a significant public health problem. This thesis 
examined the incidence and nature of adverse drug reactions following admission 
to hospital. An initial pilot study was conducted to develop methodology, which 
was then utilised in a study of 3695 patients. Approximately 15% of patients 
experienced an ADR following admission, of which one-third were serious. 
Commonly used drugs such as opioids, diuretics and anticoagulants were the 
most frequent causes of ADRs. Bleeding, renal impairment and Clostridium difficile 
were the ADRs with the greatest impact on patient length of stay and thus should 
be key areas for intervention strategies. Adoption of methods used in the 
assessment of hospital patient safety incidents such as root-cause analysis may 
help in identifying underlying factors leading to ADRs as well highlighting the 
importance of ADRs to senior hospital managers. 
One-fifth of patients readmitted to hospital within one year of discharge from their 
initial admission were readmitted due to an ADR, highlighting the need to 
effectively review patients' medicine both during the inpatient stay, and in primary 
care. The effectiveness of many medicines recommended as prophylaxis against 
ADRs is unknown. In a study of the relationship between opioids, laxatives and 
constipation in patients following neck-of-femur surgery, it was clear that the 
evidence base for using laxatives in the treatment and prevention of constipation 
was poor, making it difficult for prescribers to prevent opioid-related constipation. 
Methodological difficulties in assessing the probability that a drug caused the 
identified adverse event were highlighted in the pilot, main admission and re- 
admission studies. An assessment of three published causality- assessment 
methods found low-levels of reliability between the observers, questioning the 
validity of standardised causality assessments. 
Future research in this area must focus on strategies to reduce the ADR burden 
and provide safer healthcare to patients. 
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Chapter 1: Introduction 
1.1 Background 
Adverse drug reactions (ADRs) have been described for as long as medicine has 
been practiced. In the modern era, serious adverse events, such as the 
development of phocomelia with thalidomide [1], the abrupt worldwide withdrawal 
of rofecoxib due to its association with increased cardiovascular risk [2,3], and the 
controversy surrounding SSRIs and suicide [4] have publicly highlighted the need 
for pharmacovigilance. These events have attracted much publicity, but it should 
be recognised that ADRs are a common problem, which affect people in both 
primary and secondary care every day. 
This introductory chapter will firstly examine terminology and methodology of ADR 
research relevant to this thesis and, then will focus on reviewing the literature 
surrounding ADRs in hospitals. An abridged version of this literature review was 
published in Current Drug Safety in January 2007 [5] (Appendix 1). 
1.2 Definitions 
Adverse drug reactions (ADRs) have been subject to several definitions. Early 
studies relied on definitions such as that of Cluff et al in 1964: "Any adverse 
response to a medication undesired or unintended by the physician" [6]. This 
definition and others from the same era are vague and encompass intentional and 
unintentional overdose as well as some administration errors [7,8]. They are 
therefore less useful in analysing adverse reactions in drugs used at doses 
intended for therapy. 
In 1972 The World Health Organization (WHO) defined ADRs as "any response to 
a drug which is noxious and unintended and which occurs at doses used in man 
for prophylaxis, diagnosis or therapy of disease, or for modification of physiological 
function" [9]. This definition is intended to include all doses used clinically but 
exclude deliberate overdose and has been used widely in ADR studies [10-15], but 
was subject to criticism as is it includes all adverse reactions, no matter how 
minor, and thus may undermine current surveillance systems [16,17]. Edwards 
and Aronson suggest the following as an alternative: "An appreciably harmful or 
unpleasant reaction, resulting from an intervention related to the use of a 
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medicinal product, which predicts hazard from future administration and warrants 
prevention or specific treatment, or alteration of the dosage regimen, or withdrawal 
of the product" [16]. This definition includes doses used clinically, but excludes 
reactions requiring no intervention, and has been used in ADR epidemiological 
research [18]. 
Other definitions used in some epidemiological studies which measure ADRs, 
have a broader scope and examine adverse drug events (ADEs) as a whole. 
ADEs have been defined as "injury resulting from the medical intervention relating 
to the drug" [19]. Therefore all ADRs are ADEs but not all ADEs are ADRs. The 
terms are not interchangeable as studies of ADEs can encompass errors of 
administration, prescription, and ordering and ADEs are not necessarily due to the 
drug itself. The disparity of terms is a major source of error when comparing 
studies and their methodology. A widely accepted, formal definition would allow for 
greater co-operation between those groups studying ADRs and their impact 
worldwide. 
1.3 ADR Classification by mechanism 
Rawlins and Thompson first formally classified the mechanisms of ADRs in 1977 
[20] as Type A and type B reactions. Type A (Augmented) reactions are 
predictable through knowledge of the drug's pharmacology and dose - dependent 
e. g. hypoglycaemia with antidiabetic agents. Type B (Bizarre) reactions are 
unpredictable in relation to the known pharmacology of the drug and do not show 
a clear dose-response relationship, e. g. anaphylactic reactions to antibiotics. This 
classification system is the most widely accepted and recognized in the literature. 
This "A or B' classification system was extended and a further five categories (C- 
G) have been introduced by various authors (Table 1.1). These additional 
classifications are not universally accepted. With regard to the C (chronic) 
classification, e. g. skin discolouration with chlorpromazine, and D (delayed) 
classifications, e. g. teratogenic effects, both may be classifiable as a Type A 
reaction [21]. Genetic and genomic mechanisms can also be 'involved in type A 
and type B mechanisms. Systems that include failure of therapy as an ADR are 
controversial although interactions causing therapeutic failure in particular are of 
interest to ADR researchers. 
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Table 1.1: A-G Classification of ADRs 
Type of Reaction Features Examples 
A: Augmented [20] Common 
Dose-related Nausea and vomiting with 
Related to digoxin 
pharmacology 
Predictable 
B: Bizarre [20] Uncommon Anaphylaxis with penicillins 
Not dose- related 
Not related to 
pharmacology 
Unpredictable 
C: Chronic [22] Uncommon Skin discolouration following 
Related to cumulative long-term chlorpromazine 
dose therapy 
D: Delayed [22] Uncommon Vaginal adenocarcinoma with 
Usually dose-related diethylstilboestrol 
Occurs a 
considerable time 
after drug has been 
stopped 
E: End of Use [22] Uncommon Benzodiazepine withdrawal 
Occurs soon after syndrome 
stopping drug 
F: Failure of Dose related Oral contraceptive interaction 
Therapy [23] Can be caused e. g. with penicillins 
by interactions, 
tolerance, resistance 
G: Genetic/ Dependent on Malignant hyperthermia with 
Genomic individual genome/ suxamethonium 
Mechanisms [24] 
Aronson and Ferner found the above classification system limited and considered 
that other data such as the reaction properties (time course and appearance and 
severity), and the susceptibility of the individual (e. g. genetics and pathology) 
should be taken into account -when classifying ADRs. DoTS (Dose, Time, 
Susceptibility) was the result of this thinking and produced a three dimensional 
classification system of ADRs, an interesting concept which has yet to be adopted 
by ADR studies [25]. 
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1.4 Detection and monitoring of ADRs: pharmacovigilance 
Pharmacovigilance has been defined as "the science and activities relating to the 
detection, assessment, understanding and prevention of adverse effects or any 
other drug-related problems" [26]. Following the thalidomide disaster in the early 
1960s, legislation requiring pre-marketing efficacy and safety data for medicines 
was introduced, including amendments to the US Federal Food and Drugs Act in 
1962, and the introduction of the Medicines Act in the UK in 1968. 
Due to the relatively small, well-selected, patient populations in clinical trials, post- 
marketing surveillance is essential to identify ADRs with a relatively low incidence 
or long latency period, or those which mimic common non drug-related conditions 
in the community [27]. Effective pharmacovigilance post-marketing helps to 
develop a full drug-safety profile for medicines. A formal system to monitor the 
adverse effects of drugs was set up in the UK in 1964. The "Yellow Card" scheme 
allowed for the spontaneous reporting of suspected adverse drug reactions by 
doctors. The scheme continues and it later allowed pharmacists and nurses to 
report. In 2005 it first permitted members of the public to report adverse events. 
There have been successes with the Yellow Card scheme; for example, warnings 
were added to the summary of product characteristics regarding myocarditis 
caused by clozapine, and the antipsychotic remoxipride was withdrawn worldwide 
following reports of aplastic anaemia [28]. Clearly, the scope of the information 
received depends on the willingness of reporters to co-operate and between 85 
and 98% of doctors, depending on the country, never report an adverse event to 
their national authority [29]. Under-reporting is harmful as it delays the time taken 
for signals indicating the presence of serious ADRs to be identified in the wider 
population. Low reporting rates also make spontaneous reports unsuitable for 
recording epidemiological data (i. e. incidence) of ADRs. Detailed case reports of 
notable adverse drug reactions are published in medical journals, but these 
anecdotal reports have been found to be of little value because reports are rarely 
investigated further, or incorporated into drug reference sources [30]. 
In order to fully assess the impact of ADRs, comprehensive surveillance of all 
patients in a population is required. This surveillance can be done retrospectively 
or prospectively. Retrospective analysis relies on review of medical records and 
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chart review. As information recorded in patient notes is often incomplete [31], and 
access to the patient and relevant staff for further information is less likely, 
retrospective analysis is generally less capable than prospective monitoring of 
identifying all ADRs in a study population, although several studies have 
successfully used retrospective methods [32-34]. Retrospective studies using 
discharge coding found very low ADR rates. Data from an Australian study over a 
20-year period to 2002 showed that 0.8% of all inpatient stays were associated 
with ADRs [35]. Data from a UK coding study showed that 0.35% of admissions 
were drug-induced [36], in contrast with a UK prospective study showing the 
incidence to be 6.5% [18]. Despite this, discharge coding has been shown to 
highlight more ADRs than spontaneous reporting by healthcare professionals [37]. 
Prospective surveillance of a patient population is thought to be the most 
appropriate method for assessing the incidence of ADRs [38]. It involves collection 
of ADR data regularly, often daily, by a trained healthcare professional on selected 
wards or departments over a restricted time period to record all patients and all 
events [39]. 
Examples of early prospective studies include those conducted by the Boston 
Collaborative Drug Surveillance Program (BDSCP) [40-42]. where nurse monitors 
identified ADRs on a daily basis for the study period and the monitor and a 
physician then made a judgement regarding causality based on the collected data 
[41,42]. Similarly, in a recent study in the UK of ADRs leading to hospital 
admission, a study pharmacist or nurse assessed all admissions to two hospitals 
for ADRs over a six-month period. ADRs were then assessed for causality, 
severity and avoidability [18]. Different healthcare professionals have collected the 
data in different studies although whether or not the profession of the investigator 
has an impact on quality or number of ADR reports has not been investigated. Use 
of multiple data sources, including computerised surveillance of laboratory reports, 
medical records and prescriptions have also been suggested as methods of 
detecting ADRs in hospital [43-47]. 
Patients can be very useful in identifying ADRs. This is reflected by the fact that 
patients are now permitted to spontaneously report ADRs in the UK via the Yellow 
Card scheme. Studies of inpatients and patients in the community have shown 
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they are able to identify ADRs successfully [48-50]. Reports of subjective ADRs 
e. g. headache and dizziness can only be obtained from the patient in the first 
instance, and the patient should, where possible, be involved when considering an 
ADR as a likely diagnosis. Differences in ADR perception between clinician and 
patient were highlighted in a study of patients taking clozapine. Clinicians 
generally estimated greater incidence and severity of adverse drug reactions 
compared with patients, particularly extra-pyramidal side effects, although they 
underestimated the incidence of polyuria by 41% [49]. This may reflect different 
perceptions of ADRs and also the limitations of the clinic setting, where visible 
reactions may have greater impact on the clinician than those which can only be 
described by the patient. 
An ideal method for detecting ADRs in inpatients would be prospective and 
. ongoing, use 
trained staff to collect ADRs whilst encouraging ward staff to be 
involved in ADR detection and allow independent review of each ADR by senior 
trained staff, such as clinical pharmacologists. Embracing technology and 
developing an integrated approach to ADR detection may help to reduce the 
workload that typifies intensive prospective review [51]. 
The variability in data collection methods, definitions and analysis contribute to 
varying conclusions of ADR studies, and result in subsequent difficulties in pooling 
data. Individual studies and meta-analyses of ADR studies should therefore be 
evaluated cautiously and critically. Before discussing these studies, this review will 
focus on three main areas of ADR assessment, causality, severity and 
preventability. 
1.5 Causality assessment 
In reality, a drug either caused a reaction or it did not. However, there are many 
variables in making this decision. In the large majority of cases, due to the lack of 
available evidence, an absolute decision as to causality cannot be made. 
Estimations of the likelihood that an adverse reaction was caused by a drug are 
made based on the study of the available facts surrounding each case. 
A recent systematic review found 34 different methods for assessing causality 
[52], highlighting the extent and complexity of the research in this area. There are 
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principally three types of method for causality assessment which are practical for 
regular use; these are unstructured assessment by an evaluator or a panel of 
evaluators (global introspection), semi-structured assessment using pre-set 
guidelines, and standardised assessment using decision tables or algorithms [53]. 
A fourth method, using the application of Bayesian statistics (Bayesian Adverse 
Reaction Diagnostic Instrument: BARDI) has also been devised but its complexity 
may limit its use [54]. 
1.5.1 Global introspection 
This method of causality determination is based on the personal judgement of 
each ADR report by the investigator, following careful study of the case notes and 
application of clinical opinion. The early studies of the BCDSP used the 
assessment of the attending physicians, whereas others have used clinical 
pharmacologists. In a 1976 study comparing clinical pharmacologist and physician 
assessment of suspected ADRs, complete agreement between the clinical 
pharmacologists and the treating physicians occurred in less than half (47%) of the 
cases [55]. More recent work found poor agreement (K = 0.2) between expert 
judgements when assessing 150 drug-effect pairs by global introspection, 
particularly at the intermediate levels of causality [56]. Poorer agreement at lower 
levels of certainty is logical due to the increased subjectivity involved in making 
assessments of ADRs, when clear evidence is absent [56-57]. The character traits 
of the evaluators may also influence their assessment of the ADR [58]. This 
"global introspection" has been described as inappropriate as a serious scientific 
method for assessing adverse drug reactions [59], although despite its subjectivity 
and lack of transparency, this method of assessment is the one that is most 
binding for the evaluator [53]. 
1.5.2 Semi-structured assessment 
This method provides guidelines for assigning a causality term, i. e. 'definite', 
'probable', 'possible' and 'unlikely' ADR, without providing specific rules as to how 
the causality assessment should be carried out. The World Health Organization - 
Uppsala Monitoring Centre (WHO-UMC) has provided a tool for the assessment of 
case reports (Table 1.2), giving guidance to the general arguments that should be 
used to select one category over another [60]. Its application has advantages over 
the unstructured method in that the guidelines for categorisation of an ADR are 
17 
clear, and this will allow other observers to have an indication as to how a 
conclusion was drawn. 
Table 1.2: WHO-UMC Causality Categories [60] 
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1.5.3 Standardised assessment 
The use of unstructured and semi-structured methods of assessment leads to 
causality evaluations where the exact methods of determining causality are not 
clear. The relative importance of different factors such as the temporal relationship 
between drug and effect and the recognition of a possible ADR in the product 
literature, to the evaluator is not clear. This variation, confounded by the 
evaluators' belief system and prior knowledge means that the use of an 
evaluator's opinion is neither reproducible when several evaluators assess the 
same data, nor it has it been validated. Many algorithms have been developed to 
assess the causality of ADRS. Three of these algorithms, Karch [61], Kramer [62], 
and Naranjo [63], are discussed. The development of these methods shows 
progression from large decision tables to a concise algorithm, although there are 
inherent problems in their design and validation. 
1.5.3.1 Karch and Lasagna decision tables 
Karch and Lasagna produced an algorithm for causality assessment in 1977 [61]. 
This algorithm was designed around three decision tables intended to assess 
potential ADRs, the certainty of the link between the event and the agent, and 
evaluate the underlying causes of the identified untoward events. 
If the possibility of a link was established, it was determined as definite, probable, 
possible, conditional, or unrelated according to evaluation criteria. These criteria 
include knowledge of the reaction, temporal relationship, presence of known 
alternative causes, dechallenge and rechallenge information. Events due to 
alcohol or recreational drugs were distinguished from medicines related events. 
Compliance, drug choice and dose, drug interactions, medication errors and 
treatment of terminal illness were incorporated within the algorithm, and the 
method was used to determine whether or not an ADR occurred, or the untoward 
event had another root cause. 
The accuracy of the analysis was evaluated by comparison of 60 assessments 
with the consensus assessment agreed by a group of three clinical 
pharmacologists. The use of consensus as a standard against which the algorithm 
is assessed was flawed, but using a consensus of three experts minimises 
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individual bias and the algorithm evaluations agreed with the consensus of the 
clinical pharmacologists on 45 evaluations (71%) [61]. 
The algorithm was intended as a method whereby the result is reproducible, but 
the algorithm still requires the evaluator to make certain judgements. Therefore it 
will not always produce the same answer from the same report. There were two 
main problems with the algorithm; that the limits or identifying 'possible' ADRs 
were found to be so wide that no ADR cases were excluded, and that the criteria- 
for determining a 'definite' ADR were very narrow. Because of this, quantitative 
data based on 'definite', 'probable' and 'possible' ADRs overestimated the number 
of ADRs, yet those excluding 'possible' ADRs underestimated the overall number 
of ADRs [61]. 
This algorithm therefore has its problems, although it provides a framework for the 
systematic evaluation of ADRs with a greater degree of transparency than less 
structured approaches. 
1.5.3.2 Kramer algorithm 
In an attempt to expand on the work of Karch [61], Kramer et al [62] produced a 
set of diagnostic criteria providing specific rules for the assessment of ADRs. The 
criteria are arranged as an algorithm with a numerical scoring system for 56 
questions over six axes of decision strategy: previous general experience with the 
drug, alternative etiologic candidates, timing of events, drug levels and evidence of 
overdose, dechallenge and rechallenge. The algorithm is then applied to rate the 
candidate ADR as definite, possible, probable or unlikely [62]. Judgement still 
plays a part in the algorithm particularly with regard to the evaluation of diagnostic 
evidence. 
When the above methods were compared, assessing 200 reports, the methods 
were not significantly different in the proportion of cases they deemed definite 
(p=0.5204) or probable (p=0.2972). However, for possible and unlikely ADEs, the 
Kramer algorithm was more likely to assign a risk of possible (p=0.0001), while the 
Karch instrument was more likely to assign a risk of unlikely (p=0.0001). The 
algorithms disagreed with each other 59% of the time. It is apparent that the 
results from these algorithms are not directly comparable [64]. 
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1.5.3.3 Naranjo algorithm 
The above algorithms go some way to achieving reproducible assessment, but the 
algorithms are long and time-consuming to complete. Naranjo et al therefore set 
out to develop a simpler method [63]. They developed the ADR Probability Scale 
(Table 1.3). When six observers tested this scale, a rise in agreement was found 
between the observers using the algorithm, compared with use of conventional 
definitions [63]. The validity assessment of this algorithm used the consensus 
assessment of three experts using semi-structured assessment as an external 
standard. When the experts' results were compared with those of the observers, 
the percentage agreement between the observers and the experts was 70% to 
84%. Furthermore, when one of the experts re-assessed the events using the 
algorithm and his results were compared with those of the observers, the 
agreement increased to between 86% and 95%. The scores produced by the 
algorithm also correlated with the scores produced by the Kramer algorithm when 
it was used to score the same cases (r=82, p<0.001) [65]. 
Question 5 in the algorithm (regarding alternative causes) resulted in the most 
disagreements [63], which may be due to the complex clinical situations and 
differences in training of the observers. This serves to demonstrate that algorithms 
such as these still require the need for a degree of clinical judgement and 
therefore 100% reproducibility between observers is impossible. 
As the Naranjo algorithm produces results that are highly correlated with Kramer's 
and also takes a significantly shorter time to complete [66], it would seem more 
appropriate to use Naranjo's algorithm on a daily basis. However, a study which 
applied the Naranjo algorithm to ADRs in an intensive care unit found poor inter- 
rater agreement [67] perhaps reflecting the difficulties in assessing 'real-life 
situations' as opposed to the detailed case reports used in the initial validation of 
the Naranjo scale [63]. 
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Table 1.3: ADR Probability scale: Naranjo et al [63] 
A consensus has not been reached on which algorithm should be used universally 
and many others have also been devised e. g. Jones's algorithm has been used by 
The Food and Drug Administration (FDA) for many years [68]; Ciba-Geigy Ltd 
(now Novartis) used the method devised by Venulet et al [69,70]. Other general 
methods have been devised [71,72] as well as more specific systems, for 
example, Maria and Victorino's scale for the diagnosis of drug-induced hepatitis 
[73]. Different authors tend to apply similar parameters (experience, timing, 
rechallenge, dechallenge, alternative causes), but have disagreed on the 
weighting given to certain events and devised their own algorithms in an attempt to 
improve on what has been done previously. 
The problem is that despite attempts made to compare some of these algorithms, 
it is impossible to prove one is better or than the others because the truth (i. e. 
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whether or not the drug caused the event) is not known. Agreement between 
methods is not to be assumed. A computerised assessment of 6 causality 
assessment procedures (including those of Karch, Kramer and Naranjo [61-63]) 
found that the rate of agreement between any two methods fluctuated between 
26% and 65% [74]. It can however be argued that one method is easier to use and 
less time consuming than another, and that its results are more reproducible than 
another. When comparing studies it is important to recognise that different 
causality assessments may have been applied in each study. In France, all 
causality assessments must be done using the same method, that of Begaud et al 
[75]. This helps to standardise the research. A consensus of international opinion 
regarding the 'best' algorithm for everyday use would enable easier comparison of 
international studies. 
1.5.4 Bayesian methods 
Standardised assessment methods were criticised most effectively by Hutchinson 
and Lane [59,63]. They described that typically, the evaluator is asked if the 
timing of the reaction is consistent with drug causation, but the issue of the 
consistency of this relationship is ignored. Also, the algorithms ask if the event is a 
known occurrence as a result of the drug, but do not ask how frequently it is 
described. When validating algorithms, most authors attempt to compare the 
results with the opinions of experts, but it was the poor reproducibility of 
unstructured and semi-structured assessment that led to the development of 
standardised methods. 
A different approach (Bayesian Adverse Reaction Diagnostic Instrument (BARDI)) 
was proposed to determine causality based on Bayes' theorem [76,77]. It applies 
logic of uncertainty to the problem of causality assessment. Its goal is to calculate 
the posterior odds that a drug caused a particular event. This is the probability that 
a drug causes an adverse event given all the background and case information, 
divided by the probability that it did not cause the event given the same 
information. The goal of the assessment is to collect all relevant information as 
input and deliver as output the posterior odds. There is no limit to the number of 
factors that can be incorporated into the assessment and the mathematics 
involved is complex. 
23 
It has been successfully applied in several instances to individual ADRs, for 
example, with haematologic dyscrasia associated with ticlopidine therapy [78], and 
with Guillain-Barre Syndrome and zimeldine [79]. The complexity of the instrument 
means that it is unsuitable for routine use in clinical practice and epidemiological 
studies. When BARDI and the Naranjo method were compared it was found that 
assessments using both tools were significantly correlated (rs= 0.45, p<0.0001) 
[54]. The BARDI instrument was better at distinguishing cases that were highly 
probable or highly improbable whereas the Naranjo scale rated the majority of 
these cases in the mid range. A simple algorithm incorporating Bayesian concepts 
to assess ADRs in clinical trials has been developed [80], although whether this 
method provides a better simple algorithm than those already' described is 
unlikely. In comparison to the most sophisticated measurement of causality, 
Naranjo yielded satisfactory results, which is positive, as this algorithm is more 
practical in everyday use than BARDI. 
As Hutchison said: "it is a strange and counterintuitive practice to apply numbers 
to subjective judgements" [81]. Assessment of causality is complicated and 
confounded by many factors. Whichever system is in a study, it is vital that as 
much information as possible about each event is gathered and consistency of 
approach is applied. 
1.6 Severity assessment 
As part of a study of iatrogenic hazards in 1973, Schimmel classified 'episodes' as 
minor, if they were short and subsided without treatment; as moderate, if they 
required significant treatment, or if they prolonged hospitalisation by a day or 
more; and as major if they were life-threatening or contributed to death [82]. These 
definitions are principally adapted in later severity scales. 
1.6.1 Hartwig ADR Severity Assessment Scale 
Hartwig et a/ [83] produced a simple method of determining the severity of ADRs. 
It was adapted from a severity-ranking scale already being used to review 
significant medicines-administration errors [84] and the principles are similar to 
those of Schimmel, with length of stay, treatment required, and prognosis being 
the main axes of severity assessment. The scale has seven levels ranging from 
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level 1 (where the ADR requires no change in the drug treatment), to Level 7 
(where the ADR is fatal). The advantages of this scale are its ease of use, and 
clear definitions; it has been applied in a prospective study of ADRs in hospitalised 
patients [13]. 
1.6.2 Dormann Adverse Drug Reaction Severity Score 
Dormann et al [14] more recently devised an Adverse Drug Reaction Severity 
Score (Table 1.4). It classifies the severity of the adverse drug reaction as mild, 
moderate or severe depending on the numerical score obtained when the 
algorithm is applied to the ADR. It incorporates quality of life assessment and 
ability to work and therefore provides a more patient-focused judgement of 
severity. It may be inappropriate to use this scale routinely in inpatients, as 
assessment of a patient's long-term ability to work would be impractical. 
1.6.3 The CHM/MHRA Yellow Card Criteria 
The CHM/MHRA require 'serious' adverse reactions to established drugs (and all 
reactions to new drugs) need be reported to the CHM/MHRA Yellow Card 
reporting scheme. As in the above scales, serious reactions are defined as those 
which cause death, are life-threatening or cause permanent disability; those 
resulting in or prolonging hospitalisation, and those which are medically significant 
[85]. 
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Table 1.4: Adverse drug reaction severity score [14] 
1.6.4 World Health Organisation (WHO) Criteria 
The World Health Organisation guidance for definitions for seriousness of ADRs 
differentiates between serious, moderate and minor ADRs as follows [86]. 
Serious: Any untoward medical occurrence that at any dose results in death, 
requires or prolongs hospitalisation, results in persistent or significant 
disability/incapacity, and/or is life-threatening 
Moderate: The symptoms are marked, but the involvement of vital organ systems 
is only moderate. No loss of consciousness, no circulatory failure. Antidotes may 
be necessary. The development of certain biochemical or structural changes may 
justify classification in this category. 
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Minor: Incidental, no antidote needed. Does not substantially complicate the 
original disease. 
These definitions are clear and understandable, and all WHO 'serious' ADRs, and 
several 'moderate' ADRs would require a yellow card report in the UK. In common 
with all classification scales studied, the initiation or extension of hospitalisation 
are among the most important factors when considering the seriousness of an 
ADR. 
1.7 Avoidability assessment 
We can simply classify which ADRs are preventable by their mechanism, and 
deduce that a Type A reaction is pharmacologically predictable and therefore, is 
preventable. Type B reactions are not judged to be predictable and are therefore 
not preventable [20]. This is not realistic in a clinical situation. Though steps can 
be taken to reduce type A ADRs, sometimes there is little clinical alternative but to 
use the drug in the patient. Type B reactions can also be avoided if previous 
history of allergy or predisposition to an ADR is confirmed prior to administration. 
Structured questions to assess the preventability of a reaction were designed by 
Schumock and Thornton in 1992 [87] (Figure 1.1). They ask the assessor to 
consider possible reasons for the ADR, including appropriateness of prescribing 
and monitoring, relevant history, and compliance. 
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Figure 1.1: Schumock and Thornton Preventability assessment [87] 
Hallas et al provided definitions to assess preventability, or 'avoidability' [88]. 
These are shown in Figure 1.2. 
Figure 1.2: Hallas Avoidability Definitions [88] 
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The Hallas definitions [88] are more flexible than those of Schumock and Thornton 
[87] and how to differentiate between definitely or possible ADRs is open to 
interpretation by the assessor. However, the Hallas criteria are more structured 
and generate greater accountability in a study than merely stating that Type A 
ADRs are preventable and Type B ADRs are not. 
Having examined different methods of detecting and assessing ADRs, this review 
will examine the literature surrounding studies of ADRs in hospitalised patients. 
1.8 Overview of ADR literature 
Despite the difficulties in pooling data, Lazarou and colleagues published a meta- 
analysis of 39 prospective US studies in 1998. The analysis spanned four decades 
and combined the incidence of ADRs resulting in admissions and those occurring 
whilst patients were in hospital. The authors deduced an overall incidence of 
serious ADRs of 6.7%. The more controversial conclusion of the analysis was the 
incidence of fatal ADRs as 0.32%. When extrapolated to the hospitalised patient 
population of the US, ADRs were determined to be between the 4th and 6th leading 
cause of death in the USA [89]. The study was heavily criticised for its 
methodology and inappropriate extrapolation [90], but work from Sweden suggests 
that ADRs may be responsible for approximately 3% of all deaths, placing it as the 
7th most common cause of death in the Swedish population [91] which 
corroborates the findings of Lazarou. Regardless of the controversy, the Lazarou 
analysis highlighted the enormity of the ADR burden in hospitals. 
A review by Wiffen et a/ in 2002 [92] examined prospective and retrospective 
studies from across the world (mainly North America) for incidence data, and 
focussed on the impact of ADRs in the UK, their risk factors and preventability. 
They reviewed 69 studies (54 prospective, 15 retrospective), with a total of 
413,000 patients. Incidence of admissions to UK hospitals due to ADRs was 
estimated as 2.6%, with those in inpatients estimated as between 3.5 and 7.3%. 
The cost of ADRs to the NHS in England in 1994 was estimated as £380million, 
with 4% of bed days being taken up by patients with an ADR [92]. As with the 
Lazarou study, it is difficult to draw any exact conclusions and comparisons 
between studies. Wiffen et al examined only 9 UK studies to extrapolate the above 
figures. The inherent differences in study methodologies make generalisations 
difficult. It is interesting and useful therefore to look at individual studies when 
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discussing incidence and risk factors for ADRs, recognising that each has its own 
limitations but also a contribution to the ADR literature. 
1.9 Incidence of ADRs 
There are two main groups of patients when examining ADRs in hospital patients: 
those experiencing ADRs in the community which result in admission to hospital, 
and those who develop an ADR during their stay as inpatients. Two recent large 
UK prospective studies demonstrated that 6.5% of patients admitted to hospital 
were experiencing an ADR [18,93]. This is two and a half times the estimate by 
Wiffen and colleagues, but that estimate was based on largely North American 
studies, where the ADR rate appears to be approximately half that of Europe [92]. 
It is unclear whether this is a true difference between continents or merely reflects 
methodological problems. 
The incidence of ADRs in hospital inpatients varied widely in the different studies 
examined. Early studies from the 1960s suggest that ADRs occurred in 10-20% of 
hospital inpatients [8,94,95]. Further research has resulted in widely varying 
estimates of prevalence, from 0.86% in one Australian study [96], to 23% in an 
American study of elderly patients [97], to 37% in a Netherlands-based study, also 
of the elderly [98]. There are no current reliable figures available for UK inpatients. 
Not all patients are equally susceptible to ADRs and the potential risk factors for 
ADRs are discussed below. 
1.10 Risk factors for ADRs 
1.10.1 ADRs in the elderly 
Elderly patients are rarely included in clinical trials. This makes the determination 
of age effects impossible. Where there is an adequate age range, most studies fail 
to control for important clinical differences among subjects of different ages to 
distinguish the independent effects of chronological age [99], and therefore the 
reporting of ADR incidence post-marketing is even more important. Most studies 
have shown an increase in ADRs among the elderly population [10,100] and 
ADRs have been shown to be responsible for repeated admissions to hospital in 
the elderly [101]. Reasons for this increased rate of ADRs include polypharmacy, 
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poor prescribing, poor compliance, concurrent medical illnesses, and alterations in 
pharmacokinetic and pharmacodynamic parameters [10]. 
Pharmacokinetic changes occur with age as a result of the inevitable anatomical 
and physiological changes which occur with time, such as loss of an organ's 
functional units (e. g. nephrons, neurones) and a disruption of some regulatory 
processes between cells and organs, resulting in a decrease in function of bodily 
systems [102]. For example, first pass metabolism decreases due to a decrease in 
liver mass and blood flow [103], resulting in an increase in bioavailability of drugs 
such as propranolol which undergo extensive first pass metabolism [104]. By 
contrast, pro-drugs such as perindopril will experience slower or reduced first-pass 
metabolism [105], although the influence of ageing on the normal liver is smaller 
than the effects on the kidney and less significant in drug metabolism [106]. 
Renally cleared drugs undergo reduced clearance due to reduced renal plasma 
flow and glomerular filtration. This increases the potential for toxic effects 
particularly with those drugs with a narrow therapeutic window, such as digoxin 
and lithium [102]. Changes in body composition such as increases in body fat 
proportion and decreases in total body water result in a decreased volume of 
distribution for water soluble drugs such as digoxin, which increases their serum 
concentrations and potential for adverse effects. Changes in the handling of the 
drug by the body can also result in changes in the pharmacodynamic response. 
Thus pharmacodynamic changes with ageing include increased sedation and 
postural sway with diazepam, increased anticoagulant effect with warfarin, and an 
increased analgesic effect with morphine [102]. 
Onder found age to be an independent risk factor for ADRs [107] but other studies 
have disputed this [108-110]. Carbonin et a/ [110] studied the risk factors 
associated with ADRs in over 9000 patients and found the independent risk factors 
to be staying in a medical ward, drinking alcohol, staying in a hospital longer than 
14 days, and having more than four active medical problems. Age, gender, 
smoking and previous history of falls, were not determined to be independent risk 
factors. 
Variations in the rate and severity of ADRs, as well as the type of ADR and drugs 
implicated, can be attributed to many factors. Onder et a/ have looked at the 
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incidence of ADRs in older patients with depression [111], and with cognitive 
impairment [107]. Depression was associated with a higher incidence of ADRs. 
Neurologic and neuropsychiatric ADRs were more common (p=0.001) among 
depressed patients, but other types of ADRs, e. g. cardiovascular and 
gastrointestinal ADRs, showed no significant differences in incidence between the 
two groups, although the level of co-morbidities were similar [111]. There are 
multiple hypotheses as to why depressed patients may experience more ADRs. 
Depressed patients may amplify somatic symptoms leading to a higher rate of 
ADRs [112], or psychological distress may activate neurally regulated biological 
processes, diminishing the ability to combat pathologic processes, favouring the 
onset of negative outcomes such as ADRs [111]. Alternatively, depression may 
occur as a consequence of ADRs and the high co-morbidity associated with them 
[111]. 
Studies in elderly patients have shown that cognitive impairment is associated with 
a lower incidence of ADRs [107,113]. However, this may be misleading. These 
patients may be unable to communicate their illness; there may also be a greater 
difficulty in distinguishing ADRs from the symptoms of the underlying disease 
[107]. This was supported in further studies, which suggested that ADRs in 
geriatric patients were difficult to recognise, and may be interpreted as senile loss 
of function [114]. 
1.10.2 Polypharmacy 
It is accepted that patients taking more medicines suffer more ADRs [13,110,115, 
116]. Polypharmacy is commonly defined as patients taking four or more 
medicines [117], but attempts to define polypharmacy are problematic. Current 
research suggests that ADR risk increases linearly with the number of drugs being 
taken, therefore polypharmacy cannot be defined by a certain number of drugs 
[118]. 
Polypharmacy is likely to increase as therapeutic guidelines often promote the use 
of two or more therapies to control disease, for example myocardial infarction, 
heart failure and type 2 diabetes [119]. These guidelines are based on clinical 
trials where study patients have fewer co-morbidites and fewer concomitant 
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medicines than many of the 'real-life' population, thus the impact of additional 
medicines in these patients is unknown at the licensing stage [120). 
The prescription of multiple drug therapies increases the risk of drug-drug 
interactions. Studies have shown that 5-15% of elderly patients suffered clinically 
significant adverse effects due to interactions, with the number of elderly patients 
exposed to potential drug-drug interactions estimated to be between 35 and 60% 
[13,121]. 
1.10.3 Renal function 
The impairment of renal function, which occurs naturally with time, and when renal 
function is compromised by diseases such as diabetes, is an important factor in 
the increased risk of ADRs. If doses are not adjusted accordingly, this can result in 
more Type A, pharmacologically predictable [20] reactions for renally excreted 
drugs. It should therefore be possible to reduce the number of ADRs in elderly 
patients, and others with impaired renal function, by providing appropriate care 
[97]. Older patients with concealed impairment of renal function (i. e. reduced 
estimated glomerular filtration rate (GFR) and normal serum creatinine) are 
exposed to a greater risk of ADRs with water soluble drugs, which clearly 
highlights the need for monitoring of full renal parameters in the elderly patients 
when prescribing [122]. Steps should be taken to adjust doses and minimise the 
number of drugs taken by the renally impaired patient. 
1.10.4 Influence of Gender on ADRs 
Several studies have found that more females than males experience ADRs [10, 
97,108]. Examination of spontaneous reports found that more neuropsychiatric 
reactions were reported in women, and more cardiovascular reactions in men 
[123]. Reasons suggested for differences such as these include differences in 
perception of ADRs, pharmacology of ADRs, differences in kinetics such as 
volume of distribution leading to gender associated differences in drug exposure, 
polypharmacy and hormonal differences between men and women [124-126]. For 
example, female gender is associated with greater risk for drug-induced torsade 
de pointes [127]. The corrected QT interval is longer in women generally, but 
women are also more likely to respond adversely to drugs that can potentially 
block cardiac potassium channels such as sotalol. The reason for the gender 
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difference has been suggested to be due to specific regulation of ion channel 
expression by sex steroids [125,128]. A study of gender differences in analgesic 
response to morphine found that women experienced significantly more side 
effects with morphine although both genders experienced equi-analgesic effects 
[129]. A pilot study examining sexual dysfunction in depressed patients treated 
with Selective serotonin reuptake inhibitors (SSRIs) raises interesting question 
regarding perception of symptoms in relation to disease state and adverse effects 
[130]. It was found that women generally had an increase in sexual function 
following treatment with SSRIs as they experience greater sexual dysfunction with 
their illness. Any adverse effects on sexual functioning experienced as a result of 
the SSRI were overshadowed by the positive effects associated with treating 
depression, whereas sexual functioning in men significantly worsened, possibly 
due to the SSRI [130]. The numbers in this study were small, but they reflect the 
possible differences in response to illness, medicines and perception of ADRs that 
can exist in men and women. 
1.11 Study settings 
The majority of ADR studies have been undertaken in general medical units, 
although studies in other clinical areas have also provided interesting results. A 
1982 multi-centre study of surgical patients demonstrated that ADRs were 
associated with 2.2% of prescriptions, although the majority of reactions were 
relatively minor [41]. The issues of polypharmacy are again reflected by a study of 
adverse drug events (ADEs) in intensive care units (ICUs). The rate of preventable 
and potential ADEs was twice as high in ICUs compared with non-ICUs, but when 
this figure was adjusted for the number of drugs ordered, there was no significant 
difference between the two types of unit [131]. However, a clearer picture can be 
obtained from the same study, reported elsewhere, which differentiates between 
medical and surgical ICUs. It shows that Medical ICUs had almost double the ADE 
rate per 1000 patient days (19.4) than Surgical ICUs (10.5) [43], whilst the figures 
for surgical ICUs were comparable with general medical and surgical units. When 
corrected for drug use, the ADE rate in medical ICUs was still almost double that 
of surgical ICUs. This may be due to various factors including the use of a larger 
number of drugs in medical ICUs where the patients may be sicker and suffering 
from more complex conditions than in surgical ICUs. It is important to note 
however that ADEs, encompassing all drug related adverse events, including 
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errors in administration and transcription, and not only ADRs, were studied. The 
results for ADRs were not presented separately. Most ADR research is undertaken 
in 'developed' countries but a study of ADRs in sub-Saharan Africa found that HIV 
status played a major role in risk and severity of ADRs with a younger 
demographic and an increased fatality rate compared to `developed' countries 
[132] showing that the geographical setting may impact on the rate and type of 
ADRs reported. 
1.12 ADRs in paediatrics 
A meta-analysis of paediatric studies showed that ADR incidence in hospitalised 
children was 9.53%, and that 2.1 % of admissions are due to an ADR [133]. This is 
comparable with the lower adult estimates for ADRs from prospective studies. As 
with the elderly population, few drugs undergo clinical trials in paediatric patients. 
Many drugs are used `off-label' and ADR studies therefore can potentially identify 
previously undetected ADRs. Data from two retrospective studies of hospitalised 
children in the USA showed that the drug classes most frequently associated with 
ADRs in hospitalised children were antibiotics, opioid analgesics, anticonvulsants 
and anxiolytics [34,134] with severe reactions most commonly linked to 
anticonvulsants and antineoplastic drugs [134]. European studies found an 
increased incidence of adverse drug reactions in patients using unlicensed or off- 
label drugs [135,136]. Whilst it should be acknowledged that it is often clinically 
necessary to use unlicensed and off-label medicines in children, steps should be 
taken to monitor ADRs when drugs are used in this manner, in order to reduce the 
burden of these ADRs in paediatric patients. As with adults, the number of ADRs 
has also been shown to increase with the number of drugs taken in paediatric 
patients [135,137,138]. 
1.13 Drugs implicated in ADRs 
Studies from hospitalised patients in the 1960s reported antibiotics, diuretics, 
cardiac glycosides, and antidiabetics as the drugs most frequently linked to ADRs 
[7,82,94,95]. These drugs have remained amongst the most common causes of 
ADRs in the following decades [12,115]. NSAIDs and opioids have been 
implicated, particularly in studies involving surgical patients [15,43], with diuretics 
being prevalent as causative factors in elderly patients [10,97,111]. Similarly, 
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drugs implicated in patient admission to hospital have changed little, and are 
largely similar to causative drugs during hospitalisation, although NSAIDs, causing 
gastro-intestinal bleeding, and anti-hypertensives, causing hypotension and falls, 
have been more frequently implicated in causing admission [18,93,139-142]. 
Table 1.5 summarises several studies and the drugs implicated in ADRs. A recent 
systematic review by Howard et al showed that four groups of drugs (antiplatelets, 
diuretics, NSAIDs and anticoagulants) were associated with greater than 50% of 
preventable drug-related admissions [143]. 
Table 1.5: Adverse drug reactions and causative drugs 
Study Population Most frequent causative 
drugs/drug classes 
Leach 1986 [10] 521 Admissions Antibiotics, diuretics, insulin, 
(elderly) opioids 
Evans 1994 [11] 79,719 Admissions Antibiotics, digoxin, morphine 
and Inpatients 
Bowman 1994 [97] 1225 Admissions Anticoagulants, cardiac drugs, 
and inpatients diuretics 
Dartnell 1996 [139] 965 Admissions Anti hypertensives, 
corticosteroids, diuretics, 
NSAIDs 
Classen 1997 [12] 91 574 Inpatients Antibiotics, digoxin, morphine 
Moore 1998 [115] 328 Admissions and Antibiotics, Antidepressants, 
inpatients antidiabetics, 
anti hypertensives, digitalics, 
NSAIDs, 
Suh DC 2000 [144] 9311 Inpatients Antibiotics, anticoagulants, 
cardiovascular drugs 
Dormann 2000 [14] 379 Inpatients Antibiotics 
Vargas 2003 [15] 401 Inpatients Opioids 
(Intensive care) 
Howard 2003 [93] 4091 Admissions Antidiabetics, antiepileptics, 
diuretics 
Pirmohamed 2004 [18] 18820 Admissions Anticoagulants, diuretics, 
NSAIDs 
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If a drug frequently causes ADRs, this is important, but the severity of the ADR is 
also a crucial issue. If a drug causes few ADRs, but these ADRs tend to be 
serious, it is arguably more important to address means of preventing these ADRs 
than those of another drug that results in a larger number of minor ADRs. A study 
by Evans et al showed that morphine was both the most frequent causative drug 
overall and the drug which cause the most severe reactions, but only 1 in 50 ADRs 
with morphine were 'severe'. However the monoclonal antibody muromonab -CD3 
had the greatest ratio of severe adverse events to all adverse events (1 in 3) [11]. 
Putting these results into context, it is important to be alert when morphine is 
administered, as there are a high number of adverse events, but also, vigilance 
should be heightened whenever muromonab - CD3 is administered due to the 
frequency of severe ADRs. 
It is also important to note that inaccurate medication histories taken in hospital 
may result in possible ADRs being overlooked [145]. The use of complementary 
medicines and over-the-counter (OTC) medicines must also be assessed, as this 
is often not documented [145,146]. Interviews have shown that patients have a 
very poor knowledge of possible ADRs relating to purchased OTC medicines, 
which is worrying due to the prevalence of ADR-related hospital admissions, 
particularly to NSAIDs, which are readily available over-the-counter [18,147]. 
The benefits as well as the risks of drugs should be taken into account when 
prescribing. Clearly, for some drugs, there is growing evidence of their 
effectiveness, for example, aspirin to prevent cardiovascular events [148], but also 
of their potential to cause harm. The use of the drug in a patient should be 
accompanied by an assessment of relative harm-benefit ratio, and measures put 
into place to maximise benefits and minimise harms. This is not always easy to 
achieve. For example, some drugs will always cause adverse reactions to some 
extent, including idiosyncratic reactions. Nevertheless, it is disappointing that the 
same classes of drugs, which produce pharmacologically predictable ADRs [20], 
are still causing ADRs on a frequent basis. It is therefore imperative that we learn 
from our experiences of drug use in the real clinical world and attempt to 
implement prevention strategies for ADRs. 
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1.14 ADRs and length of stay 
The financial burden of ADRs increases substantially when ADRs either cause or 
extend hospitalisation. The average additional stay resulting from an ADR is 
between 2 and 4 days, which has major cost implications for a health service [92]. 
Whilst ADRs may prolong hospital stay, it is important to appreciate that those 
patients who stay longer in hospital are at an increased risk of ADRs, and 
therefore an association of an ADR with longer stays does not necessarily reflect 
cause and effect [142,149]. Moore et al found that patients admitted with ADRs 
did not stay in hospital significantly longer than patients without ADRs, whereas 
patients with ADRs in hospital did [115]. A study in surgical ICU found an ADR 
incidence of 9.3%, with an increase in length of stay for those suffering from ADRs 
of 3.39 days [15]. This increased length of stay may have been due to the ADRs 
themselves; an alternative explanation may be that patients who are in ICU for 
long periods are more severely ill and therefore require more medicines, 
increasing the possibility of ADRs [15]. 
Suh et al found no increase in length of stay (and total hospitalisation costs) in 
patients with ADRs aged over 65 compared with an age-matched control group 
without ADRs [144]. However, older patients also have greater rehabilitation and 
social needs compared with the younger patient population in terms of planning for 
hospital discharge. Therefore their discharge can be delayed because of a number 
of factors, which may make it difficult to assign an increase length of stay to an 
ADR. 
1.15 ADRs and readmissions 
A study of hospital admissions and readmissions undertaken in Germany found 
that of 1000 admissions (630 patients), 424 patients had a single admission and 
206 patients were readmitted at least once in a 6-month period. Of these 
readmitted patients, 82 were readmitted more than once [150]. ADRs observed at 
admission occurred in 12.1% of all patients at the first admission, 9.3% at the first 
readmission, 7.3% at the second readmission, and 6.1% of patients readmitted 
three or more times. An Australian study which looked at repeat adverse drug 
reactions and admissions to hospital found that repeat ADRs causing admission 
are increasing, and in 2003, were responsible for one third of admissions related 
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to ADRs; the most common ADRs causing readmission were nausea and 
vomiting, haemorrhage with anticoagulants and 'poisoning' by cardiovascular 
agents [101]. The level of repeated admission due to ADRs shown suggests that 
prescribing issues contributing to the ADR could originate in primary or secondary 
care. The lack of monitoring of patients post-discharge was highlighted by a US 
study of 400 general medical patients; one fifth of whom experienced an adverse 
event following discharge, 66% of which were related to medicines [151]. 
Improvements in prescribing, monitoring and communication across the primary- 
secondary care interface are essential to help prevent future admissions due to 
ADRs. 
1.16 Costs associated with ADRs 
Readmissions and increased length of stay contribute to the considerable financial 
burden of ADRs. Direct costs are theoretically quantifiable and have been 
examined in several studies. Willen of a/ estimated that the annual cost of ADRs 
to the NHS in England in 1994 was £380million, with 4% of bed days being taken 
up by an ADR [92]. A US study showed that the costs in patients with ADEs in 
hospital were increased, with the greatest effect seen in those with preventable 
ADEs [19]; it is unclear whether this effect was also seen when ADRs alone were 
examined. In France, a study showed an increase in cost of ¬11,500 for ADRs that 
increase a patient's length of stay, which totalled approximately one third of the 
ADRs in that study [152]. Hospital charges for a 31-day inpatient stay for a case 
involving an interaction between azathioprine and allopurinol totalled $181,000 
[153]. In addition, the threat of litigation has the potential to add to the high costs of 
preventable ADRs. Therefore, the financial burden of ADRs is significant; clearly, 
preventable ADRs provide the potential to save costs, and there is an urgent need 
to develop preventive strategies to reduce this cost burden. It is also important to 
note that studies to date have largely concentrated on direct costs, and there are 
no reliable estimates of the social and indirect costs of ADRs, making it difficult to 
measure the overall economic burden to the patient and society [154]. 
1.17 Prevention of ADRs 
Historically, studies have shown that between 20% and 80% of ADEs and ADRs 
are preventable [43,155-157] with the majority of latter studies showing around 
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60-70% preventability [13,18,93,139,142]. Although there are differences 
between studies in how preventability was determined, a recent systematic review 
has shown that over 70% of ADRs are preventable [143]. 
The benefits of drug use are evident, and when considering their hazards it is 
important not to become blinkered to their positive effects. The risk in different 
patients varies, and a prescriber must consider these before making a decision. 
The characteristics that differentiate preventable from non-preventable ADRs have 
been determined as appropriate prescribing, dosing, allergy reporting and 
monitoring [87]. These are logical conclusions as care in prescribing doses 
specific to the individual patient and careful documentation of medication history 
are core components of safe prescribing. Implementation of quality information 
technology (IT) systems has been proposed as a method for reducing ADRs. 
Evans et a/ significantly reduced the number of type B ADRs in their hospital by 
implementing three interventions [11]. They used computerised alerts of drug 
allergies, emphasised standardised administration rates for antibiotics, and notified 
staff of ADRs to increase their awareness. This is particularly important, as type B 
ADRs are proportionately more likely to cause serious illness or death than type A 
ADRs [158]. A computer alert system which alerted the physicians to potential 
drug related problems e. g. lactic acidosis with metformin, by analysis of multiple 
inputs e. g. laboratory results, drug orders, drug allergies, was shown to aid in the 
detection and therefore the prevention of ADEs. Almost half of the true positive 
reports were not recognized by the physician prior to the computer generated alert 
[159]. A system generating Automatic Laboratory Signals (ALS) for ADRs has 
been devised in Germany [46,160,161] which detects changes in laboratory 
values which may be indicative of ADRs. The computer-monitoring system, 
combined with chart review by study staff prospectively detected ADRs in 377 
patients over 6 months. Thirty-nine of 109 ADRs were detected by the computer 
system alone, and only 9 were not alerted by the computerised system, thus 
increasing the overall detection rate of ADRs. The problem with a system such as 
this is that it generates a large number of false positive results. Integration of the 
ALS system with individual medicines data would allow more intelligent decision- 
support [160]. This would alert the prescriber when there is a real need, rather 
than continuously, which inevitably leads to "warning fatigue" and switching off of 
the decision analysis software. Drug-drug interactions are also potential causes of 
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ADRs [162,163] and the incorporation of reliable decision support software into 
hospital information systems can be effective in averting dangerous drug 
combinations [164,165]. 
Prescription of inappropriate medicines is prevalent, particularly in the elderly 
[166]. Application of the Beers criteria to reduce inappropriate prescribing in the 
elderly has proved useful in identifying potential drug related problems [167]. For 
instance, falls in elderly outpatients were significantly reduced in one study which 
discontinued or reduced doses for fall-risk-increasing drugs e. g. anxiolytics, 
antihypertensives and opioids [168]. Improvements in monitoring drug treatment 
are also likely to reduce the ADR burden [169]. The presence of a pharmacist on 
ward rounds in intensive care units and in general medical wards has been shown 
to reduce ADEs [170,171] and increased clinical pharmacy staffing has been 
associated with lower ADR rates in US hospitals [172]. Improvements in care and 
attention to teaching of prescribing and prescribing environments have been 
recommended to reduce prescribing errors [173]. In turn, improvements in these 
areas may reduce the number of ADRs as it would encourage the prescriber to 
consider the full clinical status of the patient, including factors such as age and 
renal function, when prescribing medicines. 
1.18 Pharmacogenomics 
Pharmacogenomics is the study of pharmacologically relevant genes, their 
variation, how these variations interact to produce phenotypes, and how these 
phenotypes affect drug response [174]. For example, the more active S- 
enantiomer of warfarin is metabolised mainly by the P450 isoform CYP2C9. 
Patients with variable CYP2C9 alleles are poor metabolisers of the drug and are at 
greater risk of bleeding [175-177]. The study of pharmacogenomics will hopefully 
increase the predictability of drug response in individual patients, thereby reducing 
ADRs. It may also help in improving effectiveness as response rates with most 
drugs are between 25 and 60% [178]. The ultimate aim of pharmacogenomics is to 
go largely from the 'one-size fits all' paradigm of drug prescription, to tailored 
medicines regimens based on a patient's genetic characteristics. Thus, ADRs that 
were previously considered to be non-preventable may now be preventable 
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through modification of drug selection and/or dosage in patients based on their 
genotype [179,180]. 
1.19 Conclusions 
Extensive work has been undertaken to develop the methodology surrounding 
ADR research, providing interesting choices for the researcher looking for 
methods and tools to conduct epidemiological ADR research. Standardisation of 
terms used in ADR research would be useful to allow greater collaboration 
between research groups and improve international comparisons of data. The 
range of methodology, sample sizes and locations of ADR studies leads to difficult 
comparisons, though it is clear that the burden of ADRs in healthcare is significant, 
particularly in the elderly population and has changed little in recent decades. 
Strategies for prevention need to be developed to improve patient outcomes. 
Despite the presence of multiple studies looking at various aspects of ADR 
incidences worldwide, no studies of the ADR burden in UK hospital inpatients were 
identified. There is a need to assess this burden and to identify strategies to 
reduce this sizeable contribution to morbidity and mortality. 
1.20 Aims of Thesis 
" To assess the burden of adverse drug reactions (ADRs) in hospital 
inpatients. 
The objectives of the thesis can be summarised as follows: 
" To quantify the burden of ADRs in UK hospital inpatients 
" To identify key areas for intervention to reduce the impact of ADRs 
9 To explore possible interventions to reduce ADRs in inpatients 
" To critically evaluate the methodology used when studying ADRs in hospital 
inpatients 
In order to fulfil the aims and objectives, a step-wise process was undertaken with 
the development of methodology at the initiation of the project, with the lessons 
learnt from this being incorporated into the main inpatient study. This also led to 
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further investigation of other areas, for example, readmissions, the usefulness of 
causality assessment tools that have been developed and how contradictory 
definitions available via Government agencies can lead to confusion in ADR 
interpretation and impact. Finally, specific areas that require intervention to 
reduce the ADR burden were identified, and one area was chosen to look at 
possible avenues for intervention and the difficulties likely to be encountered in the 
implementation of prevention strategies. 
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Chapter 2: Adverse Drug Reactions in Hospital Inpatients: 
a pilot study 
2.1 Introduction 
ADRs are a common problem, which affect patients in the hospital and community 
setting. A prospective study demonstrated that 6.5% of patients admitted to 
hospital were experiencing an ADR, and that these ADRs directly led to admission 
in 80% of cases [18]. Clearly, ADRs can also occur after admission to hospital. In 
a meta-analysis, Lazarou et al showed that the total incidence of serious ADRs 
causing admission and those occurring after admission was 6.7%, of which 4.7% 
caused admission and 2.1% occurred following admission, with an overall fatality 
rate of 0.32%, placing ADRs as the 4-6th most common cause of death in the USA 
[89]. This meta-analysis proved controversial [90], though recent research from 
Sweden has implicated ADRs as the 7 'h most common cause of death [91]. 
There are no recent data on the burden of ADRs in hospital inpatients in the UK in 
terms of impact on length of stay, interventions required and costs. Most of the 
literature is pre-1990 and usually non-UK based. Furthermore, the studies have 
varied in design with differences in the methodology, terminology and populations 
studied. This has resulted in widely varying estimates of the prevalence, from 
0.86% in one Australian study [96], to 37% in a Dutch study of elderly patients 
[98]. In a systematic review, Wiffen et al estimated that the frequency of ADRs in 
inpatients may range from 3.5% to 7.3%, and "best guess" estimate of the overall 
burden on the NHS was 1.6 million bed days and 13.6 400-bed hospital 
equivalents [92]. Given the widely varying estimates of the ADR burden on 
inpatients, it was necessary to conduct a pilot study to establish a practical and 
robust methodology, and assess the feasibility of conducting a large prospective 
study. A prospective study was considered necessary to provide a better estimate 
of the burden of adverse drug reactions on inpatients than is currently available. 
An article based on this pilot study was published in the Journal of Clinical 
Pharmacy and Therapeutics in August 2006 [181] (Appendix 2). 
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2.2 Aim 
The aim of this pilot study was to establish practical and robust methodology, 
which could be used to conduct a large prospective study, in order to assess the 
impact of adverse drug reactions on inpatients in a UK university hospital. 
2.3 Objectives 
1) To determine the incidence of ADRs on the wards studied 
2) To determine the causality, severity and avoidability of each ADR 
3) To classify the mechanism of each ADR 
4) To determine the (additional) length of stay (LoS) for patients with ADRs 
5) To determine the drugs most frequently associated with ADRs 
6) To evaluate the feasibility of expanding the study to conduct a large 
prospective study of ADRs in inpatients. 
2.4 Methods 
2.4.1 Subjects and Settings 
The pilot study was carried out on five wards (general surgery, endocrinology, 
gastroenterology, care of the elderly, and rheumatology) of the Royal Liverpool 
University Hospital. Patients admitted to these wards over a two-week period in 
spring 2005 were assessed for ADRs throughout their period of hospitalisation. 
The study protocol was assessed and approved by the Liverpool Local Research 
Ethics Committee and the audit department at the hospital. 
2.4.2 Patient identification and assessment 
An adverse drug reaction was defined according to the definition of Edwards and 
Aronson [16], and in accordance with the adverse effects listed for each drug in 
their Summary of Product Characteristics [182] and the British National Formulary 
[183]. ADRs were defined as 'inpatient ADRs' if they fitted one of the three 
scenarios described in Table 2.1. 
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Table 2.1: Definitions used to categorise an adverse drug reaction as 
occurring in a hospital in-patient 
" Drug initiated in hospital during current admission, with the adverse 
reaction occurring during the stay in hospital. 
" Drug initiated prior to the current admission, but adverse reaction was not 
present on admission, and occurred during the patient's stay in hospital. 
" Drug initiated prior to the hospital admission, and patient develops an 
adverse reaction that was either not detected or addressed at admission 
(and was not the cause of admission), but required treatment during the 
hospital stay. 
Patients were assessed for ADRs during a daily ward visit by the investigator 
(research pharmacist) in which all medicines and changes in medicines were 
recorded on the Drug Usage Form (Appendix 3). Changes in medicines acted as 
a trigger to ascertain the occurrence of an adverse effect. In addition to this, all 
the study wards were informed of the study and asked to contact the pharmacist 
via a 'telephone pager' or notification report cards (Appendix 4) in the event of an 
ADR. In addition, the wards were also routinely attended by the ward 
pharmacists, who were requested to notify the research pharmacist of suspected 
ADRs. The hospital dispensary had been provided with an ADR alert drug list for 
recording any potential ADRs. This list included medicines that might be 
prescribed to treat the adverse effects of other drugs, for example procyclidine for 
oculogyric crisis, or oral vancomycin or metronidazole for antibiotic related 
diarrhoea. 
For all patients, the medical and nursing notes were reviewed, and any new 
symptoms discussed with staff and patients, where appropriate, to determine 
whether these were due to an ADR. An ADR Assessment Form (Appendix 5) was 
developed with the Royal Liverpool Hospital Audit Department. Suspected ADRs 
were recorded on the ADR Assessment Form and analysed for causality using the 
Naranjo algorithm (Table 1.3) [63]. Severity was assessed using an adapted 
Hartwig scale [83], as described in Table 2.2. Avoidability was determined using 
the criteria outlined by Hallas et a/ (Figure 1.2) [88], and the suitability for yellow 
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card reporting using the criteria set out by the Medicines and Healthcare 
Regulatory Authority (MHRA) [85]. 
Table 2.2: Adapted Hartwig Severity Scale 
Severity Description 
Level 
1 An ADR occurred but no change in treatment with suspected drug 
2 The ADR required that required treatment with the suspected drug 
be held, discontinued, or otherwise changed. No antidote or other 
treatment required. No increase in length of stay 
3 The ADR required that treatment with the suspected drug be held, 
discontinued, or otherwise changed, and/or an antidote or other 
treatment required. No increase in length of stay 
4 Any Level 3 ADR which increases length of stay by at least one 
day OR 
the ADR was the reason for admission 
5 Any level 4 ADR which requires intensive medical care 
6 The adverse reaction caused permanent harm to the patient 
7 The adverse reaction either directly or indirectly led to the death of 
the patient. For the purposes of this study, adapted as: 
7a The ADR indirectly linked to death of patient 
7b The ADR directly linked to death of patient 
The ADRs were also classified as either a Type A reaction i. e. predictable from the 
drug's pharmacology, or Type B reaction, that is, not predictable from the known 
pharmacology of the drug [20]. Whether or not the patient's stay was extended 
due to an ADR was determined by the investigator through chart review, medical 
case note review and discussion with relevant staff. When an ADR was identified, 
drugs co-administered as prophylaxis against that ADR were recorded, for 
example, proton pump inhibitors (PPIs) to protect against non-steroidal anti- 
inflammatory drug (NSAID) induced gastrointestinal bleeds. All ADRs were initially 
assessed by the research pharmacist (ED), and subsequently by two senior 
investigators. A consensus was agreed between all the investigators as to the 
appropriate final scoring for the ADRs. All drugs administered to each patient 
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during the admission were recorded, along with these drugs implicated in ADRs. 
Statistical analysis was performed by X2 analysis and Z-test, as appropriate, 
accepting p<0.05 as being significant. 
2.5 Results 
Over a two-week period, 125 patients (61 female, 64 male) were assessed for 
ADRs on the study wards. Initially, 30 suspected ADRs were found in 26 patients. 
After discussion between the investigators, three of these suspected ADRs were 
excluded for reasons described in Table 2.3. 
Table 2.3: Excluded ADRs 
Suspected Drug Summary of ADR Why excluded 
Co-amoxiclav Patient developed Clostridium Readmission occurred 
difficile diarrhoea, following 
prescription of co-amoxiclav 
during a previous admission 
Atorvastatin Patient admitted due to 
abdominal pain and distension. 
Subsided somewhat on 
atorvastatin discontinuation. 
Multiple investigations required. 
Clopidogrel Patient experiencing microcytic 
anaemia with a haemoglobin 
level of 11.7g/dl on admission, 
falling to 11.1 g/dl the next day. 
No further blood levels were 
available. Clopidogrel was 
initiated before admission and 
stopped on discharge (4 day 
stay). 
due to ADR, but drug not 
initiated, and ADR did not 
occur during this 
admission. 
Likely to be reason for or 
have contributed to 
admission, and problem 
addressed on admission. 
Difference in haemoglobin 
level minimal. Most likely 
to be laboratory variation. 
Following these exclusions, it was found that 24 patients (19.2%, 95% confidence 
interval 12 - 26%) experienced one or more ADRs. A total of 27 adverse reactions 
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were identified in the 24 patients (1.1 ADRs/patient). More females (n=15) than 
males (n=9) experienced ADRs, although this was not statistically significant (x2 = 
2.23, p=NS). The median age of patients who experienced an ADR was 69.5 
years (inter-quartile range 52-79 years), compared with 61 years (inter-quartile 
range 45-78 years) for those who did not experience an ADR (z=1.25, p=NS). The 
median length of stay for ADR patients was significantly longer at 14.5 days (inter- 
quartile range 10-21 days), compared with eight days (3-12 days) for those who 
did not experience ADRs (z= 3.49, p<0.05). A summary of the ADRs identified is 
shown in Table 2.4. The most frequent ADR encountered was constipation largely 
due to the use of opioids. 
Table 2.4: Summary of ADRs and their causative drugs 
ADR Frequency Drugs Implicated 
Constipation 9 Co-codamol, fentanyl, 
morphine, tramadol, fluoxetine, 
atorvastatin 
Hypokalaemia 3 Bendroflumethazide, 
furosemide, 5- 
fluorouracil/cisplatin 
Gastrointestinal disturbance 3 Ibuprofen, diclofenac, 5-FU, 
cisplatin, iloprost, co-codamol, 
morphine 
Decreased renal function 2 Furosemide, spironolactone 
Gastrointestinal I per rectum 2 Clopidogrel 
bleed 
Angioedema 1 Perindopril 
Tremor 1 Salbutamol 
Rash 1 Cefalexin 
Increased anti factor Xa levels 1 Enoxaparin 
Clostridium difficile infection 1 Ciprofloxacin 
Dry mouth 1 Dosulepin 
Hypotension 1 Atenolol, ramipril 
Myoclonic jerks, hallucinations 1 Fentanyl, morphine, oxycodone 
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The ADRs were assessed using the algorithms described above by three 
investigators. The ADRs were initially assessed independently by three 
investigators (ED, CG, MP), before a decision was made through consensus 
(Table 2.5). 
Using the classifications from consensus agreement, CSM/MHRA Yellow Cards 
were required to be written for 10 (37%) of the ADRs in this study. Type A 
reactions, accounted for 25 (93%) of the ADRs and 2 (8%) were type B reactions 
[20]. Using the Naranjo algorithm [63], 17 (63%) of the ADRs were defined as 
'possibly' related, 9 (33%) were 'probably' related and 1 (4%) ADR was classified 
as definitely related to the drug. In terms of prevention [88], 13 (48%) of reactions 
were classified as 'possibly' avoidable, 3 (11 %) were 'definitely' avoidable, and 11 
(41%) were recognised to be 'unavoidable'. Adverse drug reactions occurred 
despite prophylactic medicines in four cases. In three of these cases, constipation 
was the ADR, with laxatives being used as prophylaxis. In the fourth case, 
constipation may have been a factor in the GI disturbance the patient experienced, 
and a laxative was ineffective in its prevention. 
According to the Hartwig criteria [83], (Table 2.2), most (n=18) reactions required 
intervention but did not increase the length of stay (i. e. level 3). However, through 
assessment of notes and discussion with other healthcare professionals, 7 
reactions (26%) were felt to have had an impact on the length of stay, and were 
thus classified at level 4. The duration of each increase in length of stay was not 
documented during this pilot study due to difficulty in quantifying the increased 
stay in hospital with regard to the increased morbidity related to the ADR. 
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Table 2.5: Summary of ADR classifications 
Evaluator 
ED (Research CG (Senior MP (Senior Consensus 
Pharmacist) Investigator) Investigator) 
N° ADRs (%) No ADRs (%) No ADRs (%) No ADRs (%) 
n=27* n=26* n=26* n=27* 
Causality 
Definite 1 (4) 2 (8) 0 (0) 1 (4) 
Probable 15 (56) 18 (69) 6 (23) 9 (33) 
Possible 11 (41) 6(23) 20(77) 17(63) 
Severity 
Level 
2 3(11) 0(0) 0(0) 0(0) 
3 12 (44) 21 (81) 20 (77) 18 (67) 
4 9(33) 0(0) 4(15) 7(26) 
5 0 (0) 2 (8) 0 (0) 0 (0) 
7A 2 (7) 2 (8) 2 (8) 2 (7) 
7B 1 (4) 1 (4) 0 (0) 0 (0) 
Avoidability 
Definitely 4(15) 3(12) 2(8) 2(7) 
avoidable 
Possibly 16 (59) 15(58) 11(42) 14(52) 
avoidable 
Unavoidable 7(26) 8(31) 13(50) 11(41) 
Yellow 13(48) 6(23) 6(23) 10(37) 
cards 
Mechanism 
A 25 (93) '23 (89) 24 (92) 25 (93) 
B 2 (7) 3(12) 2(8) 2(7) 
*ED assessed all ADRs independently; CG and MP each assessed 26 of 27 
ADRs, and the investigation team discussed all 27 ADRs. 
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Eight (6%) patients died during their admission, three (2%) of whom had 
experienced an ADR. Two of those deaths were indirectly related to the adverse 
drug reaction that occurred during admission and were therefore classified as 
Level 7a on the adapted Hartwig scale [83], (Table 2.2). Both of these ADRs were 
classified as 'possibly' preventable. The first of these deaths was indirectly linked 
to Clostridium difficile infection following ciprofloxacin administration. The patient 
had multiple co-morbidities and his cause of death was given as a respiratory 
infection, with underlying metastatic rectal cancer. The ADR was classified as 7a 
as the treatment of the chest infection was delayed due to Clostridium difficile 
concerns. If the infection had been treated promptly without this complication, the 
patient may have survived this episode. However, co-morbidity was high and he 
may have succumbed to infection with or without intervention. 
The second ADR related to the death of a patient was an upper GI bleed 
potentially linked to clopidogrel administration prior to, and during, admission for a 
respiratory tract infection. The patient developed a GI bleed during admission 
which was then treated. The patient improved initially and then deteriorated rapidly 
following development of abdominal pain which was not investigated but 
suspected as a bowel obstruction, or perforation. The patient subsequently died. 
The cause of death was recorded as a gastro-intestinal haemorrhage. 
A total of 225 drugs were administered in the patients admitted during the study. 
Of these, 24 (11%) were implicated in the ADRs detected. In 17 cases, a single 
drug was responsible for the ADR and in 10 cases, two or more drugs were 
involved and could be deemed to be drug interactions. The drugs implicated in 
ADRs and the frequency of their use in this study is shown in Table 2.6. Opioid 
analgesia most commonly caused adverse reactions, with co-codamol being the 
drug most frequently linked with ADRs, followed by fentanyl and morphine. The 
research pharmacist found that visiting five wards daily was manageable. Once an 
ADR was identified 10-30 minutes were required to write up that adverse drug 
reaction. Recording all medicines for each patient was very time-consuming and it 
would be difficult to incorporate such extensive data collection on a larger scale 
using similar methods. 
52 
Table 2.6: Drugs implicated in ADRs 
Drug NO of ADRs related 
to the drug 
N° of patients in 
study taking drug 
Percentage of 
prescriptions 
resulting in 
ADRs 
Co-codamol 8 29 30 
Fentanyl 4 5 80 
Morphine 4 26 15 
Furosemide 3 19 16 
Bendroflumethazide 2 7 29 
Clopidogrel 2 7 29 
Atenolol 1 12 8 
Ramipril 1 5 20 
Ibuprofen 1 6 17 
Perindopril 1 5 20 
Salbutamol 1 24 4 
Cefalexin 1 2 50 
5-Fluorouracil 1 1 100 
Cisplatin 1 1 100 
Tramadol 1 14 7 
Enoxaparin 1 4 25 
Ciprofloxacin 1 14 7 
Oxycodone 1 2 50 
Iloprost 1 2 50 
Diclofenac 1 11 9 
Dosulepin 1 2 50 
Spironolactone 1 5 20 
Fluoxetine 1 4 25 
Atorvastatin 1 7 14 
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2.6 Discussion 
Despite being extensively studied, there is no doubt that ADRs still represent a 
significant clinical problem. There is therefore a need to obtain more recent, 
accurate data on the burden of ADRs on NHS hospital inpatients. This is also 
important because there have been huge changes in medical practice and NHS 
operational procedures over the last two decades. 
This study was intended to inform the design of a larger study to fully investigate 
the burden of ADRs in hospital inpatients. The pilot study allowed us to assess 
the feasibility of conducting a larger study, and to develop operational procedures 
that enabled intensive monitoring of all patients. The methodology comprises the 
use of a research pharmacist dedicated to the project, the use of expertise of 
ward-based pharmacists, and informing medical and nursing personnel on the 
wards of the study, and securing their co-operation. Importantly, the patients were 
assessed during their admission, and ADRs recorded prospectively, not 
retrospectively since data relating to ADRs are often poorly documented in the 
notes [29] and may not actually be recognised as such by the attending healthcare 
professionals. This was the case in this pilot, and hence the need to intensively 
monitor the patients to obtain an accurate record of the burden of ADRs in hospital 
inpatients. 
Despite the fact that this is a pilot, and therefore its findings should be treated with 
caution, this study shows that ADRs occurred in 19.2% of patients. This figure is 
consistent with the range of results from 1960s studies which showed ADRs 
occurred in 10-20% of inpatients [8,94,95] but almost three times higher than the 
estimate of a systematic review [92]. The contradictory figures are likely to be a 
reflection of the different methodologies used in the different studies, including 
those used in the systematic review [92]. 
Although 19% of patients suffered an ADR, fortunately the majority were mild and 
did not lengthen hospital stay, although most needed some intervention, for 
example, prescription of laxatives or change in dose. Nevertheless, such ADRs 
still result in discomfort for the patients, and should therefore be avoided if 
possible. Given that most of the ADRs were type A reactions, which are 
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predictable from the known pharmacology of the compound [20], it should be 
possible to develop strategies to prevent these ADRs. Furthermore, consistent 
with previous literature [13,139], almost 60% of the adverse reactions were 
classified as being either definitely or possibly avoidable. A typical example here 
is the occurrence of constipation with opioid analgesics, which was the 
commonest ADR identified. Previous literature has also shown that opioids 
frequently cause adverse drug reactions [12,41]. It has been stated that patients 
receiving opioid therapy should start laxative therapy concurrently to reduce the 
incidence of constipation [184]. However, it is also important to note that some 
ADRs occurred despite the use of prophylaxis, indicating either that some ADRs 
are inevitable and thus unavoidable, or that we need to develop better strategies 
for prevention of ADRs, including the use of different prophylactic drugs and 
different doses. The frequency of an ADR relative to frequency of drug-use is also 
important. For example, although co-codamol was most frequently linked with 
ADRs, it was also the most-commonly prescribed drug, with an ADR occurring in 
less than 30% of patients taking the drug. Fentanyl was linked with ADRs in 80% 
of patients who were prescribed this drug during the study period. In a larger 
study, assessing the frequency of ADRs in relation to the frequency of drug use 
will be useful in identifying strategies to reduce the burden of ADRs by targeting 
specific drug classes. In addition, targeting certain groups of patients for 
preventing ADRs may be important - for instance, although this study was not 
powered to detect this, the elderly and females seem to be over-represented in the 
ADR groups, which is consistent with previous literature [115,185]. A larger study 
will be needed to identify relevant risk factors and patients to target for preventive 
strategies. 
More serious ADRs, for example those that prolong hospitalisation or contribute to 
the death of the patient, represented 33% of the ADRs identified. Such ADRs fit 
the CSM/MHRA reporting criteria [851 - suggesting that reportable ADRs may be 
occurring in 9% of hospital inpatients (11 out of the 125 patients assessed in the 
study) further underlining the fact that most ADRs in hospitals are not reported. 
The methodology chosen for this study allowed the investigators to identify and 
assess ADRs successfully. Assessment methods obtained from the ADR literature 
were used to assess causality, avoidability and severity of adverse drug reactions. 
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Table 2.3 shows that there was considerable variability in interpretation of the use 
of these scales initially by the investigation team. This variability was addressed 
during a meeting of the investigators where issues with interpretation of the scales 
were discussed and a consensus of opinion achieved. This will support more 
uniform interpretation of ADRs using these scales in future studies. 
An issue to consider in terms of the severity of the ADRs is the difficult in 
assessing whether the ADRs prolonged hospitalisation or led to death. There are 
many aspects of patient care that affect time to discharge, for example the severity 
of illness, and need for rehabilitation or social care in the community, but it is 
usually possible to determine whether or not an ADR has been a factor in 
increasing length of stay. In this pilot, we have attempted to determine whether 
length of stay was affected by ADRs through review of case-notes and discussion 
with the attending staff. A criticism of this approach is that it involves a degree of 
subjective assessment, and because of this, the data should be interpreted with 
caution, and needs replication in a larger study. Nevertheless, a previous study by 
Classen et a/ has shown that ADRs can prolong hospitalisation by an average of 2 
days [12]. They used matched case-controls identified by a detailed hospital 
information system employing variables including diagnosis, sex, age, and patient 
acuity score to determine the effect of an ADR on length of stay [12]. Whilst this 
method may provide more objective data, it would be difficult and impractical to 
attempt to use a similar model in the UK, with the limited information technology 
system used by the study hospital. However, the pilot study provided us with 
valuable insights into methodology to be used in a larger study. More proactive 
discussion with nursing and medical staff, will ideally lead to quantification of the 
increased length of stay. Clearly, caution regarding subjective assessment also 
applies to the two ADR-related deaths reported in this pilot study. 
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2.7 Conclusion 
This pilot study of ADRs in hospital inpatients has shown that almost one fifth of 
patients suffered an ADR, with the majority of ADRs being predictable from their 
pharmacology and potentially avoidable. It is therefore plausible that the impact of 
ADRs on hospital inpatients can be reduced. The methodology piloted was largely 
successful although improvements in length of stay assessment would be 
necessary for the extended prospective study. Analysis of a larger patient 
population using similar methods will identify risk factors and vulnerable patient 
groups aiding in development of interventions to reduce the impact of ADRs in 
hospital inpatients. 
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Chapter 3: Adverse Drug Reactions (ADRs) in Hospital 
Inpatients: A Prospective Analysis of 3695 Patient- 
Episodes 
3.1 Introduction 
Adverse drug reactions (ADRs) in hospitalised patients can be divided into two 
broad categories: those that cause admission to hospital, and those that occur in 
inpatients after hospital admission. In a meta-analysis, Lazarou et a/ [89] showed 
that the total incidence of both categories of serious ADRs was 6.7%, of which 
4.7% were responsible for admission and 2.1% occurred after admission, with an 
overall fatality rate of 0.32%. In a Liverpool study of almost 19000 admissions, it 
was shown that 6.5% of patient admissions to two NHS hospitals were related to 
an ADR [18]. This incidence figure is broadly compatible with pooled data from 
older studies [89,92], and with more recent studies [93,186]. 
There are little data on adverse drug reactions following admission. Lazarou et al 
suggested that 10.9% of patients experienced ADRs of all severities following 
admission [89]. Differences in methodology and study populations have led to 
widely varying estimates in individual studies [96-98]. There are no recent large 
studies on ADR incidence in UK inpatients, although a systematic review from 
Wiffen estimated that in the NHS in England, 1.6 million bed-days, equivalent to 
13.6 (400-bed) hospital equivalents annually are due to ADRs [92]. Much of the 
data in Wiffen's review relate to studies which are dated. With the changing 
demographics in the UK, the predisposition of the elderly to ADRs, and the 
changes in medical practice over recent decades, there is a need for current data 
on the ADR burden in hospital inpatients. 
A pilot study was undertaken to establish the methodology for determining the 
burden of adverse drug reactions in hospital inpatients and is reported in Chapter 
2. The pilot study involved 125 patients and showed that 19% of inpatients 
suffered ADRs during their hospital admission episode, with patients experiencing 
an ADR spending 6.5 days longer in hospital than those without ADRs [181]. Minor 
adaptations were made to the study methodology from the pilot, including 
improvements in data collection forms, and more pro-active collection of data 
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relating to increased length of stay. The methodology adapted from the pilot study 
was then used to undertake a large prospective study to further explore the impact 
of ADRs on NHS hospital inpatients in terms of incidence, length of stay, costs 
involved, and factors that predispose patients to ADRs. 
3.2 Aim 
The aim of the study was to assess the burden of adverse drug reactions on 
inpatients in a UK university hospital. 
3.3 Objectives 
1) To determine the incidence of ADRs in the study hospital 
2) To determine the causality, severity and avoidability of each ADR 
3) To classify the mechanism of the reaction (AB) 
4) To determine the additional length of stay (LoS) for individual patients with 
ADRs 
5) To determine the difference in average length of stay in ADR patients 
compared with those without ADRs 
6) To determine the drugs most frequently associated with ADRs 
7) To examine the number of ADRs which occur despite prescription of ADR 
prophylaxis. 
8) To calculate the costs associated with ADRs for all patients 
3.4 Methods 
The study was conducted on 12 wards (9 medical and 3 surgical) at the Royal 
Liverpool University Hospital (RLUH) over a six-month period between June and 
December 2005. The RLUH is a teaching hospital which serves a population of 
about 0.5 million with a total annual activity of around 90,000 admissions. The 
study protocol was assessed and approved by the Liverpool Local Research 
Ethics Committee and the audit department at the RLUH, and the Research Ethics 
Committee at Liverpool John Moores University. 
For the purposes of this study, an ADR was defined according to the definition of 
Edwards and Aronson [16]. ADRs were identified on the basis that they were well 
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recognised as evidenced by their inclusion in either the Summary of Product 
Characteristics [182] or the British National Formulary [183]. Only ADRs that 
occurred during admission as a result of drugs initiated or continued in hospital 
were included, while community acquired longstanding ADRs that were treated 
during the hospital stay were excluded (n=17,2.3% of all ADRs detected). ADRs 
that manifested no clinical signs, for example, suspected drug-induced 
abnormalities in blood test results were included, though differentiated from those 
which caused clinical symptoms. 
The study wards were a convenience sample representative of the medical to 
surgical ward ratio at the study hospital. Intensive and critical care units, and more 
specialist units such as the renal dialysis unit were excluded as the focus of this 
study was on wards that are found in most general hospitals. There are no 
paediatric, psychiatric or obstetrics and gynaecology wards at the study hospital 
and thus the results from this study exclude those patient groups. Patients 
admitted to the study wards during the data collection period were identified daily 
(Monday to Friday) by the research pharmacist (ED) using the hospital Patient 
Administration System (PAS). Patients whose admission did not include a 
weekday were therefore excluded, as were patients recorded on the PAS system 
following the daily check of ward lists, and discharged within one day prior to the 
next morning. Study wards were visited daily by ED, and patients' drug charts, 
medical and nursing notes were reviewed for evidence of an ADR. Details of 
suspected ADRs were recorded on the ADR Assessment Form (Appendix 6) and 
manually entered into a study database developed using Microsoft Access. 
Objective markers of ADRs, e. g. laboratory results were identifiable from the 
patient notes and the hospital computer system, while subjective markers of 
ADRs, for example headache, nausea and rash were identified through patient 
notes, discussion with the ward team and, where appropriate, discussion with the 
affected patient. Clinical staff were informed that the study was taking place and 
could also refer directly either in person or through notification cards (Appendix 4) 
that were made available on the wards. The clinical ward pharmacists were 
consulted regularly regarding the possibility of ADRs on their designated wards. 
Following completion of the ward based data-collection period, retrospective case 
note analysis was performed to assess patient outcomes and to ensure that all 
available details regarding the ADR had been collected. 
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Suspected ADRs were classified in terms of causality [63] and avoidability [88] 
according to validated algorithms and were assessed for seriousness according to 
criteria for Yellow Card Reporting to the Commission on Human Medicines and to 
the Medicines and Healthcare products Regulatory Agency (CHM/MHRA) [85]. 
ADRs were also classified as either type A or type B according to the system 
introduced by Rawlins and Thompson in 1977 [16]. This classification was chosen 
instead of the more recent DoTS classification [25] so that the resultant data could 
be compared with previous studies. Severity of ADRs was recorded according to 
the Hartwig severity scale [83], which was adapted for the pilot study [181], to 
include two level 7 ADRs in order to differentiate between ADRs which directly, 
and those which indirectly, cause death. 
Analysis for causality, avoidability, severity and seriousness was done 
independently by two investigators, the research pharmacist (ED) and Senior 
Investigator (CG). Discrepancies in scoring were discussed before consensus was 
achieved through discussion between ED and CG in conjunction with a Professor 
of Clinical Pharmacology (MP). The overall incidence of inpatient ADRs was 
defined as the total number of inpatient episodes which resulted in ADRs in 
relation to the total number of inpatient episodes in the study wards during the 
study period. 
The length of stay for each patient was recorded using data from the hospital 
Patient Administration System (PAS), enabling comparisons between patients with 
and without ADRs. Analysis of whether the ADR directly increased the length of 
stay, and the duration of this increase, was made following an assessment of the 
clinical features of the underlying disease and ADR, and after discussion with the 
ward team including the ward pharmacist and medical staff, and assessment of 
relevant case-notes. Clinical judgment was used to assess the additional length of 
stay attributable to the ADR. Thus, for example, if a patient had an ADR whilst 
waiting for nursing home placement, e. g. antibiotic-related C. difficile diarrhoea 
and the wait for placement independently exceeded the duration of the ADR, no 
additional length of stay was attributed to the reaction. Conversely, if a patient was 
ready for discharge, but an ADR occurred which required the patient to stay in 
hospital, the additional length of stay until recovery from the ADR was attributed to 
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the reaction. All drugs including the causative drug(s) were recorded for all 
patients with ADRs on the ADR Assessment Form (Appendix 6). In addition, all 
medicines taken by a random control sample of 1 in 10 inpatients on the same 
study wards were also recorded using the Drug Usage Form (Appendix 7). 
ADRs which occurred despite specific prophylaxis against the ADR were recorded. 
The potential effect of polypharmacy on ADRs was measured by comparing the 
number of regular medicines taken by ADR patients on the first day of ADR with 
the number of medicines taken for the control sample (1 in 10 patients), assessed 
on the day of the inpatient stay where the patient received the maximum number 
of medicines. The most frequent ADRs relative to usage were calculated by using 
data of all drugs administered to one tenth of patients admitted. The frequency of 
the drug group causing a suspected ADR was divided by the number of times a 
drug in that class was administered in the sample of patients (if greater than, or 
equal to, 1). The resulting ratio allowed drug groups to be further ranked by 
frequency of ADRs relative to drug use. The costs to the NHS were estimated 
using number of bed-days for additional length of stay based on the standard daily 
costs of NHS hospital episodes (£228) [187], consistent with the estimates used in 
a prospective study of hospital admissions [18]. 
3.4.1 Statistical methods for analysis 
Statistical analysis was undertaken with the assistance of Professor Paula 
Williamson and Mr Stephen Taylor from the University of Liverpool Centre for 
Medical Statistics and Health Evaluation (CMSHE). 
The data were hierarchically structured, in that multiple ADR episodes can occur 
both within patients and within a particular patient admission (where a patient had 
>1 admission to hospital), hence the study had patient/admission/episode levels. 
To compare ADR incidence between hospital wards, a generalised estimating 
equation (GEE) [188] model with compound symmetry was used to account for 
within-patient correlation. This was considered more appropriate than a random- 
effects model when there are small numbers of observations within patients [188]. 
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For all other analyses, where a patient had multiple admissions and/or multiple 
ADRs, patient's first ADR episode was used and analysed at the patient level only. 
The first ADR episode was used to simply assess the affected patient population 
and the risk factors assessed (age, gender, number of medicines and placement 
on a medical or surgical ward) were identical or assumed to be broadly similar for 
patients who had multiple admissions. Comparisons between groups using 
proportions/percentages were assessed using the chi-square statistic for 
assessing significance. Comparisons between groups using continuous measures 
used the mean (SD) for describing normally distributed data, and median (IQR) for 
non-normally distributed data, using the t-test or the Mann-Whitney U-test for 
assessment of statistical significance, as appropriate. The 5% level was used for 
assessing significance. 
The risk factors for ADRs were identified by analysing data for age, gender, 
number of drugs prescribed and placement on a medical or surgical ward, in a 
time to event analysis. Kaplan-Meier curves with log-rank test were used for 
univariable analysis of categorical factors. Regression analysis was undertaken 
via the Cox proportional hazards model. Results are given in terms of the hazard 
ratio (HR) with accompanying 95% confidence interval (95% Cl). The 5% 
significance level was used when assessing factors for model inclusion. The risk 
factor `number of drugs prescribed' had data available for 10% of the total sample 
(n = 374), and therefore multivariable analysis was carried out on this sample. 
Those risk factors for which data were available for the whole sample (gender, 
ward type, age) were analysed using the whole sample and results compared to 
the 10% sample. 
3.5 Results 
Over six months, there were a total of 3695 patient episodes assessed for ADRs 
involving 3322 patients. Out of these patient episodes, 545 (14.7%, 95% Cl 13.6- 
15.9%) resulted in one or more ADRs. Initially, 742 ADRs were identified. Nine 
ADRs (1.2%) were excluded by the investigation team on the basis that the event 
was unlikely to be drug-related according to the Naranjo algorithm [88], resulting in 
a total of 733 ADRs for further analysis. At the patient level, using first recorded 
ADR, women experienced significantly more ADRs (n=308,17.8%) than men 
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(n=216,13.5%; X2 =11.6, df=1, p<0.001). The median age was significantly higher 
in the ADR group at 72 years (Q1-Q3 56-81 years) compared with 61 years in the 
non-ADR group (Q1-Q3 41-77 years; U=109, p<0.0001). More medical (n=389, 
17.2%) than surgical (n=135,12.8%) patients experienced ADRs (X2=10.5, df=1, 
p<0.01). The incidence of ADR episodes varied further according to the specialty 
of the wards studied as shown in Table 3.1 
Table 3.1: Odds of experiencing an adverse drug reaction by ward type 
Medical/Surgical Specialty Odds ratio (95%CI) in relation to N° 
breast/general surgical ward* (n = 555) patients 
Respiratory 3.65 (2.37 to 5.61) 298 
Cardiology 3.34 (2.13 to 5.25) 256 
Endocrine 3.19 (2.02 to 5.06) 242 
Elderly medicine 3.06 (2.07 to 4.55) 544 
(Two wards) 
Orthopaedic surgery 2.65 (1.81 to 3.90) 711 
(Two wards) 
Rheumatology 2.55 (1.27 to 5.13) 76 
Gastrointestinal/ Liver 2.43 (1.58 to 3.73) 390 
Pharmacology 1.53 (0.95 to 2.47) 356 
Infectious diseases 1.28 (0.75 to 2.20) 267 
*ORs adjusted for multilevel structure 
The median length of stay for patient episodes resulting in ADRs was 20 days 
(Q1-Q3 12-35 days) compared to 8 days (Q1-Q3 5-14 days; U=143, p<0.00011 for 
those episodes without ADRs. Within the group of patients experiencing an ADR , 
the mortality was higher, (n=58,10.7%), compared with 3.9% (n=126) of patients 
who did not experience an ADR (X2 =42.4, df =1, p<0.0001). ADRs contributed to 
14 out of the 184 deaths (0.4% of patients admitted, 8.2% of all deaths), with one 
(0.03% of patients admitted, 0.5% of all deaths) death being directly attributable to 
the ADR, specifically GI bleed with diclofenac and dalteparin (see Table 3.2). Of 
the 733 ADRs identified, Type A ADRs accounted for 690 (94.1%) of the ADRs 
64 
while 232 (30.1%) ADRs fulfilled the requirements for reporting to the UK 
regulatory agency. The majority (n=602,82.1 %) of the ADRs occurred as a result 
of initiation of the causative drug in hospital, of which 390 (65%) showed clinical 
signs. Of the cases where the drug had been initiated prior to hospital admission 
(n=121,17.9%), with the ADR occurring during admission, 81 of the patients 
(67%) showed clinical signs. 
Table 3.2: Deaths associated with adverse drug reactions 
Adverse No Drugs (N° of deaths) Avoidability 
drug associated (definite, 
reaction patient possible, 
deaths unavoidable) 
Renal 7* Gentamicin (1), bumetanide, 1 definite, 
failure valsartan (1), bumetanide, 2 possible, 
furosemide, spironolactone, 4 unavoidable 
ramipril (1), allopurinol, 
ceftriaxone, furosemide (1), 
diclofenac (1), furosemide, 
spironolactone (1), bumetanide, 
metolazone, perindopril, 
spironolactone, trimethoprim, 
potassium and calcium 
supplements (sando K, sandocal) 
(1, included hypercalcemia and 
hyperkalemia) 
Clostridium 5* Ceftriaxone and ciprofloxacin and 3 possible, 
difficile gentamicin (1), ceftriaxone, 2 unavoidable 
infection ciprofloxacin, lansoprazole (1), 
amoxicillin, cefuroxime, 
ciprofloxacin (plus lactulose and 
senna contributing to diarrhoea) 
(1), ceftriaxone, erythromycin, 
clarithromycin, co-amoxiclav (1), 
ceftriaxone, lansoprazole, 
trimethoprim (1) 
GI Bleed 2 Dalteparin, diclofenac (1), aspirin, 1 definite, 
dalteparin, dipyridamole, 1 possible 
enoxaparin (1) 
Ischemic 
bowel 
Glypressin (1) 1 possible 
In one patient both renal failure and C. difficile infection contributed to death 
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Drug-drug interactions were linked to 433 (59.1%) of the ADRs, and these 
interactions are described Table 3.3. 
Table 3.3: Drug-drug Interactions contributing to ADRs 
Mechanism of N° of Example (s) 
Drug-Drug Interactions 
Interaction (n=433) 
Pharmacodynamic 397 (91.7%) 
(PD) 
Pharmacokinetic 23 (5.3%) 
(PK) 
Mixed 13 (3.0%) 
  Bleeding with dalteparin and warfarin; 
Candidal infection after administration of 
prednisolone, inhaled beclomethasone, 
amoxicillin and erythromycin 
  Renal impairment following diclofenac, 
furosemide, lisinopril and spironolactone 
administration 
  Sedation with lorazepam and oxazepam 
  Gout with bumetanide, furosemide and 
metolazone 
  Bradycardia with amiodarone and digoxin 
co-administration 
  Opioid withdrawal following concomitant 
methadone and rifampicin administration 
  Increased INR with erythromycin and 
warfarin 
  Bleeding following co-administration of 
mechanisms amiodarone and warfarin (PK); plus 
(PK/PD) clopidogrel and dalteparin (PD) 
All patients with ADRs required some form of intervention which consisted of dose 
adjustment, change of therapy, replacement therapy or increased monitoring while 
one (0.1%) patient required intensive care. Tables 3.4 and 3.5 show detailed 
results of causality, severity and avoidability assessments, with corresponding 
inter-rater reliability (weighted Kappa (Kw)) scores from the initial assessments of 
the ADRs by two investigators (ED and CG). 
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Table 3.4: The adapted Hartwig severity scale and corresponding 
adverse drug reaction (ADR) frequency 
Severity Level Description Frequency of 
the ADR at 
each severity 
level; n (%) * 
1 An ADR occurred but no change in treatment 0 (0.0) 
with suspected drug 
2 The ADR required that required treatment with 152 (20.7) 
the suspected drug be held, discontinued, or 
otherwise changed. No antidote or other . 
treatment required. No increase in length of stay 
3 The ADR required that treatment with the 413 (56.3) 
suspected drug be held, discontinued, or 
otherwise changed, and/or an antidote or other 
treatment required. No increase in length of stay 
4 Any Level 3 ADR which increases length of stay 152 (20.7) 
by at least one day OR 
the ADR was the reason for admission 
5 Any level 4 ADR which requires intensive 1 (0.1) 
medical care 
6 The adverse reaction caused permanent harm 0 (0.0) 
to the patient 
7 The adverse reaction led to the death of the 
patient. 
For the purposes of this study, adapted as: 
7a The ADR indirectly linked to death of patient 14 (1.9); 
7b The ADR directly linked to death of patient 1 (0.1) 
Initial inter-rater agreement (weighted Kappa (KW) score) = 0.64,95% Cl (0.59- 
0.69) 
*The denominator used was the total number of ADRs (n=733). 
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Table 3.5: Causality and avoidability assessments of ADRs 
Assessment Categories and corresponding % Total Initial inter- 
frequencies of the ADRs (n; %)* agreem- rater 
ent agreement 
K' (95% CI) 
Causality Definite Probable Possible 
23 (3.1) 487 (66.5) 223 (30.4) 60.2% 0.23 (0.17- 
0.30) 
Avoidability Definite Possible Unavoidable 
47(6.4) 344 (46.9) 342 (46.7) 61.1% 0.35 (0.29- 
0.41) 
*Denominator used was the total number 01 AUKs, n=733. 
'Definitely' or 'possibly' avoidable 'serious' ADRs were further examined. 
Causative drug groups for avoidable ADRs were assessed and the reasons for 
their avoidability were recorded. The contribution of preventable ADRs to length of 
stay and seriousness of ADR, determined by their need for 'yellow card' reporting 
to the CHM/MHRA were also assessed. As described in Table 3.5,391 (53.3%) of 
all ADRs were classified as definitely or possibly avoidable. Almost one third (n = 
225,30.7%) of ADRs were serious, with 132 (58.7%) of serious ADRs judged to 
be definitely (n=10), or possibly (n=122), avoidable. The drug groups which most 
frequently caused serious, definitely or possibly avoidable ADRs were loop 
diuretics, anticoagulants, opioids and heparins. Electrolyte disturbances, bleeding 
and renal failure were the most common serious, definitely or possibly avoidable 
ADRs. Table 3.6 shows all serious and potentially avoidable ADRs, highlighting 
how frequently the ADR was serious in relation to the frequency the ADR 
occurred. A median of 2 (IQ range 0-5) additional bed days per patient were 
attributable to serious, potentially avoidable ADRs. Based on analysis of individual 
cases, inadequate monitoring and poor prescribing decisions were frequent 
reasons for avoidability. 
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Table 3.6 Serious and avoidable ADRS 
Description of ADR Frequency N° ADRs which were 
ADR serious, and definitely or 
occurred 
in study 
possibly avoidable 
(N=132) (%) 
Electrolyte disturbances 169 22 (13.0%) 
Constipation 100 17 (17.0%) 
Increased INR 54 9(16.7%) 
Bleeding 53 20 (37.7%) 
Renal failure 45 19 (42.2%) 
Hypotension 35 5 (14.3%) 
Hypoglycaemia 31 8 (25.8%) 
Nausea 29 3 (10.3%) 
Clostridium difficile 25 10 (40.0%) 
Diarrhoea 16 1 (6.3%) 
Opioid toxicity 12 3 (25.0%) 
Sedation 7 1 (14.3%) 
Hallucinations 6 2 (33.3%) 
Anaemia; Digoxin toxicity; opioid 4 1 (25.0%) 
withdrawal; urinary retention 
Digoxin toxicity 4 1 (25.0%) 
Opioid withdrawal 4 1 (25.0%) 
Urinary retention 4 1 (25.0%) 
Psychosis 2 1 (50.0%) 
Fall 2 1 (50.0%) 
Ileus 2 1 (50.0%) 
Benzodiazepine withdrawal 1 1 (100.0%) 
Fracture 1 1 (100.0%) 
Ischaemic bowel 1 1 (100.0%) 
Lithium toxicity 1 1 (100.0%) 
Seizure 1 1 (100.0%) 
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In patient episodes associated with an ADR, the number of medicines taken was 
significantly higher (median of 9 regular medicines (Q1-Q3 6-13), in comparison to 
the control sample of patient episodes (median of 6 regular medicines Q1-Q3 4-10 
(U=92644; p<0.0001)). The drug groups most frequently implicated in the ADRs, 
and causative drugs relative to usage in the study population are shown in Table 
3.7. 
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Table 3.7: Drugs most frequently implicated in causing ADRS 
Drug group N° (%) Rank: Rank by Drugs (N° of Adverse drug reactions 
ADRs Freque- freq- ADRs for each 
t ncy drug uency of causative drug)* 
in class use of 
contrib- drugs 
uted to 
ADR 
Opioids 118 1 1 Morphine (88), Confusion, constipation, 
(16.1) tramadol (53), sedation, dizziness, 
Dihydrocodeine(10) respiratory depression, 
, fentanyl (8), hallucinations ileus, 
codeine(8), hypotension, itching, 
oxycodone (7), nausea, rash, dependence 
pethidine (2) 
Loop 151 
diuretics (20.6) 
Systemic 87 
cortico- (11.9) 
steroid 
2 14 
3 18 
Beta- 85 4 
agonists (11.4) 
(inhaled) 
Penicillins 66 5 
(9.0) 
Oral 72 
anticoagulant (9.8) 
Cefalo- 67 
sporins (9.1) 
=12 
=6 
6 52 
7 10 
Compound 64 8 
analgesics (8.7) 
(with opioid) 
Macrolide 50 9 
antibiotics (6.8) 
8 
29 
Furosemide (123), 
bumetanide (40) 
Prednisolone (67), 
dexamethasone 
(14), 
hydrocortisone 
(11), methyipredni- 
solone (1), 
fludrocortisone (1) 
Salbutamol (85), 
terbutaline (4), 
salmeterol (3) 
co-amoxiclav (34), 
Amoxicillin (24), 
flucloxacillin (15), 
benzylpenicillin (7), 
penicillin v (1), 
ampicillin (1) 
Warfarin (72) 
Ceftriaxone (40), 
cefuroxime (24), 
cefradine (3), 
cefaclor (2), 
Cefalexin (1), 
ceftazidime (1) 
Co-codamol (58), 
co-dydramol (7) 
Erythromycin (34), 
clarithromycin (27) 
Electrolyte disturbances, 
gout, hypotension, ileus, 
nausea, renal failure 
Electrolyte disturbances, 
increased INR, bleeding, 
hallucination, 
hyperglycemia, fracture, 
hypertension, neutropenia, 
candidal infection 
Electrolyte disturbances, 
nausea, tachycardia 
CDT, bleeding, rash, 
nausea, diarrhoea, 
increased INR, candidal 
infection 
Increased INR, bleeding 
CDT, bleeding, increased 
INR, rash, nausea, 
neutropenia, candidal 
infection, worsening renal 
function 
Confusion, constipation, 
hypotension, sedation 
CDT, bleeding, renal 
failure, deranged LFTs, 
diarrhoea, increased INR, 
rash, candidal infection, 
nausea 
Low MWH 50 10 =6 Dalteparin (41), Bleeding, heparin induced 
(6.8) Enoxaparin (12) thrombocytopenia, 
electrolyte disturbances 
Abbreviations: CDT - Clostridium difficile toxin disease; LFTs - liver function tests; INR - international normalised ratio; MWH - molecular weight heparins; t -Often greater than one 
causative drug group per ADR; $- Often greater than one causative drug from group per ADR 
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The most frequent causative drugs relative to usage were anticoagulants 
(warfarin), fibrinolytics (streptokinase) (4 ADRs), unfractionated heparin (3 ADRs), 
loop diuretics and allopurinol (5 ADRs). Drugs which caused ADRs which were 
not prescribed in the sample of non-ADR patients were metyrapone, linezolid, 
procyclidine, atovaquone and daunorubicin (all 1 ADR). Warfarin was the most 
common causative drug relative for use and therefore in-depth analysis of ADRs 
involving this drug are detailed in Figure 3.1. 
Clostridium difficile infection is a common ADR, resolution of which is currently a 
high priority for the NHS, particularly since the Healthcare Commission report 
regarding C. difficile deaths at Maidstone and Tunbridge Wells NHS Trust [189], 
and constipation is among the most frequent ADRs and therefore further details of 
these ADRs are described below: 
3.5.1 Focus on Clostridium difficile 
There were 25 cases of C. difficile classified as an ADR in this study. Of these, 5 
(20%) were linked to death and 13 (52%) directly increased the length of stay, 
resulting in a total of 174 additional days in hospital attributable to C. difficile 
ADRs. Approximately half (12,48%) of these ADRs were possibly avoidable. Of 
the possibly avoidable ADRs 11 involved broad-spectrum cefalosporins. One 
patient received antibiotics from 5 classes (cefalosporin, macrolide, quinolones 
trimethoprim, penicillin) plus a proton-pump inhibitor during a lengthy admission 
with a necrotic heel ulcer. In a separate case, a patient admitted with community 
acquired pneumonia received a cefalosporin, macrolides and broad spectrum 
penicillin within the first 6 days of the admission. The patient's length of stay was 
extended due to diarrhoea, and subsequent dehydration led to acute renal failure. 
This was treated but diarrhoea persisted despite metronidazole and the admission 
continued; the patient died due to ruptured abdominal aortic aneurysm (AAA) on 
day 26 of admission. The AAA was the cause of death, but the patient had been in 
hospital as a result of problems related to C. difficile for 21 days prior to this event. 
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3.5.2 Focus on constipation 
Constipation was the second most common ADR (N=100) in the study population. 
Constipation was defined as "failure of the bowel to open for three consecutive 
days" [190]. Most ADRs relating to constipation were minor, with 83 (83%) having 
no effect on length of stay. Length of stay was increased due to drug-induced 
constipation in 17 (17%) episodes, contributing a total of 68 additional bed days to 
these patient episodes. Opioid analgesia contributed to the majority (N=93,93%) 
of these ADRs, with morphine the most frequently implicated drug, contributing to 
half (N=50,50%) of these ADRs. Prophylactic laxative prescription was 
prescribed, but ineffective in 30 (30%) of patients with constipation. 
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ADRs occurred despite prophylaxis in 67 (9.1 %) cases involving 10 types of ADR 
(constipation (35), electrolyte disturbances (10), renal failure (8), bleeding (5), 
raised INR (3), nausea (2), opioid withdrawal, opioid dependence, oral Candida 
infection, and diarrhoea (all 1)). ADRs (n=156) directly increased length of stay in 
147 (26.8%) patients with an ADR (See Table 3.8), equating to 4.1 % of all 
inpatients and accounting for 934 out of 50145 (1.9%) bed days or 0.25 
days/patient admission episode. 
Table 3.8: ADRs and length of stay (LoS) 
Additional LoS No ADRs Detail of ADRs 
due to ADR (days) (N=156) 
1-3 68 Electrolyte disturbances (13); Bleeding, renal 
failure (9); constipation (8); Nausea (4); 
hypoglycaemia, hypotension, increased INR (3); 
anaemia, bradycardia, opioid toxicity, rash (2); 
anaphylaxis, C. difficile, diarrhoea, gout, 
hyperglycaemia, sedation, neutropenia, urinary 
retention (1) 
4-7 56 C. difficile, constipation (7); hypoglycaemia, 
increased INR (6); Bleeding (5); deranged LFTs, 
electrolyte disturbances, hypotension, renal, 
failure (3); diarrhoea (2); benzodiazepine 
withdrawal, confusion, extra-pyramidal reaction, 
fracture, gout, hyperglycaemia, nausea, opioid 
toxicity, rash, seizures, urinary retention (1) 
8-15 20 Bleeding (5); Renal failure (4); C. difficile, 
constipation, electrolyte disturbances (2); 
confusion, deranged LFTs, diarrhoea, digoxin 
toxicity, urinary retention (1) 
16-30 10 C. difficile (3); Hypoglycaemia, renal failure (2); 
Bleeding, ileus, Lithium toxicity (1) 
31+ 2 Bleeding, C. difficile (1) 
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Multivariable statistical analysis was used to assess the ADR and non-ADR 
groups for probable risk factors for ADRs. Univariable Kaplan-Meier analyses tor 
the two categorical risk factors, gender and ward type, using the 10% sample, 
showed that neither was a significant predictor of time to the ADR episode (log- 
rank p=0.86 and 0.48, respectively). Age was also a non-significant predictor 
(HR 1.00). The only significant predictor from univariable analyses was the 
number of medicines (p < 0.0001; HR 1.14; 95% Cl 1.09,1.20). Multivariable Cox 
regression confirmed these results (Table 3.9), with the number of medicines as 
the only significant predictor. Theretore, on average, each additional medicine 
increases the hazard of an ADR episode by 1.14. There may be a power issue in 
using the 10% sample, since the full dataset showed that both gender and age 
were significant risk factors for the ADR episode (p = 0.001 for both factors; 
respective HR (95% Cl) of 1.33 (1.12,1.59) and 1.01 (1.0,1.01)). Comparing 
these with the 10% sample showed that the mean values from the full dataset 
were contained within the 95% confidence intervals of the 10% sample. 
Table 3.9: Risk factors for adverse drug reaction assessed by 
multivariable analysis 
Factor N Parameter Standard Chi-sq (df Pr >Chi Hazard Ratio 
Estimate Error Square 
Gender 374 -0.026 0.240 0.012 (1) 0.9125 0.974 
(F v M) 
Ward 374 0.101 0.279 0.131 (1) 0.7178 1.106 
Type 
(medical 
v 
surgical) 
Age 374 -0.002 0.007 0.060 (1) 0.8070 0.998 
Number 374 0.130 0.025 26.617 (1) <. 0001 1.138 
of 
medicines 
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3.6 Discussion 
This is the largest prospective study of adverse drug reactions in UK hospital 
inpatients. The data collated suggest that at least 1 in 7 inpatient episodes is 
complicated by an adverse drug reaction. The incidence figure of 14.7% is 
consistent with the pilot study (Chapter 2) [181] and with studies from the 1960s 
which showed that ADRs occurred in 10-20% of inpatients [8,94,95]. However, 
this figure is higher than the 3.5-7.3% incidence suggested in a systematic review 
[92]; this may be explained by the fact that pooling data from ADR studies with 
different designs can be problematical [5,90] as illustrated by the widely differing 
estimates of ADR incidence determined in different studies (from 0.86% [96], to 
37% [98]). In order to improve the accuracy of these assessments, individual 
causality assessments were undertaken using the Naranjo causality assessment 
tool [63]. Causality assessments are difficult, and inter-rater agreement varies 
enormously [52], but the use of published algorithms enabled the investigating 
team to apply consistent criteria to the assessment of cases. The prospective 
nature of this study, and the intensive nature of data collection and follow-up, 
similar in nature to two major recent studies of ADRs causing admission [18,93] 
has aimed to provide an accurate assessment of ADRs in adult hospital inpatients. 
3.6.1 Impact of ADRs on the NHS 
A clear limitation of this study is that it was conducted in one hospital and there is 
likely to be a variation between hospitals due to the differences in the local 
population characteristics and specialties within the hospitals. The patients 
included were from study wards selected as a convenience sample representative 
of the medical and surgical ward ratio in the study hospital, and representative of 
clinical specialties commonly found in most UK NHS acute hospitals (see Table 
3.1). The age distribution of the patients was comparable to figures for all inpatient 
admissions in England in 2006-07 [191] and by including a large sample size 
which was thoroughly assessed, it is thought that the results from this study are 
broadly transferable to the inpatient population as a whole. Intensive care units are 
known to have a higher rate of ADRs [192]. Therefore, specialist units such as 
intensive and critical care units, and the kidney transplant unit were excluded to 
increase the relevance of the results to most UK general hospitals. Hospital 
episode statistics from the Department of Health state that in 2006-7 there were 
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9,133,758 adult admission episodes to NHS hospitals (excluding maternity 
admissions) [191]. There are 126,976 NHS beds in England, with 108,370 
occupied at 85.3% capacity [193]. In this study, 935/50145 (1.9%) bed days were 
due to an ADR. Therefore, using actual bed day data, it can be estimated that 
2059 bed days are due to an ADR at any one time, which is equivalent to roughly 
three 800-bed NHS hospitals at 85% capacity. If this is added to the estimate that 
the equivalent of seven 800-bed hospitals are filled with patients admitted with 
ADRs [18], the combination of ADR-related admissions and ADRs occurring as 
inpatients, lead to the occupancy of ten 800-bed NHS hospitals. The estimate of 
additional bed days is in keeping with the medium to high estimates given by 
Wiffen et al in their systematic review [92]. An accurate assessment of the 
financial cost of these ADRs is difficult, but a crude estimate based on an average 
cost of a bed day in the NHS suggests that the total costs are likely to exceed 
£171 million annually. This is however likely to be an underestimate since the 
direct and indirect costs to patients such as loss of earnings due to extended stay 
or increased morbidity have not been measured, and neither were the costs which 
could be attributed to treating ADRs such as the prescribing of more medicines 
and investigations, and involvement of clinical teams external to the specialty to 
which the patient was admitted, all of which add to the overall ADR burden. Taken 
together with the figure of £466 million for ADR-related admissions [18], it is 
estimated that ADRs cost the NHS in excess of £637 million annually. However, 
the figures provided here need to be interpreted cautiously as they represent an 
extrapolation from one hospital to the NHS without an assessment of the causative 
fractions for the implicated drugs, which is difficult at an individual patient level. 
3.6.2 Implicated drugs and severity of reactions 
The most frequently implicated drugs were opioid analgesics, diuretics, systemic 
corticosteroids, anticoagulants and antibiotics. This is in accordance with several 
other studies of hospital inpatients [10,12,144]. When adjusted for the frequency 
of prescription, warfarin, fibrinolytics and unfractionated heparin were the top three 
causes of ADRs. It is worrying to note that the same drugs, warfarin, loop 
diuretics and opioids, are being consistently implicated in different studies of 
ADRs; this may partly reflect their high usage, but nevertheless suggest that 
lessons have not been learnt from previous studies, and relevant preventive 
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strategies have not been put in place. Figure 3.1 shows us that ADRs caused by 
warfarin administration can be complex, with serious clinical symptoms, and often 
require blood transfusions or vitamin K administration. Interacting medicines are 
frequently involved. It also highlights that ADRs can occur even when the INR is in 
range highlighting the need for close monitoring of patients with warfarin and 
better prescribing with regard to interacting medicines and the prescription of new 
drugs. It is clear that current work by the NPSA and in the research community to 
manage warfarin more appropriately is necessary. 
Constipation is a frequently occurring ADR with laxative prescription being a 
commonly accepted method of prophylaxis [184]. The majority (70%) of 
constipated patients had received no prophylaxis and subsequently suffered 
constipation. However, a significant minority of those constipated had received 
prophylactic laxative treatment unsuccessfully, leading us to question the value of 
laxatives as prophylactic treatment against constipation, and the choice and 
dosage of prophylactic therapy given (see Chapter 7). 
Approximately three quarters of adverse drug reactions were scored at level 3 or 
below on the Hartwig scale (Table 3.3) and were therefore relatively minor, 
although all required intervention. These interventions ranged from stopping the 
causative medicine(s) to administration of specific antidotes, for example, 
naloxone for opioid-induced respiratory depression. The remaining ADRs were 
sufficiently serious to result in an increase in length of stay or admission to 
intensive care, and in some cases, death. The assessment of the cause of death 
and in particular whether it is due to the underlying disease or due to an ADR, can 
be extremely difficult; in our study, careful assessment showed that one fatality 
was due to an ADR (classified as definitely avoidable), and resulted from a gastro- 
intestinal (GI) bleed involving prescription of the combination of diclofenac and 
dalteparin. 
Reducing ADR burden on length of stay is an important consideration for the 
patient and their carers, and also for the hospital in the current UK political climate. 
The impact of ADRs on length of stay is shown in Table 3.8. Interestingly, the 32 
ADRs that increased patient stay by 8 days or more were responsible for more 
bed days than the 124 ADRs responsible for up to an additional week in hospital. 
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Bleeding, renal failure and C. difficile were responsible for more than half of these 
high impact ADRs suggesting that focussing on reducing these three types of ADR 
may be a logical start to attempt to reduce the ADR burden. 
3.6.3 Prevention of adverse drug reactions 
In this study, just over half of the ADRs were deemed avoidable, slightly less than 
the 60-70% suggested in the literature [13,18,93,139]. Given the considerable 
burden of ADRs, there is a need to put into place preventive strategies. Given the 
wide variety of drugs implicated, and the huge array of ADRs that were identified 
affecting almost every organ system in the body, prevention is likely to require 
complex multi-faceted intervention strategies. Identification of risk factors may 
allow targeting of these interventions to certain high risk groups. In our study, 
increasing age, admission to a medical ward, female gender, and number of 
regular medicines were identified as risk factors. Univariable and multivariable 
analysis showed that the only significant risk factor was the number of medicines 
the patient was taking, which may in itself be a reflection of age, gender and status 
as a medical patient. This is consistent with a number of previous studies [110, 
194,195]. Given the increasing age of the population, the high number of 
potential drug-drug interactions demonstrated in this study, and the trend towards 
polypharmacy, even in younger patients, the problem of ADRs is likely to remain a 
significant, if not increasing burden on our hospitals. 
Computerised prescribing and monitoring systems [11,159,160], the presence of 
pharmacists on ward rounds [170,171], the need for better monitoring [169], and 
enhanced education of prescribing, leading to error reduction [173], are amongst 
the possible intervention strategies that have been suggested to be important in 
reducing the burden of ADRs. There is however a need for further research in this 
area, not only for the development of a robust evidence based to allow for 
prevention of ADRs, but also in the implementation of these strategies into hospital 
healthcare systems. Although it would be prudent to initially focus on the more 
serious ADRs, it is important to remember that even so-called non-serious ADRs, 
for example constipation from using opioids, can have a significant impact on the 
patient's quality of life, and also require the development of preventive strategies. 
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The design has clear limitations. Deciding if a patient has experienced an ADR or 
not is often difficult as ADRs can mimic disease, and vice versa, and a patient's 
condition can change rapidly as an inpatient. In order to ensure those ADRs 
identified could be accurately attributed to the drug two assessors examined each 
report independently and disputed decisions were discussed with a Professor of 
Clinical Pharmacology. The initial inter-rater agreement between ED and CG for 
use of the Naranjo causality algorithm was fair [196]. This agreement is lower than 
expected from the results achieved in the paper detailing algorithm design [63], but 
the discrepancies may be explained by the fact that this study used reports 
generated from the observational study as opposed to published case reports, 
although this warrants further investigation. 
Patients were included once they reached the ward, thereby limiting the study to 
those patients who required transfer beyond the hospital assessment units. This 
may have resulted in a sample bias towards the more unwell patients in the 
hospital. Also, those admitted and discharged over a weekend would be excluded 
and day cases may have been omitted due to unavailability of patient details on 
the administration system when records were checked once daily during data 
collection. All medicines for one tenth of patients admitted was a practical quantity 
of data which could be could be recorded within the time and personnel restraints 
of this study. This was due to the need to manually check handwritten patient 
charts for all medicines and record the data. If electronic prescribing/administration 
systems had been in place, it would have been possible to record all medicines 
prescribed to all patients enabling more comprehensive background data to be 
compiled. 
3.7 Conclusion 
To conclude, this study shows that ADRs are a significant problem in hospital 
inpatients, contributing to morbidity and mortality and resulting in considerable 
financial burden. Over half are definitely or potentially avoidable, and steps should 
be taken to introduce strategies to reduce their impact. 
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Chapter 4: Interpreting adverse drug reaction (ADR) 
reports as hospital patient safety incidents 
4.1 Introduction 
The National Patient Safety Agency (NPSA) is a Special Health Authority in the 
National Health Service (NHS) and was set up in 2001 in response to two reports 
on patient safety in the NHS: An Organisation with a Memory [197] and Building a 
Safer NHS for Patients [198]. The role of the NPSA is to collect, analyse and 
respond to adverse events in the NHS, identifying risks and providing solutions to 
improve patient safety in the organisation [199,200]. Variations in taxonomy 
between countries, organisations and individuals result in different estimates of 
incidence of hospital patient safety incidents [201]. However, a commonly-quoted 
estimate from the UK suggests that approximately 11 % of patients experience an 
adverse event in hospital [199,202], similar to the figure shown in a more recent 
US study [203]. 
The NPSA includes adverse drug reactions (ADRs) as a reporting category in 
medicines-related patient safety incidents [204,205] although a recent NPSA 
document, Safety in doses: medication safety incidents in the NHS [206], states 
that: 
"Where medicine has caused harm to a patient but no error took place, the 
incident is judged to be `non-preventable' and is usually called an adverse drug 
reaction (ADR). For example, a patient experiencing a side effect to a medicine for 
the first time, which could not have been predicted. Data on ADRs are not 
collected by the NPSA, but these should be reported to the MHRA 
Pharmacovigilance 'Yellow Card' System. " 
The above definition of an ADR contrasts with ones from the ADR literature which 
include preventable and non-preventable ADRs [9,16], although the same NPSA 
report also prominently uses data from the Liverpool ADR studies to emphasise 
the scale of medicines-related patient safety incidents [18,181,206]. Using ADR 
data in this way may considerably alter estimates of hospital incidents such as 
those described by Vincent et al [202]. These inconsistencies may potentially 
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have a negative impact on reporting of ADRs due to the confusion surrounding 
which organisation ADRs should be reported to, depending on whether or not the 
incident was regarded as avoidable. Reporting of ADRs via Yellow Cards to the 
Medicines and Healthcare products Regulatory Agency (MHRA) in the UK has 
been encouraged since 1964 although under-reporting remains a long-standing 
problem. For example, the Liverpool ADR admission study generated 
approximately 980 yellow cards from two hospitals in six months. These were 
reported to the MHRA, and of these, over 70% were categorised as being either 
definitely or possibly avoidable [18]. It is also not clear from the NPSA definition 
whether the ADRs classified as being possibly avoidable should be in the same 
category as those that are definitely avoidable. 
However, since many ADRs are considered to be preventable and are in effect 
patient safety incidents, the issues raised in the NPSA alert offer another 
opportunity to review adverse drug reactions, and for organisations, an opportunity 
to look at the burden of ADRs in manner that fits with their more commonly used 
reporting systems and allows comparison to other patient safety incidents. Thus, 
the purpose of this study was to take a cohort of patients who had experienced an 
ADR, and categorise the incidents in line with the methods suggested by the 
NPSA and those commonly used by NHS trusts in the UK. 
4.2 Aim 
To classify adverse drug reactions already identified through a large prospective 
study according to NPSA Incident grading systems [15,16] and to discuss the 
suitability of the system for grading and reporting ADRs. 
4.3 Objectives 
1. To assess each ADR for its impact on individuals and the organisation 
according to the NPSA grading system. 
2. Compare the incident gradings in the context of ADR avoidability. 
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4.4 Methods 
All 733 adverse drug reactions identified in a six-month prospective study of 3695 
inpatient episodes (Chapter 3) at the Royal Liverpool University Hospital were 
included in this analysis. These ADRs were assessed according to causality, 
severity and avoidability algorithms from the ADR literature [63,83,88] as well as 
eligibility for reporting to the MHRA [85]. The adverse drug reactions were 
reclassified by a research pharmacist (ED) according to their impact on the patient 
and their impact on the organisation, and recorded on the readmissions study 
assessment form (Appendix 8). Data were then manually entered into a Microsoft 
Access database. 
" The impact of the ADR on the patient was classified according to 
the grading system determined in the National Patient Safety agency 
document `Seven steps to patient safety' (Table 4.1) [207] ; and 
" the organisational impact was determined using the framework defined in 
the Department of Health document `Doing Less Harm' (Table 4.2) [208]. 
The organisational impact risk matrix employs a four-level traffic light system 
based on the likelihood of recurrence and potential impact on the organisation if 
the incident recurs. The draft document 'Doing Less Harm' [208] has been 
superseded by the 'Seven steps to patient safety' guidance [207], and the NPSA 
do not require the impact on the organisation to be reported to them. However, 
many organisations continue to use the risk matrix grading systems, and follow the 
same principles as the 'Doing Less Harm' guidance. Therefore this study will 
assess the ADRs for impact on the organisation according to the published matrix 
system. 
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Table 4.1: NPSA terms and definitions for grading patient safety 
incidents [207] 
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Table 4.2: Potential future risk to patients and the Organisation [208] 
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4.5 Results 
All inpatient adverse drug reactions (733,100%) identified in a six-month 
prospective study of 3695 inpatient episodes at the Royal Liverpool University 
Hospital were assessed. Data from this study showed that 545 (14.7%) patient- 
episodes resulted in ADRs, that 391 (53.3%) ADRs were definitely or possibly 
avoidable, and that 226 (30.1%) of the ADRs were suitable for Yellow Card 
reporting to the MHRA [85]. 
The impact on the patient according to the "Seven steps to patient safety" 
document criteria [207] is shown in Table 4.3. 
Table 4.3: Impact of ADRs on the patient 
Impact on patient No of ADRs (n=733) No of Yellow 
Cards (n=226) 
Low (minor treatment) 537 (73.3%) 53 (23.5%) 
Moderate (moderate increase in 181 (24.7%) 158 (69.9%) 
treatment, no permanent harm) 
Severe (permanent harm) 14(l. 91%) 14 (6.2%) 
Catastrophic (direct cause of l (O. 14%) 1 (0.4%) 
death) 
Of the 14 'severe' ADRs, one was a case of Type 2 diabetes mellitus resulting 
from prednisolone use. A further 13 cases were linked to deaths, with drug- 
induced renal impairment (n=7), Clostridium diffrcile infection (n=5), and ischaemic 
bowel (n=1) as contributory factors to death, although these ADRs were not 
judged to be the direct causes of death. In the 'catastrophic' ADR, the patient 
death was directly related to a drug-induced gastro-intestinal bleed. According to 
NPSA guidance for 'low' and 'moderate' impact incidents, organisations should 
record data, investigate demographics and contributory factors when possible, and 
conduct root-cause analysis where themes emerge. For 'severe' and `catastrophic' 
incidents, root-cause analysis including involvement of the patient or carer should 
be conducted [207]. 
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The results of the assessment of ADRs on the organisation are shown in Table 
4.4. 
Table 4.4: Impact of ADRs on the organisation [208] 
According to the definition of ADR used for the prospective study [16], there were 
no ADRs that caused 'no harm' since all had an adverse effect. In addition, all 
ADRs included in this study were recognised from the BNF [183] or Summary of 
Product Characteristics [182] for each product. This indicates that all ADRs are 
likely to recur in the hospital. Consequently, no ADRs were classified as 'green' or 
`very low risk'. 
The ten most frequent ADRs and their organisational impact are shown in Table 
4.5. 
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Table 4.5: Most frequent ADRs and organisational impact 
ADR Impact on Organisation 
Insignificant Minor Moderate Major 
Electrolyte disturbances 147 (87.5%) 19 2 (1.2%) 0 (0.0%) 
(11.3%) 
(n=168) 
Constipation (n=100) 79 (79.0%) 19 2 (2.0%) 0 (0.0%) 
(19.0%) 
Increased INR (n=54) 40 (74.1%) 14 0 (0.0%) 0 (0.0%) 
(25.9%) 
Bleeding (n=53) 21(39.6%) 22 8 (15.1%) 2 (3.8%) 
(41.5%) 
Renal impairment (n=45) 21(46.7%) 18 4 (8.9%) 2 (4.4%) 
(40.0%) 
Hypotension (n=35) 29 (82.9%) 6(17.1%) 0 (0.0%) 0 (0.0%) 
Candidal infection (n=33) 32 (97.0%) 1 (3.0%) 0 (0.0%) 0 (0.0%) 
Hypoglycaemia (n=32) 18 (56.3%) 12 0 (0.0%) 2 (6.2%) 
(37.5%) 
Nausea (n=29) 23 (79.3%) 6 (20.7%) 0 (0.0%) 0 (0.0%) 
Clostridium difficile infection 0(0.0%) 18 3(12.0%) 4 
(n=25) (72.0%) (16.0%) 
From the results, it is clear that the ADRs that cause incidents of greater 
significance relate to bleeding, renal impairment and Clostridium difficile infection. 
Tables 4.6 and 4.7 describe the avoidability of the ADRs according to the Hallas 
avoidability criteria [88] in terms of the impact on the patient (Table 4.6) and in 
terms of the impact on the organisation (Table 4.7). It can be seen that only 47 of 
the adverse reactions would fall into the category of medication errors according to 
the NPSA definition if the correlation was restricted to those cases where the ADR 
was definitely avoidable. 
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Table 4.6: Impact on patient and avoidability 
Definitely Possibly Avoidable Unavoidable 
Avoidable n=344 (%) n=342 (%) 
n=47 (%) 
Catastrophic 1(2.1%) 0 (0.0%) 0 (0.0%) 
Severe 1 (2.1%) 9 (2.6%) 4 (1.2%) 
Moderate 9(19.1%) 92 (26.7%) 80 (23.4%) 
Low 36 (76.6%) 243 (70.6%) 258 (75.4%) 
None 0 (0.0%) 0 (0.0%) 0 (0.0%) 
Table 4.7: Impact on organisation and avoidability 
Definitely Possibly Avoidable Unavoidable 
Avoidable n=344 (%) n=342 (%) 
n=47 (%) 
Catastrophic 0 (0.0%) 0 (0%) 0 (0.0%) 
Major 0 (0.0%) 7 (2.0%) 5 (1.5%) 
Moderate 1(2.1%) 11(3.2%) 13 (3.8%) 
Minor 14 (29.8%) 103 (29.9%) 71(20.8%) 
Insignificant 32 (86.5%) 223 (64.8%) 253 (34.5%) 
Table 4.8 describes the frequency and nature of each ADR in terms of both patient 
and organisational impact. 
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Table 4.8: Impact of ADR on both patient and organisation 
Patient 
Impact 
Organisation W -of f 
impact reactions 
(%) 
Low Insignificant 489 
(66.7%) 
Adverse drug reactions n= 733 
Electrolyte disturbances (142); constipation 
(78); increased INR (40); candidal infection 
(32); hypotension (30); nausea (22); rash (23); 
hypoglycaemia, renal impairment (18); bleeding 
(15); diarrhoea (11); deranged LFTs (9); opioid 
toxicity, sedation (5); hallucination, itching (4); 
confusion, tachycardia, toxic drug level (3); 
anaemia, chest discomfort, dizziness, 
headache, heparin induced thrombocytopenia, 
opioid withdrawal (2); bone marrow 
suppression, bradycardia, chest pain, cough, 
digoxin toxicity, dyspepsia, ECG changes, 
heartburn, hypertension prolonged 
prothrombin time, urinary retention, wheeze (1) 
Low Minor 48 Clostridium difficile (6); increased INR, opioid 
(6.5%) toxicity (4); abdominal pain, digoxin toxicity, fall, 
hallucination, hyperglycaemia, hypoglycaemia, 
opioid withdrawal (2); bleeding, constipation, 
electrolyte disturbances, renal impairment (3); 
candidal infection , confusion, diarrhoea, ischaemicfoot, nausea, rash, sedation (1) 
Moderate Insignificant 118 Electrolyte disturbances (22); constipation (15); 
(16.1%) bleeding (14); renal impairment (12); increased 
INR (9); hypoglycaemia (8); deranged LFTs (7); 
hypotension, nausea (5); diarrhoea, urinary 
retention (3); anemia, bradycardia, Clostridium 
difficile (2); arthralgia, confusion, gout, 
neutropenia, rash, sedation, seizures, swollen 
lips (1) 
Moderate Minor 51 Bleeding (15); Clostridium difficile (10); renal 
(7.0%) impairment (4); opioid toxicity (3); 
hypoglycaemia (2); constipation; confusion, 
diarrhoea, digoxin toxicity, electrolyte 
disturbances, extra-pyramidal reaction, fluid 
retention, fracture, gout, hyperglycaemia, ileus, 
increased INR, nausea, psychosis(1) 
Moderate Moderate 2 Psychosis, bleeding (1) 
(0.3%) 
Moderate Major 10 Bleeding, Clostridium difficile, hypoglycaemia, 
(1.4%) renal impairment (2); ileus, lithium toxicity (1) 
Severe Insignificant 3 Renal impairment (3) 
(0.4%) 
Severe Minor 6 Clostridium difficile, renal impairment (2); 
(0.8%) hyperglycaemia, ischaemic bowel (1) 
Severe/ Moderate 3 Bleeding, Clostridium difficile, renal impairment 
(0.4%) (1) 
Severe Major 2 Clostridium difficile (2) 
(0.3%) 
Catastrophic Moderate 1 Bleeding (1) 
(0.1%) 
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4.6 Discussion 
Spontaneous ADR reporting rates are low [29] and this limits the ability to 
accurately assess the burden of ADRs and their impact. It is interesting to note 
that there is a core list of medicines which most commonly cause ADRs of all 
severities [143]. Despite this, however, little has changed to improve the 
prescribing and monitoring of these drugs and thereby reduce the incidence of 
ADRs [18]. 
It was possible to classify all ADRs included in this study according to NPSA 
guidance and with the organisational risk matrix used by many Trusts. From the 
data available on individual yellow cards, it is often not possible to undertake a 
detailed assessment of the individual circumstances surrounding ADRs, which 
may be possible at a local level where incidents are collected and reviewed. 
Theoretically, if large numbers of ADRs were analysed using techniques such as 
root cause analysis to evaluate systems and processes, new interventions to 
prevent serious and in some cases, fatal ADRs could be identified. This approach 
may also give organisations new insight into the potential burden of ADRs shown 
in Chapters 2 and 3 of this thesis [18,181], and encourage them to take a more 
robust approach to introducing proactive interventions to prevent or react to the 
occurrence of ADRs and importantly, in a manner that is relevant to their own 
organisation. However, the results of this study suggest that root-cause analysis 
would be unnecessary for the vast majority of ADRs and thus, the value of using a 
patient-safety incident reporting system over and above that of the Yellow Card 
Scheme for ADRs is not likely to be great. Nevertheless, the NPSA 
recommendation that severe or catastrophic incidents should be analysed using 
root cause analysis [207] usually involves senior managers within organisations, 
and this may be a method by which to raise the profile of ADR reporting in NHS 
Trusts. 
Although ADRs are a common occurrence, affecting approximately 15% of 
inpatient episodes (Chapter 3) and causing 6.5% of admissions [18], the majority 
of ADRs had little impact on the patient or the organisation according to the 
categorisation recommended by the NPSA. This is a clear limitation of this 
classification as it ignores the patient perspective, especially effects on quality of 
life. It is however important to note that 25% of ADRs increased the length of stay 
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or level of care. Thus, for NHS Trusts, an estimated 2.5% of their patient 
population will have an ADR which falls in this category. All hospitals are paid for 
their activity, and this percentage represents a significant expenditure according to 
payment by results. In addition, given the incidence of hospital acquired infections 
and the publicity surrounding this, it is noteworthy that C. difcile infection provided 
the highest number of incidents with a major impact on organisations. This is in 
line with the recent Maidstone and Tunbridge Wells reports which received a 
significant level of publicity both in the medical and general media [189,209]. 
Many hospitals are conducting investigations into C. difficile infections to reduce 
their frequency, but this is more related to adverse publicity surrounding hospital 
acquired infections, rather than in an effort to reduce ADRs. 
Consistency between hospitals in using the "Doing Less Harm" system [208] for 
grading the impact of events on organisations was reported as being difficult to 
achieve. The revised guidance from the NPSA in "Seven steps to patient safety" 
[207] does not require a patient safety incident to be graded for potential impact, 
likelihood of recurrence, and impact on organisations. This is reasonable since 
the consistency of the reporters' interpretations would not be guaranteed and 
assessing the likelihood of recurrence can only be based on local demographics 
and knowledge, which would be meaningless nationally [207]. Thus, many NHS 
organisations still collect these data locally which is why this study assessed the 
organisational impact of the ADRs studied. In the context of this, when initially 
identified, each ADR was assessed by at least two investigators (Chapter 3). 
However, for this study only one investigator re-assessed the ADRs according to 
the NPSA systems. This is a limitation of the study as interpretation of events by a 
sole investigator is open to scrutiny, and it has been suggested that multiple 
methods of data collection are necessary to detect actual and potential adverse 
events [210,211 ]. 
Incident reporting within organisations is also variable [210] and inconsistencies in 
reporting are also likely for the impact of incidents on the individual although 
national data are still collected regarding these aspects of patient safety incidents. 
A study of intra-hospital variations in incident reporting supported previous findings 
that doctors are more committed to 'closed' peer-group collegial forms of quality 
improvement, which exclude non-medical staff, showing that participation in 
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reporting was greater when reporting was based within rather than outside the 
medical department [210]. This would suggest that doctors are less likely to report 
ADRs to a hospital management-led risk management. Research regarding ADR 
reporting has shown that between 85 and 98% of doctors, depending on the 
country, never report an adverse event to their national authority [29]. The 
perception of hospital incident reporting systems are also strongly linked with 
nurse-reporting of incidents such as `needle-stick' injuries and falls [210] and a 
cultural change in reporting would be required to ensure consistent reporting of 
patient safety-incidents" such as those involving ADRs which may lead to in-depth 
discussion of clinical-decision making. 
ADR definitions are inconsistent between the MHRA and the NPSA, with the 
NPSA asserting that ADRs are not preventable [206], leaving approximately 50% 
of the ADRs from this study classifiable by the NPSA as medication errors and not 
ADRs. However, it is also unclear from the NPSA criteria as to whether, possibly 
and definitely avoidable ADRs should be treated in the same manner. This study 
reports that relatively few ADRs are classified as 'definitely avoidable', although 
almost half are 'possibly' avoidable. From the ADR data collected, only two ADRs 
had a major or catastrophic effect on the patient and were 'definitely avoidable', 
and thus would be certain to require investigation by root-cause analysis according 
to the NPSA specifications. Even when using published guidance, such as the 
Hallas criteria [88], the judgement of whether an ADR is 'definitely', 'possibly' 
avoidable, or indeed unavoidable, is open to interpretation. Overall, the different 
definitions used by the two Government organisations is likely to lead to confusion. 
Indeed, this is acknowledged by the NPSA, and the importance of the NPSA and 
MHRA working together to share ADR data has been highlighted [206]. Collation 
of data of ADRs currently perceived as unavoidable ADRs is also important, as 
assessment of trends in the types of patients experiencing these ADRs may, in the 
future, contribute to a method for avoiding these ADRs. Definitions of patient 
safety incidents can have profound implications for a hospital's capacity to gather 
information about patient safety [212]. Healthcare professionals are unlikely to 
report a large number of incidents, but even less likely to report the same incident 
via two separate mechanisms, and confusion regarding ADR definitions and the 
use of ADR data is a barrier to progress in this important area. Clear guidance 
from the NPSA and MHRA is needed to ensure that healthcare professionals have 
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a coherent message as to the appropriate actions to be taken in response to the 
occurrence of an ADR. 
4.7 Conclusion 
Classification of ADRs according to NPSA guidance offers a different way of 
viewing the impact of ADRs on patients and on organisations, and root-cause 
analysis of ADRs may provide useful new strategies for reducing the number of 
ADRs and responding to serious ADRs for example, rapid referral or closer 
monitoring. A consistent message however needs to be sent out to prospective 
reporters of the burden caused by ADRs, the need for reporting using established 
systems (e. g. Yellow Cards) and the need for continued vigilance in prescribing 
rationally, and preventing and detecting ADRs. Whether the NPSA can provide 
something that the MHRA cannot requires some clarity and promotion of dual 
methods for this purpose may undermine reporting through the established Yellow 
Card system. Clearly, any change in the manner in which ADRs are dealt with in 
regulatory terms would be subject to some political debate and collaboration 
between the NPSA and the MHRA. 
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Chapter 5: Emergency readmissions to hospital due to 
adverse drug reactions: A retrospective study 
5.1 Introduction 
Adverse drug reactions are a burden to hospital patients; a Liverpool study 
showed that 6.5% of hospital admissions are due to ADRs [18], while the inpatient 
study demonstrated that almost 15% of patients experience an ADR during their 
admission (Chapter 3). There has however, been little research conducted into 
readmissions to hospital due to ADRs. This is particularly important in the UK as 
NHS organisations are assessed for their readmission rates as part of their 
performance indicators. A German study from 2004 found that 37% of admissions 
to internal medicine wards were readmitted, most within six weeks of discharge, 
but ADR occurrence in previous admissions did not increase risk of ADR in 
subsequent admissions [150]. Importantly, Dormann et al noted that due to the 
high turnover of inpatients, ADRs caused by in-house therapy are not entirely 
distinct from community acquired ADRs [150]. Recurrent ADRs causing multiple 
admissions for the same patient were found to be increasing in an Australian 
study, and were responsible for one third of ADR-related admissions [101]. 
Nausea and vomiting, haemorrhage with 'anticoagulants, drug-induced 
osteoporosis, and `poisoning' by cardiovascular agents, were the most common 
ADRs causing readmission [101]. 
Possible problems that might result in ADR-related readmissions might include 
failure to optimally titrate drugs, failure to adequately monitor biochemical or 
haematological markers following changes in, or additions to drug therapy, and the 
possibility of interactions which may not become manifest until the patient has 
been discharged. 
With the importance of readmission rates primarily in terms of patient care, but 
also in achieving governmental targets, it is important to identify strategies to 
reduce the incidence of readmission to hospital. This study will assess the rate of 
emergency readmission to hospital within one year to hospital due to drugs 
prescribed in the initial (index) admission. The one-year time period enabled the 
identification of ADRs which may not be immediately apparent following 
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commencement of new medicines. As 28-day readmission is an NHS 
Performance Indicator [213], this time period was also examined. This study aimed 
to distinguish ADRs that originated in hospital from those originating elsewhere, 
and potentially identify which of these ADRs, and subsequent admissions, are 
preventable in secondary care. 
5.2 Aim 
To evaluate the contribution of adverse drug reactions (ADRs) to readmission 
rates in hospital. 
5.3 Objectives 
1. To assess the incidence of readmission within 1 year for 1000 patients 
admitted to RLBUHT. 
2. To assess the incidence of readmission within 28 days for 1000 patients 
admitted to RLBUHT. 
3. To assess the number of readmitted patients, which were readmitted due to 
ADRs for both the 1 year and 28 day time-periods. 
4. To assess the whether prescription of the causative drugs for readmission 
ADRs originated in the index admission 
5. To conduct a causality, severity and avoidability assessment for each 
reaction 
6. To classify the mechanism (NB) of each reaction 
7. To identify the causative drugs for ADRs 
8. To propose risk factors for readmission due to ADRs 
9. To suggest possible methods of prevention of readmission due to ADRs 
5.4 Methods 
The first 1000 patients initially admitted to 12 (9 medical, 3 surgical) wards from 
27th June 2005 were included in the study. If they were readmitted within 12 
months of discharge from their initial (index) admission, the cause of their 
readmission was assessed. As a secondary analysis, the readmission rate within 
28 days of discharge was also calculated. These patients were part of a large 
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study of adverse drug reactions in hospital inpatients (Chapter 3). Data on whether 
or not the patients had an ADR during their index admission was obtained from 
Chapter 3. Admission and discharge data were extracted from the hospital PAS 
system with the assistance of the RLBUHT Audit Department using InfoCom and 
Microsoft Access. A research pharmacist (ED) conducted a retrospective casenote 
review examining the clinical information available for evidence of ADRs relating to 
readmission. Data was collected manually using the 'Readmission Assessment 
Form' (Appendix 8) and transferred to a Microsoft Access database. An adverse 
drug reaction was defined according to the definition of Edwards and Aronson [16]. 
This definition includes all doses prescribed clinically, but is intended to exclude 
accidental or deliberate overdose. An ADR related re-admission was defined as: 
An ADR, which is the reason for, or contributes to the admission to hospital of a 
patient in the defined cohort. Adverse drug reactions corresponded with those 
listed for each drug in their Summary of Product Characteristics [182] and the 
British National Formulary [183]. 
The reasons for index admission and subsequent readmission(s) were recorded 
and the readmissions were coded according to the rationale given in Table 5.1. 
Table 5.1 Reasons for index admission and subsequent readmission(s) 
Category Reason for readmission 
A Manifestation of same disease state as 
index admission 
B Manifestation of different disease state 
to index admission 
C Social Issues 
D Other (e. g. rehabilitation) 
The causative drug for the ADR was then classified, depending on the origin of its 
prescription, according to the criteria in Table 5.2. 
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Table 5.2: Classification of Readmission ADR 
Category Description 
A Causative drug was initiated during the index admission 
B Causative drug had dose changed during the index 
admission 
C Causative drug continued unchanged during the index 
admission 
D Causative drug prescribed/ dose changed elsewhere since 
the index admission 
Suspected ADRs were analysed for causality using the Naranjo algorithm [63], 
while severity was assessed using an adapted Hartwig scale [83] as used in 
previous chapters. Avoidability was determined using the criteria outlined by 
Hallas et a/ [88], and suitability for yellow card reporting using the criteria set out 
by the Medicines and Healthcare Regulatory Authority (MHRA) [85]. All ADRs 
were initially assessed by the research pharmacist (ED), and a co-investigator (a 
Director of Pharmacy at an NHS Trust with previous experience of using this 
methodology); consensus was agreed between the investigators as to the 
appropriate final scoring for the ADRs. The ADRs were also classified as either a 
Type A reaction, i. e. predictable from the drug's pharmacology, or Type B reaction, 
that is, not predictable from the known pharmacology of the drug [20]. 
Approval for the study was obtained from the Trust Audit Department; Ethics 
Committee approval was sought but was not required. Statistical analysis was 
performed using StatsDirect version 2.6.2 and P values of <0.05 were interpreted 
as statistically significant. 
5.5 Results 
Of the 1000 patients included in the study, 955 (95.5%) were assessed for 
readmission (45 (4.5%) died during their index admission). Of these, 403 patients 
(40.3%) were readmitted to the hospital in the year following the index admission. 
The patients' demographic details are shown in Table 5.3. 
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Table 5.3: Demographic data - Readmitted vs. Not readmitted patients 
Variable Overall Readmitted Not P Value 
(N= 955) (N=403) Readmitted (Readmitted 
(N=552) vs Not 
Readmitted) 
Age (Median, 62 years 68 years 56 years 
(Q1-Q3)) (42-76) (47-79) (39-74) <0.0001 
Sex (% Male) 453 199 254 >0.3 
(47.4%) (49.3%) (46.1%) 
Type of patient 679 316 363 <0.0001 
(medical or surgical) (71.1%) (78.4%) (65.8%) 
at index admission 
(% medical) 
Figure 5.1 shows ADR prevalence at admission and at readmission for the 955 
patients who were discharged from their index admission. Using this data, 73 
patients of the 403 readmitted (18.1%), had at least one ADR related readmission. 
However, the outcome was unknown for 100 patients. If the patients with unknown 
outcomes are excluded, 73 of 303 (24.1%) patients had one or more ADR related 
readmissions within a year of discharge from the index admission. 
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Figure 5.1: Flow chart showing numbers of patients with ADRs during 
index admission and those readmitted within one year of discharge 
from index admission (Patient Level Data) 
r "N 
Patients admitted to selected wards 
as index admission i 
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Patients who experienced ADRs during their index admission did not have a 
significantly increased risk of being readmitted to hospital than those who did not 
experience an ADR during their index admission (77/163 (47.2%) vs 326/792 
(41.2%) X2 = 2.05, P= 0.15). Similarly, there was no significant difference for 
readmission ADR rate for patients who experienced an ADR and those who did 
not during the index admission (16/163 (10.5%) vs 57/792 (7.2%), X2 = 1.31, P= 
0.25). Adjusting the results for patients with unknown outcomes produced similar 
results. 
It is possible to calculate the incidence of readmissions using another approach. 
Figure 5.2 shows the incidence of readmissions for the 1000 patients included in 
the study at index admission, and details the prevalence of missing data for 
retrospective follow-up. A total of 950 readmissions were identified in the 403 
patients who were readmitted to hospital. The median time to the first readmission 
was 65 days (Q1-Q3 22-154 days). The number of readmissions for individual 
patients ranged from 1 to 28, (median 1 (Q1-Q3 1-3 readmissions)). Using the 
data from Figure 5.2, it is shown that of the 403 patients readmitted to the RLUH 
within one year, there were 290 (72.0%) patients for whom all ADR related 
readmission data were available. Of these, 60 (20.8%) patients had one or more 
readmissions relating to an ADR within one year of discharge. 
There are therefore a number of ways to estimate incidence with this data, each 
giving slightly different incidence figures. However, from these data it can be 
concluded that approximately one in five readmitted patients are readmitted due to 
ADRs. 
Within 28 days of the index discharge, 121 patients (12.7%) were readmitted. 
Complete data for these admissions was available for 100 (83%) patients, and 23 
(23.0%) of these patients experienced an ADR- related readmission in this time- 
period. 
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Figure 5.2 shows that there were 669 readmissions which were assessable for 
ADR data. The reason for readmission and number of ADRs identified for these 
readmissions are shown in Table 5.4. 
Table 5.4: Reasons for readmission and ADRs 
Readmission 
Code 
Reason for 
readmission 
No of readmissions 
(N=669) 
ADR related 
readmission 
(N=86) 
A Manifestation of same 312 (46.6%) 25(29.1%) 
disease state as index 
admission 
B Manifestation of 333 (49.8%) 58 (67.4%) 
different disease state 
to index admission 
C Social Issues 4 (0.6%) 1 (1.2%) 
D Other (e. g. 1 (0.1%) 0 (0.0%) 
rehabilitation) 
U Unknown reason for 19 (2.8%) 2 (2.3%) 
index admission 
From available data (Figure 5.2), patients readmitted due to ADRs had a median 
age of 74 years (Q1-Q3,61-82 years). A total of 30 of 403 males (7.4%), and 43 of 
451 (9.5%) females were readmitted due to ADRs, (X2 = 1.17, P>0.1). Median 
length of stay for index admission was not significantly different between those 
readmitted due to ADRs (10 days, Q1-Q3,8-16 days) and those not readmitted 
due to ADRs (9 days, Q1-Q3,5-16 days). 
A total of 91 ADRs were identified in 73 patients, in 86 readmissions. ADRs were 
directly responsible for admission in 67 of 669 assessable readmissions (10.0%), 
and contributed to readmission in 19 (2.8%) cases. 
Of the 403 patients readmitted during the year following the index admission, 56 
(13.9%) died following a readmission to hospital. Of the 344 patients for whom 
data on at least one readmission are available (See Figure 5.2), 13 (3.8%) died 
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following an ADR related readmission. The median length of stay for readmissions 
directly resulting from ADRs was 8 days (Q1-Q3,3-14days). 
The majority of ADRs (N= 88,97%) were Type A ADRs [20]; ADRs occurred 
despite prophylactic treatment in 19 (20%) of cases. These ADRs were bleeding 
(10), constipation (3), gastritis (2), C. difficile infection (1), fractures (1), gastric 
ulcer (1), and seizure (1). Drug-drug interactions contributed to 38 (42%) ADRs, of 
which 36 (95%) were pharmacodynamic drug-drug interactions. The two 
pharmacokinetic interactions involved warfarin and amiodarone causing an 
increase in International Normalised Ratio (INR), and warfarin and erythromycin 
causing epistaxis (also with increased INR). 
Table 5.5 shows the Adapted Hartwig Scale [83] and describes the results of the 
severity assessment for the 91 ADRs identified and the inter-rater reliability 
between initial scoring of ADRs by the research pharmacist and co-investigator. A 
total of 78 (86%) ADRs were eligible for reporting to the CHM/MHRA Yellow Card 
Scheme [85]. 
105 
Table 5.5: Adapted Hartwig severity scale and results 
Severity Description Frequency of 
Level the ADR at 
each severity 
level; n (%)* 
1 An ADR occurred but no change in treatment 0 (0) 
with suspected drug 
2 The ADR required that required treatment with 1 (1) 
the suspected drug be held, discontinued, or 
otherwise changed. No antidote or other 
treatment required. No increase in length of stay 
3 The ADR required that treatment with the 18 (20) 
suspected drug be held, discontinued, or 
otherwise changed, and/or an antidote or other 
treatment required. No increase in length of stay 
4 Any Level 3 ADR which increases length of stay 63 (69) 
by at least one day OR 
the ADR was the reason for admission 
5 Any level 4 ADR which requires intensive 0 (0) 
medical care 
6 The adverse reaction caused permanent harm 0 (0) 
to the patient 
7 The adverse reaction led to the death of the 
patient. 
For the purposes of this study, adapted as: 
7a The ADR indirectly linked to death of patient 7 (8) 
7b The ADR directly linked to death of patient 1 (1.1) 
Initial inter-rater agreement): % Initial total agreement = 89%, Weighted 
Kappa (KW) (95% CI)= 0.78 (0.63-0.93) 
The denominator used was the total number of ADRs (n=91). 
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Table 5.6 shows detailed results of causality and avoidability assessments, with 
corresponding inter-rater reliability (weighted Kappa (KW)) scores from the initial 
assessments of the ADRs by the research pharmacist and co-investigator. 
Table 5.6: Causality and avoidability assessments of ADRs 
Assessment Categories and corresponding % Initial Initial 
frequencies of the ADRs (n; %)* total inter-rater 
agreement agreement 
Kw (95% 
Cl) 
Causality Definite Probable Possible 
1 (1.1) 52 (57.1) 38 (41.8) 76.9 0.59 (0.44- 
0.74) 
Avoidability Definite Possible Unavoidable 
13 39 (42.9) 39 (42.9) 58.2 0.43 (0.28- 
(14.3) 0.58) 
*The denominator used was the total number of ADRs (n=91). 
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As can be seen from Table 5.5, eight ADRs contributed to the death of the 
affected patient and these deaths are described in Table 5.7. 
Table 5.7: ADRs linked with deaths 
Adverse N° Drugs (number of deaths) Avoidability 
drug associated 
reaction patient 
deaths 
(definite, possible, 
unavoidable) 
(n=8) 
Renal 4 Amiloride (1), atenolol (1), 1 definite 
impairment bumetanide (2), enalapril 2 possible 
(1), furosemide (2), ramipril 1 unavoidable 
(2), spironolactone (1) 
Gastro- 3 
intestinal 
bleeding 
Torsades 1 
Aspirin (2), clopidogrel (1) 
Chlorpromazine (1), 
3 unavoidable 
1 unavoidable 
de Pointes quetiapine (1) 
A detailed description of the ADRs and their causative drugs is shown in Table 
5.8. Anti-platelets and loop diuretics were the most common causative drug 
groups, with bleeding and renal impairment the most frequent ADRs. 
108 
Table 5.8: Adverse drug reactions within one year of index discharge 
and causative drugs 
Description of No of Causative drug (number of ADRs) 
reaction reactions 
n=91, K' 
patients) 
Bleeding 17 (13) Aspirin (7); clopidogrel (5); warfarin (3); diclofenac, 
citalopram (2); alendronate, dalteparin, erythromycin, 
prednisolone (1) 
Renal impairment 11 (8) Furosemide, spironolactone (6); bumetanide, ramipril (5); 
digoxin (2); amiloride, atenolol, diclofenac, enalapril, 
metformin, telmisartan (1) 
Constipation 
Electrolyte 
disturbances 
Hypoglycaemia 
C. difficile infection 
Fall 
Fracture 
Seizures 
Anaemia 
Gastritis 
Increased INR 
Convulsive reaction 
Abdominal Pain 
Anaphylaxis 
Bradycardia 
Candidal infection 
Diarrhoea 
Elevated LFTs 
Erythema Nodosum 
Flushing 
Gastric ulcer 
Gout 
Hyperglycaemia 
Hyperpyrexia 
Neutropenic sepsis 
Opioid dependence 
Rash 
8 (7) Iron supplements (4); amitriptyline (3); phenytoin (2); 
citalopram, hyoscine butylbromide, morphine, tramadol (1) 
8 (7) Calcitriol, furosemide (2); bumetanide, calcium 
supplements, citalopram, fludrocortisone, potassium 
supplements (1) 
5 (4) Biphasic isophane insulin (5) 
4 (2) Amoxicillin, lansoprazole (3); ceftriaxone, ciprofoxacin, 
clarithromycin, omeprazole (1) 
4 (4) Perindopril (2); amisulpiride, atenolol, bisoprolol, 
carbamazepine, co-amilofruse, furosemide, lamotrigine (1) 
4 (4) Prednisolone (4); fluticasone (3) 
3 (1) Citalopram (3) 
2 (2) Aspirin, clopidogrel, diclofenac, prednisolone (1) 
2 (2) Asprin, citalopram, prednisolone (1) 
2 (2) Warfarin (2); amiodarone (1) 
2 (1) Trimethoprim (2) 
1 (1) Aspirin, diclofenac (1) 
1 (1) Flucloxacillin (1) 
1 (1) Bisoprolol (1) 
1 (1r Mycofenolate, prednisolone(1) 
1 (1) Amoxicillin, cefalexin, ciprofloxacin (1) 
1 (1) Atorvastatin (1) 
1 (1) Azathioprine (1) 
1 (1) Sulfasalazine (1) 
1 (1) Aspirin, diclofenac (1) 
1 (1) Furosemide (1) 
1 (1) Olanzapine (1) 
1 (1) Trifluoperazine (1) 
1 (1) Cancer chemotherapy agents (1) 
1 (1) Pethidine (1) 
1 (1) Flucloxacillin (1) 
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A total of 64 different drugs, and 148 prescriptions contributed to ADRs. The data 
were analysed to identify the whether the prescription for the causative drug had 
been commenced or changed during the index admission, or whether the 
prescription had been initiated since the index admission (see Table 5.2). Table 
5.9 shows the results from this analysis. 
Table 5.9: Relation of prescription of causative drug to index 
admission 
Category Description ADR Readmission 
Within 28 Within one 
days: N° of year: No of 
causative drug causative drug 
prescriptions prescriptions 
n=37, (%) n=148, (%) 
A Causative drug was initiated 11 (29.7) 33 (22.3) 
during the index admission 
B Causative drug had dose 2 (5.4) 3 (2.0) 
changed during the index 
admission 
C Causative drug continued 19 (51.4) 68 (45.9) 
unchanged during the index 
admission 
D Causative drug prescribed 5 (13.5) 37 (25.0) 
elsewhere/dose changed since 
the index admission 
U Unknown - Data regarding 0 (0) 7 (4.7) 
medicines use missing from 
patient case-notes for index 
admission. 
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5.6 Discussion 
This study has shown that one fifth of those patients readmitted to hospital within 
one year of discharge from their index episode are readmitted due to an adverse 
drug reaction, and that approximately half of these ADRs are definitely or possibly 
avoidable. Different studies of readmissions use varying time-periods for 
readmission, and different definitions for drug-related problems including ADRs, 
but have commonly found that drug-related problems are a significant, and often 
avoidable, factor in readmission [101,150,214,215]. 
The measurement of the rate of emergency readmission to hospital within 28 days 
of discharge from hospital is a NHS Performance Indicator, with previous data 
suggesting that approximately 5% of patients discharged from NHS hospitals are 
readmitted as an emergency within 28 days [213]. Data from our study showed 
that 13% of patients were readmitted to the study hospital within the 28-day time 
period. This study has shown that approximately 23% of these readmissions were 
related to ADRs. 
This study has shown a 28-day readmission rate from the Royal Liverpool Hospital 
which appears to be considerably higher than the national estimate of 5% [213]. 
This may be due to several factors including the acknowledged variation between 
hospitals for readmissions figures [213]. The patients included in this study were 
sufficiently ill during their index admission to be admitted to a hospital ward. They 
were therefore likely to have greater morbidity than patients who would have 
remained on the admissions unit for a relatively short hospital stay. This increased 
patient morbidity suggests that readmissions may be more likely in this cohort, 
hence the high readmission incidence demonstrated here. 
In common with an Australian study of ADR related hospitalisations [101] 
increasing age was a significant factor in readmissions overall, and particularly in 
readmissions due to ADRs. Interestingly, no differences were found in readmission 
or ADR rates with gender. Gender differences may have been expected in this 
study as previous work in the study hospital (see Chapters 2 and 3) [18,185] and 
in the ADR literature [10,97,108] have suggested that the ADR rate is higher in 
females, although overall, evidence in the literature is not conclusive [110,123]. 
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Status as a medical patient, rather than a surgical patient, increased the risk of 
readmission. This may be a reflection of the increased number of medicines and 
co-morbidities associated with medical patients. Duration of length of stay during 
the index admission did not affect whether or not the patient experienced an ADR. 
In agreement with Dormann et a/ [150], the presence of an ADR during the index 
admission did not increase risk of readmission overall, or readmission due to 
ADRs. 
Approximately 14% of readmitted patients died in hospital within one year of their 
index admission. Of the eight deaths specifically linked to ADRs, the majority were 
unavoidable. Potentially avoidable deaths were associated with renal impairment 
with diuretics and anti-hypertensive medicines. The need for strategies to improve 
diuretic management was identified in an earlier study of hospital inpatients 
(Chapter 3) as a key area for reducing ADR-related deaths and this is reiterated in 
this readmissions. study. As the majority of ADRs resulted directly in hospital 
readmission, most ADRs were serious and therefore fitted CHM/MHRA Yellow 
Card reporting criteria. 
In common with the Liverpool ADR admissions study [18], bleeding was the most 
common ADR, with antiplatelets (aspirin and clopidogrel) amongst the most 
common causative drugs. Diuretics and anti-hypertensives also resulted in many 
ADRs. These findings match those of Zhang et al, who found cardiovascular drugs 
to be those most frequently responsible for repeat ADR admissions [101], 
Over 22% of drugs causing readmission were newly prescribed for the patient 
during the index admission, with the figure for 28-day readmissions rising to 
almost one third of prescriptions. This suggests that more needs to be done to 
ensure adequate follow-up of patients commenced on new medicines in hospital. 
For both readmission periods, the majority of drugs causing the readmission ADR 
had been initiated prior to the index admission, and remained unchanged 
throughout the admission. This data may suggest that the drug and dose were 
appropriate for the patient during the index admission, and problems developed 
following discharge, resulting in the subsequent ADR-related readmission. It may 
also suggest that the drug prescription was not sufficiently reviewed for 
appropriateness during the index admission. In order to decrease readmission 
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rates, prescription review in hospital needs to be improved to optimise patient 
care. In addition, liaison between primary and secondary care and the individual 
patient is essential to ensure that medicines are continually reviewed for suitability 
in the patient's home environment [151,216]. 
Despite this being the largest study of ADR related readmissions in the UK, the 
limitations of this study are clear. The admission to hospital used as the 'index 
admission' in this study is unlikely to have been the first ever hospital admission 
for many of the patients in this study, and it therefore serves as an arbitrary 
baseline assessment. This study identified similar characteristics to the Liverpool 
admissions study in terms of types of ADR, drugs causing ADR, length of stay 
resulting from ADR related admission and ADR rate increasing with age [18]. In 
contrast, this readmissions study shows no increased incidence of ADR related 
readmission with female gender, and estimated a lower rate of avoidability than 
the Liverpool admissions study. As previously discussed, retrospective studies rely 
on the accuracy of the data recorded in the patient case-notes [31]. In the study 
hospital, casenotes are paper-based, often in several volumes, making case-note 
tracking difficult and resulting in frequently missing data. Extrapolations made to 
generate incidence rates for readmissions in this study were made with caution in 
the knowledge that the majority of data was available for analysis, and statistical 
advice was sought to confirm the study findings. 
Readmission within one year was chosen as the primary outcome measure in this 
study to enable ADRs which were not immediately apparent following 
commencement of to be identified. The 28-day rates are given for comparison as 
these formed the basis of the NHS Performance Indicators. Emergency 
readmissions to the study hospital alone were assessed. It is possible that the 
patients may have been readmitted to another hospital, which would have resulted 
in a higher readmission and possibly a higher ADR rate. The absence of data on 
morbidity and mortality for patients not readmitted to the study hospital also limits 
outcome comparison. 
The readmissions study was planned in the knowledge that ADRs which may 
occur days or weeks after hospital discharge, or those that only occur after chronic 
administration, may not be identified in a study of hospital inpatients. For example, 
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amiodarone toxicity with insidious onset. More recently, an increased risk of heart 
failure with rosiglitazone has been demonstrated [217]. Although an ADR such as 
this is unlikely to manifest itself during a short hospitalisation, it may become more 
apparent with studies of readmissions. In reality, a trend towards the emergence of 
such ADRs was not demonstrated in this study. 
A valid criticism of studies, and political targets, which assess readmission as a 
health-related outcome, is that they fail to consider that avoiding readmission is 
not a direct objective of hospital care and that some readmissions are planned and 
some are unavoidable [218]. This study ensured that only emergency 
readmissions were assessed, and that each ADR was assessed for avoidability in 
order to maintain objectivity when assessing the impact of ADRs on hospital 
readmission. 
Future work in this area would encompass a large study examining admissions 
related to ADRs and readmissions simultaneously to discover if ADRs causing first 
admission and those causing readmission were significantly different in the study 
population. In common with of many studies of ADRs, the elderly are the most 
vulnerable. Focusing on improving prescribing new drugs and monitoring longer 
term medicines may help to reduce the readmission rate due to ADRs. Increasing 
communication with the patient and the multi-disciplinary team at the primary- 
secondary care interface may help to identify potential ADRs and prevent 
readmissions to hospital. 
5.7 Conclusion 
One fifth of patients readmitted to hospital within one year of discharge from their 
index admission are readmitted due in part to an adverse drug reaction. There are 
consequently significant burdens on NHS resources due to avoidable ADRs. In 
common with general admissions studies, aspirin and diuretics are among the 
most frequent causative drugs, and the elderly are the most at risk. This study 
further highlights the need to effectively review patients' medicines both during the 
inpatient stay, and in primary care. 
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Chapter 6: An investigation of the reliability of causality 
assessment of adverse drug reactions (ADRs) 
6.1 Introduction 
Methods to aid identification and assess causality of ADRs have been in existence 
since the 1970s. They vary considerably with different levels of complexity and 
standardisation, and include 
" unstructured assessments based solely on the evaluator's opinion; 
" semi-structured assessments where categorisation follows broad 
guidelines; 
" structured algorithms which lead to categorical causality assessment; and 
" in-depth Bayesian approaches to the assessment of ADRs [53,56]. 
There is a body of literature which compares these different methods of 
assessment [54,56,57,64,65,74,219,220]. However, there is limited data 
surrounding inter-assessor reliability for the same algorithm, particularly with 
regard to different professions assessing ADRs independently. This is especially 
important now given that different healthcare professionals are able to act as 
independent prescribers. 
Causality assessment of ADRs is inherently flawed as absolute certainty that a 
drug has caused an ADR is currently impossible to obtain, and causality 
assessment does not eliminate or quantify uncertainty; at best, it categorises it in a 
semi-quantitative way [221]. When assessing 733 ADRs for a large 
epidemiological study of ADRs (Chapter 3) using the Naranjo algorithm [63] two 
independent assessors showed statistically low inter-assessor agreement (K`" 0.23, 
percentage agreement, 60%), which is comparable with Arimone et als 
assessment of comparability of expert judgement using global introspection [56]. 
However, this was much less than the original inter-assessor agreement found on 
algorithm validation [63]. The sample size in the original paper was small and used 
published cases as opposed to those generated in an epidemiological study which 
may confound the comparison. 
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Sample sizes for algorithm validation and comparison vary considerably, with 
some [57,65,74,219] studies being relatively small given the literature that 
surrounds the statistics of inter and intra-assessor agreement [222,223]. The 
types of ADRs assessed ranged from those collected spontaneously [54,56,57, 
219,220] to case reports reported in the medical literature [64,65]. Undertaking 
causality assessment of ADRs is accepted practice in assessment of spontaneous 
ADR reports in some regulatory agencies, for example in France. It has also been 
utilised in ADR epidemiological studies, but this may potentially be without value if 
the inter-assessor reproducibility is consistently poor. Furthermore, whether 
individuals with different backgrounds have even more differences in causality 
assessments is unclear - evaluation of this may provide useful insights into 
problems of causality assessments, and with the possibility of developing better 
tools for the future. 
6.2 Aim 
Using three assessment methods, this study aims to compare inter-assessor 
agreement of causality assessments of ADRs generated via an epidemiological 
study between individuals and healthcare professions, and also to look at intra- 
assessor agreement between algorithms. 
6.3 Objectives 
1. To assess each ADR for causality according to 3 recognised methods 
2. To compare the results for each assessor individually for each algorithm 
(inter-assessor reliability). 
3. To compare results of each assessor across algorithms (intra-assessor 
reliability). 
4. To make judgements regarding suitability of algorithms for assessment of 
ADRs in epidemiological studies and for assessing spontaneous reports. 
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6.4 Methods 
Six assessors (two pharmacists, two physicians and two nurses), were given 200 
adverse drug reaction (ADR) reports to assess for causality using 2 algorithmic 
scales [63,70] and the global introspection criteria set out by WHO [60]. The 
ADRs were selected at random from 733 adverse drug reaction reports generated 
during an epidemiological study of ADRs (Chapter 3). These reports contained 
anonomised demographic data for the affected patient, details of suspected and 
concurrent medication, brief past medical history, and a description of the adverse 
reaction, treatment and outcome. The assessors recorded their assessment 
results on the 'ADR Assessment Scales' reporting form (Appendix 9). The 
professional training of the assessors varied. Both pharmacists were senior 
pharmacists in hospital and academic settings with experience of identifying and 
reporting ADRs in epidemiological studies and/or daily practice. Both physicians 
were specialist registrars in clinical pharmacology. Both nurses are experienced 
specialist practising clinicians although from outside of pharmacology-based 
settings. The sample size for each profession was too small to make 
generalisations about the suitability of members of each profession to assess 
ADRs for causality, but the relevant experience of the individual assessors may 
reflect on their differences of opinion. The assessors were not given training on the 
use of the algorithms, in order to reflect the concept that these scales are adopted 
for unrelated studies worldwide without standardised training. 
The Naranjo ADR Probability Scale [63] is shown in Chapter One, Table 1.3. It 
utilises the answers to ten questions regarding the ADR and provides a 
subsequent assessment of causality. 
The World Health Organisation (WHO) causality term assessment criteria [60] are 
shown in Chapter One, Table 1.2. This provides guidance to assessors as to how 
to judge an ADR but provides no guidance on to how the evidence should be 
weighted with regard to classifying the ADR. It provides two categories 
'Conditional / Unclassified' and 'Unassessable/Unclassifiable' which allow for the 
assessor to agree that an ADR may have occurred but that there is not enough 
data to provide an assessment of causality. ADRs assessed according to these 
two categories were excluded from the final results of this study. 
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Table 6.1 shows the three-part Venulet algorithm [70]. It attempts to draw on the 
ADR itself, prior knowledge of the patient and the experience of the assessors. 
The causality is attributed using a numerical scoring system [70], and is dependent 
on the assessment of the category of the ADR (i. e. dose-related, Type I allergic 
etc). The numerical scores can then be translated into categorical classifications 
(Definite, probable, possible and unlikely/unrelated). 
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Table 6.1: The Venulet algorithm [70] 
Category of ADR: Circle at least one 
A- DOSE RELATED 
B- DOSE UNRELATED 
C- TYPE I ALLERGIC 
D- AT SITE OF APPLICATION 
F- DRUG DEPENDENCE 
G- IRREVERSIBLE 
H- WITHDRAWAL SYMPTOMS 
I- FOETAL MALFORMATION 
E- INTERACTION Z- UNCLASSIFIED 
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6.4.1 Statistical analysis 
Inter- and intra- assessor reliability between the assessors and algorithms was 
compared using weighted kappa (KW), and the observed proportion of overall 
agreement between assessors (Pa (w)). Although the use of weighted kappa has - 
recently been questioned in describing inter-assessor reliability [224] a literature 
review failed to identify a suitable alternative. Kappa values will be interpreted 
according to the guidance from Landis and Koch [225], shown in Table 6.2. 
Table 6.2: Interpretation of kappa statistic [225] 
The results between assessors and algorithms were compared with the emphasis 
on inter-assessor reliability and the implications of this for the quality of causality 
assessment, the feasibility of using the algorithms and recognition of ADRs 
between individuals and professions. 
6.5 Results 
Each assessor received 200 reports, although there were some missing or illegible 
assessments, resulting in a sample size of <200 for most assessor comparisons. 
Tables 6.3,6.4 and 6.5 show the frequency of ADR assessment in each causality 
category for the Naranjo [63], WHO [60] and Venulet [70] methods respectively. 
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Table 6.3: Distribution of causality categorisation using the Naranjo 
algorithm (n=200 for all assessors) 
Definite Probable Possible Doubtful Missing 
data 
Pharmacist 18 98 87 34 
(4.0%) (49.0%) (43.5%) (1.5%) (2.0%) 
Pharmacist 2 21 101 76 2 0 
(10.5%) (50.5%) (38.0%) (1.0%) (0.0%) 
Physician 1 21 98 76 2 3 
(10.5%) (49.0%) (38.0%) (1.0%) (1.5%) 
Physician 2 31 107 54 0 8 
(15.5%) (53.5%) (27.0%) (0.0%) (4.0%) 
Nurse 1 1 48 141 3 7 
(0.5%) (24.0%) (70.5%) (1.5%) (3.5%) 
Nurse 2 5 105 83 6 1 
(2.5%) (52.5%) (41.5%) (3.0%) (0.5%) 
For the Naranjo algorithm (Table 6.3), the majority of assessments were either 
`probable' or 'possible' for all assessors. The pharmacists and physicians 
appeared more likely to attribute a 'definite' causality assessment to the ADR than 
the nurses. 
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Table 6.4: Distribution of causality categorisation using the WHO 
criteria (n=200 for all assessors) 
Certain Probable Possible Unlikely Conditional/ Missing 
Unassess- data 
able 
Pharmacist 12 81 102 203 
1 (6.0%) (40.5%) (51.0%) (1.0%) (0.0%) (1.5%) 
Pharmacist 63 43 62 7 25 0 
2 (31.5%) (21.5%) (31.0%) (3.5%) (12.5%) (0.0%) 
Physician 1 37 95 57 7 2 2 
(18.5%) (47.5%) (28.5%) (3.5%) (1.0%) (1.0%) 
Physician 2 44 127 20 1 0 8 
(22.0%) (63.5%) (10.0%) (0.5%) (0.0%) (4.0%) 
Nurse 1 2 37 141 11 2 7 
(1.0%) (18.5%) (70.5%) (5.5%) (1.0%) (3.5%) 
Nurse 2 9 68 78 25 17 3 
(4.5%) (34.0%) (39.0%) (12.5%) (8.5%) (1.5%) 
Using the WHO 'global introspection' criteria, the pharmacist and physician 
assessors attributed 'certain' causality assessments more than the nurses; 
however most assessments for all assessors were again 'probable' or 'possible'. 
Pharmacist 2 and Nurse 2 were unable to make a full assessment for 25 and 17 
ADRs respectively, citing that further information was required. 
122 
Table 6.5: Distribution of causality categorisation using the Venulet 
algorithm (n=200 for all assessors) 
Definite Probable Possible Unlikely/ Missing 
Unrelated data 
Pharmacist 1 12 63 95 27 3 
(6.0%) (31.5%) (47.5%) (13.5%) (1.5%) 
Pharmacist 2 20 45 114 21 0 
(10.0%) (22.5%) (57.0%) (10.5%) (0.0%) 
Physician 1 19 58 92 29 2 
(9.5%) (29.5%) (46.0%) (14.5%) (1.0%) 
Physician 2 15 58 112 9 6 
(7.5%) (29.0%) (56.0%) (4.5%) (3.0%) 
Nurse 1 1 23 88 81 7 
(0.5%) (11.5%) (44.0%) (40.5%) (3.5%) 
Nurse 219 69 120 1 
(0.5%) (4.5%) (34.5%) (60.0%) (0.5%) 
When assessments were made using the Venulet algorithm, both nurses attributed 
many more 'unlikely' or 'unrelated' scores than either the physicians or 
pharmacists. For pharmacists and physicians, the majority of results were again 
probable or possible, but there was a higher frequency of 'unlikely' ratings when 
using the Venulet algorithm compared with equivalent assessment levels from the 
other methods of causality determination. 
The results of inter-assessor agreement between algorithms are shown in Table 
6.6. The sample size is also shown. For the WHO criteria, assessments scored as 
'unassessable' or 'conditional' were excluded. 
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Table 6.6: Inter-assessor agreement between algorithms 
Algorithm 
Naranjo WHO Venulet 
Assessors* n Po (w) Kw n Po(w) Kw n Po (w) Kw 
P1 v P2 196 0.837 0.253 172 0.740 0.150 196 0.789 0.229 
P1 v D1 193 0.827 0.212 193 0.788 0.175 195 0.722 0.035 
P1 v D2 189 0.819 0.208 190 0.786 0.200 192 0.802 0.231 
P1 v N1 189 0.833 0.162 888 0.823 0.134 190 0.739 0.143 
P1 v N2 195 0.840 0.203 178 0.785 0.142 196 0.668 0.038 
P2 v D1 197 0.838 0.288 172 0.756 0.223 198 0.751 0.128 
P2 v D2 192 0.840 0.306 167 0.781 0.250 194 0.825 0.315 
P2 v N1 193 0.810 0.178 168 0.655 0.005 193 0.731 0.124 
P2 v N2 199 0.806 0.107 159 0.690 0.095 199 0.663 0.019 
D1 v D2 189 0.817 0.219 188 0.796 0.177 192 0.752 0.079 
D1 v N1 190 0.798 0.134 187 0.724 0.068 191 0.686 0.007 
D1 v N2 196 0.793 0.050 177 0.688 -0.024 197 0.626 -0.043 
D2 v N1 185 0.771 0.131 183 0.671 0.032 187 0.726 0.108 
D2 v N2 191 0.801 0.140 172 0.702 0.077 193 0.660 0.045 
N1 v N2 12 -0.816 0.0 11 172 0.762 -0.100 192 0.780 0.040 
Mean 
values 
192 0.816 0.179 178 0.743 0.107 194 0.674 0.100 
Kappa Agreement [20]: < 0, Less than chance agreement; 0.01 - 0.2 Slight 
tiý_ ýýý. ' agreement; 0.21 - 0.4 Fair agreement; 06[ 
0.61 - 0.8 Substantial agreement; 0.81 - 0.99 Almost perfect agreement 
*P = Pharmacist, D= Physician, N= Nurse 
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Interpretation of the results from this study show that inter-assessor agreement 
was no greater than `fair' for any comparison of two assessors according to the 
commonly accepted interpretation of the kappa scale described in table 6.2 [225]. 
For three comparisons, inter-assessor agreement was less than that expected by 
chance. Conversely, the proportion of observed agreement (Po (w)) was good 
(>0.6) for all assessments. 
Table 6.7: Intra-assessor agreement between algorithms 
Algorithms for comparison 
Assessor Naranjo v WHO Naranjo v Venulet WHO v Venulet 
n PO (w) K'" n Po (w) Kw n Po (w) Kw 
Pharmacist 1 196 0.918 0.608 196 0.866 0.467 197 0.856 r, 427 
Pharmacist 2 175 0.795 0.323 200 0.835 0.408 175 0.743 0.274 
Physician 1 195 0.898 0.598 197 0.777 0.222 1 66 0.737 0.176 
Physician 2 192 0.873 0.416 192 0.813 0.309 192 0.735 0.131 
Nurse 1 191 0.913 1) 403 193 0.798 0.189 191 0.805 0.183 
Nurse 2 180 0.856 199 0.643 0.042 180 0.689 0.109 
Mean values 188 0.876 196 0.789 0.273 189 0.761 0.235 
Kappa Agreement [20]: < 0, Less than chance agreement; 0.01 - 0.2 Slight 
agreement; 0.21 - 0.4 Fair agreement; _j 41 u 
0.61 - 0.8 Substantial agreement; 0.81 - 0.99 Almost perfect agreement 
Table 6.7 shows that intra-assessor agreement between scales was highest for 
the Naranjo algorithm versus the WHO algorithm, with `substantial' agreement 
between assessments made by Pharmacist 1. The lowest level of agreement 
within assessors came from Nurse 2 when comparing the Naranjo and Venulet 
algorithms, where agreement was 'slight'. 
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6.6 Discussion 
To decide whether a drug has caused an adverse reaction is a difficult process 
which requires taking into account many different variables. In the large majority 
of cases, due to the lack of available data or specific tests, absolute certainty of 
causality is not possible. Estimation of the likelihood that an adverse reaction was 
caused by a drug based on the study of the available facts surrounding each case 
is therefore the only alternative. However, the literature shows that such causality 
assessments are problematic. A recent systematic review of the methods used for 
causality assessments found 34 different methods, from global introspection to the 
use of Bayesian statistics [52]. It concluded that no method has proved consistent 
and reproducible in its assessment of ADR causality, and none is universally 
accepted [52]. The findings of this study are largely consistent with this 
conclusion. 
Research by the investigators has applied the Naranjo algorithm [63] to assess 
causality in four studies (Chapter 2,3,5 and 7), reporting low levels of inter- 
assessor agreement (Kw) where assessed. Anecdotal reports from the 
investigators have also indicated frustration with the assessment instrument, with 
subjective judgement between assessors in key questions such as Question 5: 
"Are there alternative causes (other than the drug) that could on their own have 
caused the reaction? " [63], becoming the subject of contention, particularly where 
patients have multiple co-morbidities. The need to explore the use of other 
methods of causality assessment, and their interpretation was therefore identified. 
Sample sizes were often small in algorithm validation, using case reports from the 
literature, which may question the algorithm validity when applied to reports from a 
prospective study. The authors of the Naranjo algorithm questioned whether the 
high reproducibility of their results using the algorithm were due to the use of 
published case reports, where only three causality categories were used 
'possible', 'probable' and 'definite', generating spurious reproducibility [63]. 
Similarly, whilst published case-reports were not assessed in this study, all 200 
reports distributed to the assessors were identified as ADRs in a prospective study 
(Chapter 3) and subsequently had previously been assessed by two investigators 
according to the Naranjo algorithm as either 'possible', 'probable' or 'definite' in 
order to enable their inclusion in the prospective study. This minimised the 
likelihood of 'doubtful' causality assessments by subsequent assessors in this 
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study, particularly when using the Naranjo algorithm, and may have produced bias 
in these results which show the highest overall levels of agreement with the 
Naranjo algorithm. 
The key elements to any causality assessment involve questions regarding the 
temporal relationship between drug administration and adverse event, the effects 
of de-challenge, possible re-challenge, and alternative causes for the clinical 
condition which arises. In order to score, and suggest a `definite' or 'certain' ADR, 
a re-challenge is often required, which is not ethically possible in many cases. 
There are usually few 'doubtful' ADRs as it is difficult to disprove an association 
between a drug and a recognised adverse event. Consequently, most ADRs are 
logically graded as 'probable' or 'possible' and this is reflected in the results from 
this study. Exceptionally, there is a high frequency of 'unlikely' and 'unrelated' 
among the results of Nurse 1 and Nurse 2 for the Venulet algorithm (Table 6.5). 
This appears to be due to Part III of the Venulet algorithm involving the experience 
of the assessor. Both nurses may have placed greater emphasis on alternative 
causes of the reaction, above that of the potential drug reaction, giving lower 
overall scores and negative outcomes using the Venulet algorithm. Across all 
assessors however, an 'unlikely' rating were much more frequent with the Venulet 
algorithm than with WHO or Naranjo. With short individual reports, there is little 
scope for assessment of the patient's past adverse reaction history, leaving Part 11 
of the Venulet Scale largely redundant. The weighting therefore falls heavily on the 
concepts of re-challenge, de-challenge and alternative causes for the ADR in 
Parts I and III. Due to the more detailed questioning of the reaction in the Venulet 
algorithm, multiple confounding factors are assessed and may contribute to a 
lower score. This is in contrast to the Naranjo algorithm, where a single question 
regarding alternate causes forms only a small, though essential, part of the 
weighting scheme, and with the WHO criteria, where the assessor decides upon 
the weighting. 
Agreement between assessors using the weighted kappa statistic (KW) was 'fair at 
best, although the proportion of agreement between observers Po (w) was 
relatively high for all assessments, probably due to the intrinsically high rate of 
'probable and 'possible' ratings. This paradox of low kappa, but high Po has been 
discussed in several statistical papers [226-228] and is related to the 'skewness' of 
127 
the data. A high level of weighted kappa agreement is unlikely with the 
assessments of reported ADRs as the results will typically be skewed away from 
'doubtful/unlikely' ADRs, as events unlikely to be ADRs will rarely be reported in a 
prospective study, or to regulatory authorities, although this did not prove to be the 
case for all assessors using the Venulet algorithm. The highest levels of 
agreement between the assessors was with the Naranjo scale, perhaps due to its 
relatively simple application, and the difficulty of achieving a `definite' or 'doubtful' 
result. Poorer levels of agreement were found with the WHO criteria and the 
Venulet algorithm. This may be due to the need to apply personal experience and 
greater subjectivity to both scales. The varying experience of the assessors may 
have led them to apply the criteria or answer the algorithm questions differently, 
resulting in more profound differences in results. 
Agreement between methods for the same assessor (intra-assessor agreement) 
was highest between the Naranjo and WHO methods, which showed at least 
moderate agreement for the majority of assessors reflecting some comparability 
between methods. Agreement was again lower for comparisons involving the 
Venulet algorithm, perhaps, as before, reflecting its complexity and the differences 
in the experience of the assessors. The methodology for this study required the 
assessors to record their results on a single report form (Appendix 9). On this form 
both the final categorical results for the WHO and Naranjo methods are visible to 
the assessor, but the results for the Venulet algorithm are not. This may have 
influenced the assessors, particularly in view of the increased correlation between 
the Naranjo and WHO methods compared to either of those methods with Venulet. 
In future studies, extended time periods between application of the three methods 
may be necessary to minimise this potential bias. 
This study has shown a low level of comparability between algorithms in common 
with other studies which compare ADR causality assessment procedures, [57,74, 
220,229]. This is in contrast to the original validation of the Naranjo algorithm 
which showed high levels of inter-assessor reliability, although all assessors were 
attending physicians in the same hospital and the sample size was small (63 
cases) using published case reports which must contain evidence of cause and 
effect to justify publication [63,229]. Low inter-assessor reliability was found when 
applying the Naranjo algorithm to adverse drug reactions in the intensive-care unit, 
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perhaps again reflecting the difficulty in applying the algorithm to everyday 
situations [67]. 
Louik et al concluded that the usefulness of algorithms in drug surveillance 
programs was limited due to the poor reliability of the results [229]. Our results are 
in accordance with these conclusions which were made over two decades ago, as 
none of the methods assessed in this study showed high levels of inter-assessor 
reliability. The value in such assessments lies in their ability to lead the assessor 
through a logical process for assessing the ADR, serving as an 'aide-memoire' for 
a systemic analysis for the case [53]. 
Attempts have been made to improve on causality assessment procedures 
involving the incorporation of Bayesian statistics [76,77]. However, the complexity 
of the instrument means that it is unsuitable for routine use in clinical practice and 
epidemiological studies such as those assessed in this study. Comparison of 
Naranjo and BARDI instruments showed significant correlation between the two 
instruments [54] which suggests that Naranjo is the `best' method for assessing 
adverse drug reactions in routine practice. 
6.7 Conclusions 
True validation of causality assessments is currently impossible [221]. This study 
shows that comparability between assessors is `fair' or less for the ADR causality 
assessment methods examined in this study. The most consistent results were 
produced by the application of the Naranjo algorithm, and the least consistent with 
the Venulet algorithm. The experiences of the assessor appear to have 
implications on how the assessment methods are applied. Low levels of 
agreement shown in this study question the value of causality assessments 
overall, and also highlight the need to be cautious when interpreting studies of 
ADRs. Despite many studies now showing that causality assessment tools are 
imperfect, it is surprising that better more reliable tools have not been developed. 
Perhaps, this is never going to be possible, or alternatively we need to be 
developing different assessment tools for different situations. 
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Chapter 7: The use of opioids and laxatives, and 
incidence of constipation, in patients requiring neck of 
femur (NOF) surgery 
7.1 Introduction 
Constipation is one of the most frequent adverse drug reactions (ADRs) occurring 
in hospital inpatients as shown in Chapters 2 and 3 of this thesis [181]. Whilst the 
effects on the patient are often relatively minor, prolonged bowel dysfunction can 
cause severe pain and/or have other serious consequences including faecal 
impaction, exacerbation of post-operative ileus, intestinal obstruction and urinary 
retention [230]. Constipation may theoretically be preventable with appropriate 
laxative prescribing which is relatively inexpensive in comparison to other 
therapeutic areas. Recommendations for laxative use with opioids in post- 
operative care however are usually taken from oncology and palliative care [184, 
231]; there does not seem to be an evidence base to demonstrate that laxatives 
should be routinely prescribed with opioids post-operatively in patients undergoing 
surgery. Reflecting this, a point prevalence audit of opioid prescribing in 40 
orthopaedic inpatients at the Royal Liverpool University Hospital showed that 
regular laxatives were not initiated as prophylaxis against constipation at the same 
time as opioid therapy was initiated, on any occasion [232]. In order to reduce the 
heterogeneity caused by different forms of surgery, patients admitted as 
emergencies for neck-of-femur (NOF) surgery were selected. A research paper 
based on the results from this study was accepted for publication by the Journal of 
Clinical Pharmacy and Therapeutics in June 2008 (Appendix 10) [233]. 
7.2 Aim 
The aim of the study was to determine the current nature of opioid and laxative 
prescribing in patients who require emergency surgery, and the corresponding 
incidence and impact of constipation in these patients. 
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7.3 Objectives 
1. To assess how many patients undergoing neck of femur surgery were given 
oploid analgesia 
2. To assess how many patients were given laxative therapy and whether 
laxative therapy was used as prophylaxis against constipation, or as 
treatment for constipation. 
3. To assess how many patients became constipated during their stay 
4. To compare characteristics of patients who experienced constipation in 
comparison to those who did not, in terms of. age, sex, opioid dose 
received, laxative use, previous bowel disorders, cognitive impairment, 
nutritional status and mobility. 
5. To assess the effect of constipation on length of stay in hospital 
6. To quantify the cost of laxative intervention 
7. To assess the patient for side-effects of laxative therapy 
8. To draw conclusions regarding the appropriate use of opioids and laxatives 
in the study population 
7.4 Methods 
Patients admitted to the orthopaedic wards for emergency surgery for fractured 
NOF in the Royal Liverpool Hospital over an eight week period in Spring 2007 
were included in the study. A research pharmacist (ED) reviewed prescription 
charts daily for the duration of the patient stay on the acute orthopaedic wards. 
The cause of admission, all medicines taken during admission, time to 
mobilisation, date of surgery, and length of stay were recorded on the Opioid 
Intervention Form (Appendix 11). Constipation was defined as "failure of the bowel 
to open for three consecutive days" [1901. Constipation was then determined by 
asking nursing staff and patients, and by examining patient case-notes for 
information regarding frequency of bowel movements. 
Adverse effects of laxative prescribing and the cost of laxative therapy were 
recorded. Time to mobilisation was documented as the number of days required to 
begin post-operative mobilisation exercises out of bed or chair. Nutritional status 
was documented as 'poor' if clerking indicated poor nutritional status on hospital 
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admission, if nutritional supplements were prescribed during admission or if a 
need for better nutrition was documented in the case notes during the patient's 
admission. Cognitive impairment was determined by an Abbreviated Mental Test 
(AMT) score of <_ 8/10, [234] or in the absence of an AMT, if dementia or chronic 
confusion were documented in the case-notes. A patient was documented as 
having previous 'bowel problems' if they were prescribed laxatives prior to 
admission. 
Trust approval for the study was obtained from the Trust Audit Department; Ethics 
Committee approval was not required. Statistical analysis was performed using 
StatsDirect version 2.6.2 and P values of <0.05 were interpreted as statistically 
significant. 
7.5 Results 
During an eight-week period, 46 patients were admitted to the orthopaedic wards 
for emergency treatment of a NOF fracture. The median age of the patients was 
81 years (IQR 75-87 years), with 29 (63%) being female. The median day of 
surgery for patients was day 3 (IQR 2-3 days) after admission, while patients 
stayed for a median of 15 days (IQR 10-27 days). The most common type of 
surgery was a dynamic hip screw (DHS) operation for 12 (26%) of patients, but a 
number of other surgical interventions to repair fractured NOF were also 
undertaken. 
Overall, 33 (72%) patients became constipated, and this occurred post-operatively 
in 32 (70%) patients, 15 (47%) experienced clinical symptoms such as bloating, 
abdominal pain and discomfort. In two patients, this discomfort warranted an 
abdominal x-ray for investigation of pain. One patient was constipated pre- 
operatively, although this patient had an extended time to surgery (9 days) due to 
investigations for underlying disease. Of the 13 (28%) patients who did not meet 
our definition for constipation, two patients were described as having 'stubborn' 
bowels and one was diagnosed with overflow diarrhoea, secondary to 
constipation. 
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The demographic details and characteristics of the patients with and without 
constipation during their admission are described in Table 7.1. There were 
statistically significant differences only for age and nutritional status between the 
two groups. The length of stay was not directly extended due to constipation in any 
of the patients An this study. The range of length of stay overall and post- 
operatively was increased in constipated patients when compared with non- 
constipated patients, but this difference was not statistically significant. There were 
no significant differences in time to mobilisation or in numbers of patients who did 
not mobilise at all during the admission. Most patients with constipation (30,91 %), 
and all of those without constipation were taking other medicines, in addition to 
opioids, which include constipation in their side-effect, profile. 
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Table 7.1: Demographics and characteristics of constipated and non- 
constipated patients 
Variable All patients 
(n=46) 
Patients not 
constipated 
(n=13) 
Constipated 
Patients 
(n=33) 
P values 
Age 81 (52-97) 76 years (52- 86 years (53- P=0.007 
(median, 86) 97) 
range)) 
Male Gender 17,37% 4,31% 13,39% P=0.42 
(n, %) 
LoS* post-op 13 days 12 days (4-28) 13 days P=0.25 
(median, (3-70) (3-70) 
range)) 
LoS* overall 15 days 13 days (17- 16 days P=0.26 
(median, (5-72) 30) (5-72) 
range)) 
Did not 12 2 10 P=0.63 
mobilise 
during 
admission 
Previous bowel 11 38 P=0.63 
problems 
Poor nutrition 18 2 16 P=0.04 
Cognitive 17 2 15 P=0.06 
impairment 
*LoS - length of stay 
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The majority of patients (43,93%) received opioids pre- and post-operatively, with 
2 (4%) and 1 (2%) receiving doses pre- and post operatively only, respectively. 
Figure 7.1 shows the number of patients remaining in the hospital following 
admission up to 27 days post-operatively, and the mean daily dose of opioids 
(expressed as equivalents of parenteral morphine [235,236]). 
Figure 7.1: Opiold dose and length of stay 
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Figure 7.2 shows the mean daily post-operative opioid use (in equivalents of IV 
morphine) in patients who were constipated compared with those who were not. 
As length of stay increased, the number of patients remaining in hospital 
decreased and the results therefore became more sensitive to the differences in 
dosing between individuals. There were no significant differences in opioid dose 
between constipated and non-constipated patients, although initially post- 
operatively opioid doses in constipated patients appeared higher. 
Q No of patients 
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Figure 7.2: Opioid use post-operatively in constipated patients and 
non-constipated patients 
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The choice of opioids prescribed is described in Table 7.2. Morphine was the 
most commonly prescribed analgesic on admission, and immediately post- 
operatively. Patients were prescribed 1-4 different opioids during their stay. 
Morphine, followed by regular analgesic preparations such as co-codamol and or 
tramadol were the most common combinations, although there were no clear 
patterns in prescribing. 
Table 7.2: Opioid choice and constipation incidence in patients 
following admission for emergency NOF surgery 
Opioid choice Constipated 
(n=33 (%)) 
Not 
constipated 
(n=13 (%)) 
Morphine 28 (85%) 10 (77%) 
Co-codamol/ Co-dydramol 21 (64%) 8 (62%) 
Tramadol 14 (42%) 7 (54%) 
Fentanyl 1 (3%) 0 (0%) 
Codeine 9 (27%) 3 (23%) 
Dihydrocodeine 1 (3%) 0 (0%) 
Diamorphine 1 (3%) 0 (0%) 
post 1-3 post4-6 post 7-9 post 10-12 post 13-15 post 16-18 post 19-21 post 22-24 post 25-27 
Time(days) 
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Laxatives were prescribed in 33 (72%) patients requiring emergency NOF surgery. 
Of these, 20 (44%) patients received laxatives to prevent constipation but despite 
this, 12 (60%) subsequently developed constipation. Of the 26 patients not 
prescribed prophylactic laxatives, 21 (80%) developed constipation. This failed to 
achieve statistical significance (Z test, P=0.1,95% Cl for the difference -0.5 to 
0.06). 
Senna and lactulose in combination were the most frequent laxatives used for 
prophylaxis in both patient groups (14/20 patients (70%), 8 (57%) of whom 
developed constipation). Lactulose alone was used as prophylaxis in 5 patients (4 
(80%) of whom became constipated) with lactulose and Movicol used together in 
one patient who did not develop constipation. Multiple combinations of laxatives 
were used to treat constipation. For those already on prophylactic laxatives, 
treatment involved the addition of macrogols (4 patients), an enema (4 patients), 
or senna (1 patient), with a maximum of two additional laxative agents. If no 
prophylaxis was used, up to 5 laxative agents were used in a single patient. 
A summary of interventions in response to constipation is shown in Table 7.3. The 
majority of interventions involved the use of laxatives, while two patients required 
abdominal x-ray. Using cost estimates of laxatives from the British National 
Formulary [183], the cost of laxative prescribing in this study was £1.67 per 
patient/per admission. This cost estimate relies solely on the cost of 
pharmacological intervention as support from the multi-disciplinary team members 
such as physiotherapists and nutritionists was not documented in this study. The 
cost per abdominal x-ray within the trust is given as £18 internally (excluding 
overhead costs) and £29 to external trusts [237]. 
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Table 7.3: Pharmacological and non-pharmacological interventions 
directly related to constipation 
Pharmacological Intervention 
Initiate laxatives 
None 
N° of patients (n=33, %) 
12 (36%) 
7(21%) 
Continue prophylactic laxatives 6 (18%) 
Additional laxatives added to prophylaxis 6 (18%) 
Reduce opioid dose 1 (3%) 
Stop opioids and add laxatives 1 (3%) 
Direct non-pharmacological 
Intervention 
Abdominal X-ray 2 (6%) 
Laxative therapy has recognised side-effects, the most frequent of which is 
diarrhoea. Diarrhoea occurred in 9 (27%) patients taking laxatives. Using a 
validated causality assessment scale [63], four instances of diarrhoea were judged 
as being 'possibly' due to laxatives, while five were 'probably' due to laxative 
therapy. 
7.6 Discussion 
This study has examined the relationship between opioids, laxatives and 
constipation in patients following emergency NOF surgery. No previous studies 
examining the incidence of constipation in patients following treatment for 
fractured neck of femur were identified in the literature. Although our sample size 
is small and therefore the data need to be interpreted with caution, the study 
raises some interesting issues which need to be explored in future studies. 
The majority (72%) of patients in this study experienced constipation during their 
stay. Studies of the elderly population in the community suggest that constipation 
prevalence is around 20% [238-240]. Studies of constipation in cancer patients 
and patients with chronic pain report an incidence of between 52% and 87% [238, 
241]. The prevalence of constipation in patients requiring opioids acutely in this 
study was therefore greater than the incidence in the community, which may be 
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expected given the reduced mobility due to fracture, and opioid therapy. It is 
interesting that the incidence of constipation in the study population receiving 
opioids acutely appears to be similar to that in patients requiring long-term opioids. 
This suggests that other factors, in addition to opioid therapy may also be 
influential in the aetiology of constipation in the patient population studied. 
There is a need to be aware of the limitations of current definitions of constipation. 
We used a simple definition developed to assess acutely unwell patients [1901 
instead of the more complicated definitions of constipation that have been used in 
some other studies, principally for chronic constipation, where the size, stool form, 
comfort of stool passage, and frequency of bowel motions are all assessed [242- 
244]. This made the assessment of constipation less complex, although 
modification of the definition may be necessary to ensure that all patients who 
experience pain and discomfort from constipation are included in the incidence 
figures [245]. Two patients who appeared constipated clinically could not be 
included in the incidence data as they did not fit the criteria determined by the 
definition used. Conversely, about half of the patients who were recorded as 
being constipated in this study did not experience any clinical symptoms. 
Constipation is a multi-factorial problem resulting from a number of factors 
including drug therapy, nutritional intake and mobility, as well as anxiety, 
depression and decreasing cognitive function [245-248]. More patients with 
constipation were documented as having cognitive impairment and poor mobility, 
although the differences were not significant. Significantly more patients with 
constipation were documented as having nutritional problems in this study, 
although the methods to assess nutritional status were subjective and further 
studies would benefit from the use of a validated nutrition assessment score such 
as the Mini Nutritional Assessment (MNA) [249] or the Malnutrition Universal 
Screening Tool (MUST) [250]. 
Increasing dietary fibre and encouraging oral fluids, as well as encouraging 
exercise, are established interventions to both prevent and treat constipation [183, 
251]. Increasing age was a significant factor in our patients with constipation. 
There is conflicting evidence around age as a risk factor for constipation [252-254]. 
Ageing does not have major effects on the large bowel, including colonic or 
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rectosigmoid motility and water transport across the bowel wall; only minor 
changes in intestinal transit time have been reported and therefore the ageing 
process itself should have little impact on constipation incidence [253-256]. 
However, factors such as drug use, concomitant bowel disease, co-morbidities, 
decreased mobility, poor nutrition and inadequate hydration are factors which 
cause constipation are more prevalent in the elderly [255], resulting in the 
increased incidence of constipation with increasing age. The length of stay in our 
patients with constipation was longer, although this increase was not statistically 
significant. This may not be causal but may reflect the fact that these patients had 
a more complex illness and therefore time-course in hospital. In our study of 
adverse drug reactions in hospital inpatients, 100 instances of constipation were 
identified, the majority of which were associated with opioid use, with 17 (17%) 
directly increasing length of stay (Chapter 3). When considering patients admitted 
as an emergency with fractured NOF, other discharge issues involving social 
circumstances and rehabilitation placement can act as important confounders in 
the increased length of stay. 
Opioids can cause constipation, mainly by their action at mu opioid receptors in 
the gastro-intestinal (GI) tract. This reduces GI propulsion, slows the movement of 
intestinal contents, decreases pancreatic and biliary secretions and increases fluid 
and electrolyte absorption [257]. Given the pharmacological action of opioids, it is 
assumed that greater opioid use would result in greater levels of constipation, 
although this effect may be diminished when taking into account other possible 
causes of constipation. Opioids are given to patients with co-morbidities which are 
often also associated with constipation, and thus it can be extremely difficult to 
assess causality in individual patients. This is consistent with the fact that the 
choices of opioids were broadly similar in both the constipated and non- 
constipated groups. There is little convincing clinical data in the literature to 
indicate that different opioid agents, or different routes of administration, result in 
less GI adverse effects at equianalgesic doses [258]. 
Reviews of laxative use in the elderly and patients with cancer and chronic pain 
have concluded that it is impossible to determine which laxative treatments are the 
most clinically effective, or cost-effective, because of the lack of evidence [246, 
259,260]. There are also no national guidelines for laxative use to prevent 
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constipation in surgical patients. The Scottish Intercollegiate Guideline Network 
(SIGN) has stated that the best prophylactic treatment for preventing opioid- 
induced constipation in patients with cancer pain is a combination of a stimulant 
and softening agent [261-263]. In this study, senna, a stimulant laxative, and 
lactulose, an osmotic laxative, were used in combination as the most commonly 
prescribed combination for prophylaxis, followed by lactulose alone. However, 
there was no difference in the incidence of constipation in those patients receiving 
prophylaxis, although the numbers were small. Treatment for constipation when 
no prophylactic therapy had been prescribed was haphazard, with the addition of 
up to five agents to relieve constipation. Taken together, this highlights the need 
for more studies in this area to improve the evidence base. There also needs to 
be more pharmacologically diverse agents available for the treatment of 
constipation. This is evidenced by the fact that, as dehydration is a cause of 
constipation and opioids can result in more efficient absorption of water and 
electrolytes [247-251], an osmotic laxative may not be appropriate 
pharmacologically to treat opioid-induced constipation, although the evidence in 
the literature is inconclusive [246,259]. Another issue to consider with laxative 
use is the possibility of adverse effects. One third of patients in this study 
experienced diarrhoea linked to their laxative therapy, which is a particularly 
unwelcome side-effect in immobile patients. 
7.7 Conclusion 
In conclusion, constipation is an uncomfortable and often embarrassing complaint 
for patients and reducing its incidence through simple means would improve 
patient quality of life, and may decrease the patient length of stay. Further work 
with a larger patient group is necessary to determine if laxatives truly prevent 
constipation in patients suffering NOF fracture, and those undergoing other types 
of surgery, and therefore if structured interventions are necessary to improve their 
prescribing. There is an absence of useful literature in this area and further 
research is essential to produce recommendations for prevention and treatment of 
constipation in all conditions including post-operative patients. Laxative therapy is 
inexpensive, and if length of stay could be reduced by laxative use, it would likely 
be a cost-effective intervention. However, this must be weighed against the risk of 
adverse effects from laxatives. Although laxatives represent one option, one 
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should also remember that prescribing of opioids should be for the shortest time 
possible (where this is appropriate), and at the lowest effective dose; this is also 
likely to represent an effective preventive strategy for constipation, even in patients 
who have other predisposing factors, where opioids are acting as contributory as 
opposed to sole causal agents. 
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Chapter 8: Thesis Discussion 
The overall aim of this thesis was to assess the burden of adverse drug reactions 
(ADRs) on hospital inpatients. The pilot study, reported in Chapter 2, examined 
ADRs in hospital inpatients for a two-week period and reported an incidence of 
19.2% (95% confidence interval 12-26%) of patient episodes. Approximately one 
third of reactions were serious and reportable to the CHM/MHRA. The pilot study 
tested chosen methodology before a larger study was undertaken, and was largely 
robust, although quantifying additional length of stay proved a challenge which 
was addressed for the expanded study with more pro-active co-operation between 
the investigator and the multi-disciplinary team. The subsequent expanded 
prospective study of over 3500 patients (Chapter 3) was the largest study of its 
kind undertaken in the UK. It aimed to quantify the burden of ADRs in hospital 
inpatients, and identified common adverse drug reactions and key patient groups 
affected by ADRs. The incidence of ADRs reported for the expanded study of 
hospital inpatients was 14.7%, which is within the confidence intervals of the pilot 
study, thus validating the pilot's findings. The incidence figure was considerably 
greater than that suggested by a previously published systematic review (3.5- 
7.3%) [92]; this may be explained by the fact that pooling data from ADR studies 
with different designs can be problematic [90] as illustrated by the widely differing 
estimates of ADR incidence determined in different studies in different populations 
[96,98]. The financial burden of ADRs on the National Health Service (NHS) was 
estimated to be greater than £171 million annually, and combined with data 
regarding ADR-related hospital admissions [18], the equivalent of ten 800-bed 
NHS hospitals are occupied as a result of ADRs at any one time. Using descriptive 
statistics, factors affecting increased risk of ADRs appeared to be female sex, 
increasing age, placement on a medical ward, and the number of regular 
medicines taken, although multivariable analysis showed that the only significant 
risk factor was number of medicines, with each additional medicine increasing the 
hazard of an ADR episode by 1.14. This is in common with a study of adverse 
drug effects (ADEs), encompassing medication errors in addition to ADRs, which 
found no consistent risk factors for ADEs in hospital inpatients [264]. 
It is clear that observational research of this nature has many limitations, although 
efforts were made to minimise these through the chosen methodology. Daily ward 
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visits were made by one pharmacist observer, and though aided by the multi- 
disciplinary team, particularly the clinical pharmacists, it is probable that some 
ADRs were missed. This form of manual data collection is similar to that used in 
studies from the 1970s and 80s [40-42], Within the study hospital, neither the 
individual patient record nor the prescription system was electronic, and therefore 
are not integrated with the on-line laboratory test reporting system, making 
searching for ADR signals electronically impossible in the current climate. In this 
electronic age it is likely that methods of detection can be improved upon with 
integrated information technology (IT) systems. Much work has been carried out 
internationally to attempt to improve ADR detection and reporting using IT. 
Computerised systems have been shown to produce many more ADR reports than 
spontaneous reporting [46,265], with subsequent research demonstrating that IT 
systems with drug-databases linked to laboratory systems were able to detect 
ADRs such as hepatotoxicity, renal disturbances, and falls in haemoglobin 
(although with many false positives). Intensive surveillance by an observer was 
required to detect more subjective symptoms such as dyskinesia and increased 
sedation [44,47]. Further improvements in specificity and sensitivity of electronic 
systems will make them increasingly useful [45,160]. There is an opportunity 
within the NHS to implement electronic monitoring of ADRs, a form of intensive 
surveillance, with the likely introduction of the National Programme for Information 
Technology (NPfIT). 
The nine medical and three surgical wards included in the large prospective study 
(Chapter 3) were a convenience sample chosen to reflect a balance of medical 
and surgical wards in the study hospital. Highly specialist wards such as the 
intensive care units, renal transplant unit, and colo-rectal surgery were excluded 
as our focus was on ADRs occurring in wards that are found in most UK general 
hospitals. The study hospital does not have psychiatric, paediatric or obstetrics 
and gynaecology wards, and thus our estimate of the incidence of ADRs excludes 
such patient groups. This ward choice is likely to affect the estimate of ADR 
incidence, as medical wards have been reported in the literature as having a 
higher rate of ADRs than surgical patients [89,110] and adverse drug events are 
reportedly twice as frequent in medical intensive care units when compared with 
surgical intensive care units and general wards [131]. 
144 
Haematology and oncology wards were also excluded again due to their specialist 
nature and the desire to ensure that results from our prospective observational 
study would be transferable to adult general hospitals. However, this is an 
important area in pharmacovigilance that, warrants further study. A previous study 
examined ADRs in a French cancer institute in 1993 and found a relatively low 
incidence with ADRs occurring in 5% of patients (171/3429) [266]. This low 
incidence may be due to the method of detection that relied upon use of diagnosis 
codes and retrospective follow-up. However, in almost all cases, the drugs 
involved in serious ADRs were antineoplastic agents, and they primarily 
concerned patients with incurable cancer. ADRs, both major and minor, can impair 
the outcomes for cancer patients [266]. An important issue to be addressed with 
some cancer and HIV drugs is their accelerated licensing due to their emergence 
in new therapeutic areas and great potential importance. Whilst potentially 
expediting breakthroughs in the treatment of disease, this means that there are 
fewer data available regarding safety when the drug is marketed. Between 1996 
and 2002,79% of all cancer or HIV drugs that received accelerated approval in the 
US were identified as being associated with serious ADRs, compared with 25% of 
non-accelerated drugs [267]. 
With regard to other excluded groups, new research projects to quantify and 
reduce the burden of ADRs in children have commenced in Liverpool as part of 
the Medicines for Children Research Network, which should, amongst other 
findings, begin to address the risk of unlicensed and off-label medicines use in 
children [135,136]. Anaesthetics is an area largely neglected in 
pharmacovigilance, and no reliable data regarding the overall incidence of ADRs 
in the operating theatre is available. Developing pharmacovigilance strategies in 
this area is important to improve patient safety throughout the inpatient stay in 
hospital. Recent work which examined CHM/MHRA Yellow Card data for reported 
anaesthetic adverse drug reactions found that the highest mortality was with 
inhalational anaesthetics, and the lowest from local anaesthetic agents, with the 
peak `at risk' time being at induction of anaesthesia [268]. This analysis of 
spontaneous reports does not have any reliable denominator data, and thus may 
not reflect the overall picture of ADRs in anaesthetics [268], highlighting the need 
for detailed prospective examination of adverse drug reactions in this clinical area. 
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The methods used in the prospective study are good at detecting short-term 
adverse reactions, but fail to identify those which may occur days or weeks after 
hospital discharge, or those that only occur after chronic administration. This leads 
to a higher rate of ADRs reported for drugs where the adverse effect is apparent 
soon after initiation, although other drugs may be responsible for many ADRs of 
insidious onset, which may or may not be clearly distinguished from underlying 
disease. For example, increased risk of heart failure with rosiglitazone [217], or 
increased cardiac risk with Cox-II inhibitors [2]. Admittedly, these insidious 
reactions are more likely to be relevant to studies of hospital admission or 
readmission, in terms of estimates of ADR prevalence, than inpatient studies. The 
identification of delayed reactions is however, of great importance in 
pharmacovigilance. Detection of such adverse effects are more likely to come to 
prominence through pooled spontaneous report data or longitudinal trial data, than 
in an observational study, due to the difficulty in detecting the ADR in individuals, 
given the high prevalence of the underlying disease and a tendency to look at 
recent changes in condition or prescribing for a trigger for an ADR. 
The readmissions study (Chapter 5) attempted to explore the risk of readmission 
following recent discharge from hospital. In the current NHS climate, patient length 
of stay is minimised as much as possible. This increases patient turnover, and 
apparent efficiency, particularly in view of the Payment by Results (PbR) 
remuneration system. In PbR, additional length of stay beyond that expected for a 
particular episode or procedure carries financial penalties for the NHS Trust 
involved, as well as being personally distressing and inconvenient for the patient. 
The readmissions study (Chapter 5) aimed to explore drug-related reasons for 
readmission to hospital and examined if drugs prescribed in the first admission 
were implicated in subsequent admissions, with the expedited discharge of 
patients possibly proving counter-productive. Results from the readmissions study 
showed that one in five patients readmitted to hospital within one year of discharge 
were readmitted due to an ADR. The drugs contributing to the ADR were initiated 
during the index admission in approximately 20% of cases, with half of the 
causative drugs continued unchanged throughout the index admission. These 
results suggest that improving drug monitoring may help to reduce readmissions 
from ADRs, as continual monitoring of long-term drug therapy is important to 
minimise adverse effects. For example, an optimal dose of a diuretic or anti- 
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hypertensive during the index admission may require adjustment in primary care 
following discharge in light of a patient's fluctuating clinical condition, to prevent 
readmission due to dehydration or falls. Improved communication between the 
clinical teams and the patient, and between secondary and primary care may help 
to improve patient outcomes. In terms of positive interventions in improving post- 
discharge morbidity, pharmacist counselling of patients at discharge has been 
shown to reduce the number of drug related problems following hospitalisation 
[269]. In the community, pharmacist telephone counselling appeared to improve 
outcomes for patients receiving polypharmacy [270], but home-based medication 
review by pharmacists have not been shown to reduce hospital admissions in 
heart failure patients [2711, a key group for intervention considering the delicate 
risk-benefit balance of using diuretics in heart failure. 
Quantifying additional length of stay due to ADRs was a difficult task for the 
extended prospective study of hospital inpatients (Chapter 3), although much 
improved on the pilot study, with more pro-active involvement of the clinical team. 
Factors affecting length of stay included social and rehabilitation issues prior to 
discharge, fluctuations in underlying disease state and the ADR mimicking 
underlying disease. In view of the extensive confounding, the investigators were 
conservative in attributing additional length of stay to the ADR. This difficulty, and 
others in the assessment of ADRs, was eloquently summarised by Koch-Weser et 
a/ in 1977; "How, except by educated guesswork can anybody judge for most 
ADRs the precise morbidity they caused, how much they prolonged hospitalisation 
or whether they contributed to the death of a patient" [58]. 
Identification of ADRs and assessment of the relationship between the drug and 
event (causality assessment) are a particular area of concern among ADR 
researchers undertaking epidemiological research. This has led to the 
development of multiple methods of assessment [52], none of which is universally 
accepted. Four chapters of this thesis (Chapter 2,3,5 and 7) used the Naranjo 
algorithm [63] for causality assessments. Using the same algorithm throughout 
these studies ensured consistency of approach throughout the thesis, but the 
agreement between different assessors was much less than that found in the 
original research describing the development of the Naranjo algorithm [63]. The 
same two investigators assessed all ADRs for causality according to the Naranjo 
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algorithm [63] in three of the ADR studies in this thesis. For the first (pilot study), 
percentage agreement was 39% and weighted Kappa (Kw) was 0.021, meaning 
agreement between the assessors on initial analysis was barely greater than that 
expected by chance. Agreement improved for the larger prospective study to a Kw 
of 0.23 (`fair' agreement [225]) and a percentage agreement of 60%. This low level 
of agreement and anecdotal dissatisfaction with the difficulty of achieving a 
'definite' classification of ADR led to the development of the study described in 
Chapter 6. Assessment of the ADRs collated for the readmissions study showed a 
further improvement in Kw of 0.56 (moderate agreement) and a percentage 
agreement of 77%. Following the initial assessments, for which the statistics 
above describe, the investigators discussed the ADRs with a view to achieving 
consensus regarding causality. Improvements in agreement do not necessarily 
show that they became `better at assessing ADRs, but it does show that 
application of the algorithm became more uniform as this thesis progressed. 
Chapter 6 demonstrated that application of three methods of causality assessment 
[60,63,70] was inconsistent. Six assessors (2 doctors, 2 nurses and 2 
pharmacists) analysed 200 ADR reports according to the selected methods. 
Correlation of causality assessment results for different individuals using the same 
algorithm, and for the same individual using different algorithms, was often poor. 
This demonstrates one of the problems in comparing different studies of ADRs, 
and shows that ADR recognition varies from person to person. 
To assess severity of ADRs, the studies in this thesis have consistently applied the 
Hartwig scale [83] adapted for the pilot study (Chapter 2) to include two categories 
of fatal ADR, category 7a, which suggests an ADR is related to, but not the direct 
cause of, the patient's death, and 7b, which asserts that the death was directly 
related to the ADR. Whilst this scale was useful, ADRs at severity level 1 "An ADR 
occurred but no change in treatment with suspected drug" were not included as 
these ADRs are excluded, by definition, when using the Edwards and Aronson 
ADR definition [16]. Few ADRs in any of the studies in this thesis were categorised 
as severity levels 5, "ADRs which require intensive medical care", or 6, "ADRs 
which cause permanent harm to the patient", although several were directly or 
indirectly linked to death (level 7). Future adaptations of the scale may be 
appropriate to consider adapting, amalgamating, or removing levels which were of 
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little use in. out epidemiological research. Using the CHM/MHRA 'Yellow Card' 
criteria [85] was a useful way of establishing the number of 'serious' reactions, 
however, Yellow Card criteria also require all reactions to new (black triangle) 
drugs to be reported, whether 'serious' or not. In an epidemiological study, this 
theoretically may have led to an upward estimate of 'serious' reactions. The 
number of black triangle drugs used in hospitals in inpatients is very small relative 
to overall drug use, and is likely not to have had a significant impact on the results 
reported here. 
Work from this thesis suggests that approximately 50% of ADRs in inpatients may 
be avoidable, consistent with the studies from the ADR literature [43,272]. It is 
difficult to make judgements as to the preventability of ADRs, even when using 
guidelines such as the Hallas criteria [88], if the extent of how preventable adverse 
effects are unknown. This is partly due to the lack of knowledge regarding the 
effectiveness of drugs used as prophylaxis against ADRs. The lack of evidence 
surrounding the effectiveness of laxative use and opioid -induced constipation is 
one example of this, with 30% of those taking laxatives to prevent constipation in a 
study of patients post neck-of-femur surgery, experiencing laxative-induced 
diarrhoea (Chapter 7). The Hallas criteria states that an ADR is 'definitely 
avoidable' when the event was due to a procedure inconsistent with present day 
knowledge or good medical practice [88]. Long-term NSAID use leading to a 
gastro-intestinal bleed, without co-prescription of a PPI may therefore be deemed 
'definitely avoidable' although there is no data to suggest how effective the PPI 
protection is in varying age groups in people with multiple co-morbidities and 
therefore in most patients it could be argued that there is insufficient data to deem 
this ADR as 'definitely avoidable'. 
Decisions regarding the benefit-harm ratio and drug therapy are difficult, especially 
as most available data from evidence-based medicine comes from randomised 
controlled trials designed to assess the benefits of new therapies, and not to focus 
on the harms [30]. Data on the frequency of adverse effects is limited. Clinical 
trials are relatively short in duration, the populations limited, and access to trial 
data is often restricted by the manufacturer. Spontaneous reporting is too poorly 
undertaken in practice to allow ADR incidence to be accurately assessed in the 
general population. Vandenbroucke argued that pharmacoepidemiologists could 
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learn from systematic reviews of pooled trial data, and that those conducting trials 
could adopt some of the best methods of observational pharmacoepidemiology in 
order to gain a better insight into the associated harms of new drugs, as well as 
assessing their benefits [273]. 
Considering ADRs form such a large economic and social burden, the application 
of prevention strategies to prevent ADRs is of great importance. Clearly, more 
research is needed into interventions to help reduce the ADR burden in hospital 
inpatients. Key areas identified in Chapter 3 included reducing warfarin-related 
ADRs, renal impairment with diuretics, Clostridium difficile infection linked with 
poor antibiotic use, and the high incidence of opioid-induced constipation. Chapter 
7 reported a study which examined the use of opioids and laxatives, and the 
incidence of constipation in patients following emergency admission for a fractured 
neck of femur (NOF). Commonly accepted practice suggests that opioid-induced 
constipation is preventable with prophylactic laxative use; however there is no 
clear evidence to support this suggestion [246]. This study therefore examined the 
relationship between constipation, opioids and laxatives in a small population, and 
concluded that constipation is a multi-factorial problem, and questioned the lack of 
an evidence base surrounding recommendations for laxatives to prevent opioid- 
induced constipation. Further work surrounding the preventability of ADRs and the 
true benefit of commonly recommended prevention strategies would be useful. For 
example, exploring the role and capability of proton-pump inhibitors (PPIs) to 
prevent non-steroid anti-inflammatory drug (NSAID) -induced gastro-intestinal 
bleeding outside of the manufacturer's clinical trial environment. Indeed, "the 
therapeutic challenge lies not in the recognition of new adverse reactions but in 
having enough data to guide the management of well-established safety concerns" 
[30]. 
Improvements in IT systems have long been hailed as potential methods of 
reducing ADRs [11,160], with potential for decision-support systems to improve 
prescribing and reduce adverse events [164,274,275]. Pharmacogenomics aims 
to ultimately produce tailored medicines regimens based on a patient's genetic 
characteristics. Although the reality of this is decades away for most drugs and 
conditions, a practical application of pharmacogenomics is available for patients 
treated with azathioprine. Dose selection based on TPMT (thiopurine 
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methyltransferase) enzyme testing may minimise the risk of neutropenia, offering 
the prospect of safer, more effective treatment [276]. 
Discussion surrounding the conflicting methodology and definitions of ADR when 
presenting research from Chapters 2 and 3 at research conferences led to the 
exploration the concept of ADRs as hospital patient safety incidents (Chapter 4). 
The Patient Safety Division of the National Patient Safety Agency (NPSA) is a part 
of the NHS for England and Wales and suggests that preventable ADRs should be 
reported as incidents to the NPSA [206]. Incident reporting analysis methods were 
successfully applied to ADRs in Chapter 4, and using these methods would 
introduce the concept of root-cause analysis being applied to ADRs. Root-cause 
analysis would potentially assist in identifying systems failures which contribute to 
adverse drug reactions, for example, poor prescribing and insufficient monitoring 
of medicines. In the absence of a clearly defined intervention group, the reduction 
of such systems failures have been suggested into be the most likely way of 
successfully reducing ADEs [264]. Current pooling of data by the Yellow Card 
scheme does not allow for detailed assessment of the individual circumstances 
surrounding ADRs, and root-cause analysis may raise the profile of ADRs both 
clinically and politically. However, due to the large underlying ADR problem 
identified by the prospective study, it is unlikely that current NHS Trusts would 
have the resources to conduct root-cause analysis on the scale that would be 
required. Requiring ADRs to be reported to two organisations (MHRA and NPSA) 
may cause confusion and undermine the current reporting system (Yellow Card 
scheme), which is already underused [29]. It is clear that the NPSA, in seeking to 
improve systems and processes from a patient safety perspective, and the MHRA, 
seeking to collate data about medicines use and risk may have some overlapping 
goals, and collaboration between the two organisations could provide new 
strategies for preventing ADRs. 
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Chapter 9: Thesis Conclusion 
This thesis has demonstrated that ADRs are a significant problem, affecting 
almost 15% of UK hospital inpatients. Approximately half of these ADRs may be 
avoidable, and action must be taken to reduce the ADR burden. Action should be 
multi-faceted, improving the quality of drug prescribing and monitoring. 
Improvements in the NHS infrastructure, including upgraded IT systems, and 
analysis of the high-pressure environment in which prescribers work should also 
be encouraged in order to improve patient safety. Commonly used drugs, causing 
well-known reactions are the most frequently occurring ADRs in hospital 
inpatients, suggesting that strategies for their prevention should be identifiable. 
Warfarin related bleeding, Clostridium difficile infection linked to poor antibiotic 
prescribing, and renal impairment resulting from over-diuresis are the ADRs with 
the highest impact, increasing patient morbidity and mortality. Pharmacological 
methods for preventing ADRs are largely unproven. More research into effective 
methods of ADR prophylaxis is essential to ensure that intervention strategies are 
safe and evidence-based. 
Variations in pharmacovigilance methods, including multiple methods of ADR 
identification and validation, limit the extrapolation of the work derived from a 
single research centre. Standardisation of terms and definitions may help to 
increase the level of comparability of pharmacovigilance studies internationally, 
despite the inevitable underlying variations in study populations. 
In summary, this thesis has provided the most robust estimate of the extent and 
nature of the burden of ADRs in UK hospital inpatients to date. Clearly the 
methodology has led to identification of the burden posed by known ADRs. 
Different types of methodologies need to be used to identify new signals of ADRs. 
Given the huge burden of ADRs causing admission to hospital, and occurring 
within hospital, there is an urgent need to develop robust methods for prevention 
of ADRs in the future. 
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APPENDIX 5: ADR Assessment Form (Chapter 2: Pilot 
Study) 
Draft 
ýecüon 1. 
R Assessment Form. (Part 1) Broadgreen University Hospitals 
NHS Tut 
Identification Details 
Eospital No. Q 
(BG or RLI1 fn mbe i only) 
roreramts: 
a. 0. ß: [I 'f I1 
Weight: 
Report ID: L 
Patient Study 
Number: 
Date sf [ 
Admission: 
-L 
J, 
Section 2. Medical Details 
; ''resenting Complaint: 7 
gnosis: 
past ? dica History. 
11p 
I Diabetes Q hypertension Q 
1l'pe 
2 Diabetes O Heart Failure Q 
Attbna Q Chronic/Acute Renal Failure Q 
'VPd Q Chronic/Acute Hepatic Impairment 11 
O Cancer (Specify) Q 
O Infection (Specify) QL 
0 Other (Specify) Q 
ýmrrrna: - 
I 
'"wer Relevant History 
P ºa do g Allerg e fSesuiti' 
11ONK 01 .'M Pr=. I ADDR Assessment Form. The Royal Liverpool and. 
oaf .. Broadgreen University Hospit8is Hospital No. Q 
NHS Trust 
(BG or RLHXnumbers only) 
Section 3. Details ofADR 
'1 " suspected Drug 
Contra-indicated inpatient Q Yeso 
Reaction: 
BNF Chapter of Drug: Dosage: 
Indication for-I? rug: 
'Lj 
Date Reaction started: Date Reaction Stopped. 
Date Drug started Date Drug Stopped. 
[Zl/t I1/ OIý_1ý_ýh1 a 
Suspected Drug 
Reaction: 
BNF Chapter of Drug: 
Indication for Drug: 
Contra-indicated in patient Q Yes Q No 
Dosage: 
Date Reaction started: Date Reaction Stopped 
[malu H/ FTI H i' I l/ 
Date Drug started: Date Drug Stopped: 
1 11 rr/m/ CD/CD/ 
Section 4. 
Name of Drug: 
1.1 . -1 
Concurent Medication 
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L- ýj 
Indication: 
Other: 
Route Q PR 11 PO Q IV 13 IM 11 INH 
Date Drug started: Date Drug Stopped: 
Interaction with suspected drug Q Yes Q No Interaction with another listed drug 0 Yes Q No 
Contrainicated in patient Q Yes Q No 
First Draft 22/04/2005 Developed by T. Parnell 
Page 2 of 5 
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(BG or RLHlnumbers only) 
The Royal Liverpool and (ý! 
_Broadgreen University Hospitals NHS Trust 
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2.1 
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Interaction with suspected drug Q Yes Q No Interaction with another listed drug 0 Yes Q No 
Contrainicated in patient 
Name of Drug: 
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Dosage: Indication: 
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E::::: 
-ý- 
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Q I/mi m/mý 
Interaction with suspected drug Q Yes Q No 
Contrainicated in patient Q Yes Q No 
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4, 
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Interaction with another listed drug Q Yes [] No 
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First Draft 22/04/2005 Developed by T. Parnell Page 3 of 5 
ADR Assessment Form. The Royal Liverpool and Draft Broadgreen University Hospitals 
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Section 5. Prophylactic Medication 
Name of Drug(s): 
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Section 6. Relevant Biochemistry 
Section 7. Interventions 
Section S. Additional Length of Stay. 
Additional length of stay due to ADR : 
Actual Length of Stay: Potential Length of stay: 
Days Days 
Section Date of Discharge 
Section 10. Notes 
First Draft 22104/2005 Developed by T. Pamell 
1 
Page 4of5 
.; 
NO 
ADR Assessment Form. (Part 2) The Royal Liverpool and it. Draft 
---- -Broadgreen-University Hospitals 
Hospital No. Q NHS Trust 
(UG or RU! j=bas only) 
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Causality. 
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I Severity score 13 1 O2 E33 Q4 05 Q6 O7 
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Classification 0AQB 
Part3. 
Number of visits required to conTlete daa: 
approximate time taken to collect data: 
Workload Assesment. 
Approximate time taken to complete assessment: 
0 
0 
0 
Fat Oral 22104 05 Developed by T. Pamell Page 5 of 5 
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Study) 
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APPENDIX 7: Drug Usage Form (Chapter 3: Main Study) 
Drug Usage Form 
Main Study 
Main Study - Version 1 06/05 
Drug Usage Form -1 in 10 
Patient Study Number: Date of Admission: 
Addressograph: Date of Discharge 
Length of stay: 
Consultant: 
Medication 
Drug Dose Route Started Stopped On At Indication 
Home? 
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APPENDIX 9: Causality Assessments Reporting Form 
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